Document:

Note Purchase Agreement

 Exhibit 10(z) 
  

 SIGMA-ALDRICH CORPORATION 
 $100,000,000 5.11% Series 2006-A Senior Notes 
 due December 5, 2011 
  

 NOTE PURCHASE AGREEMENT 
  

 DATED AS OF DECEMBER 5, 2006 
  

 Exhibit 10(z) (continued) 
 TABLE OF CONTENTS 
  

					
	 SECTION
	  	 HEADING
	  	PAGE
	 SECTION 1.
	  	AUTHORIZATION OF NOTES	  	1
			
	 Section 1.1.
	  	Description of Notes	  	1
	 Section 1.2.
	  	Interest Rate	  	1
			
	 SECTION 2.
	  	SALE AND PURCHASE OF NOTES	  	2
			
	 Section 2.1.
	  	Series A Notes	  	2
	 Section 2.2.
	  	Additional Series of Notes	  	2
			
	 SECTION 3.
	  	CLOSING	  	4
			
	 SECTION 4.
	  	CONDITIONS TO CLOSING	  	4
			
	 Section 4.1.
	  	Representations and Warranties of the Company	  	4
	 Section 4.2.
	  	Performance; No Default	  	4
	 Section 4.3.
	  	Compliance Certificates	  	4
	 Section 4.4.
	  	Opinions of Counsel	  	5
	 Section 4.5.
	  	Purchase Permitted By Applicable Law, Etc.	  	5
	 Section 4.6.
	  	Sale of Other Notes	  	5
	 Section 4.7.
	  	Payment of Special Counsel Fees	  	5
	 Section 4.8.
	  	Private Placement Number	  	5
	 Section 4.9.
	  	Changes in Corporate Structure	  	5
	 Section 4.10.
	  	Funding Instructions	  	6
	 Section 4.11.
	  	Proceedings and Documents	  	6
			
	 SECTION 5.
	  	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  	6
			
	 Section 5.1.
	  	Organization; Power and Authority	  	6
	 Section 5.2.
	  	Authorization, Etc.	  	6
	 Section 5.3.
	  	Disclosure	  	6
	 Section 5.4.
	  	Organization and Ownership of Shares of Subsidiaries; Affiliates	  	7
	 Section 5.5.
	  	Financial Statements; Material Liabilities	  	8
	 Section 5.6.
	  	Compliance with Laws, Other Instruments, Etc.	  	8
	 Section 5.7.
	  	Governmental Authorizations, Etc.	  	8
	 Section 5.8.
	  	Litigation; Observance of Agreements, Statutes and Orders	  	8
	 Section 5.9.
	  	Taxes	  	9
	 Section 5.10.
	  	Title to Property; Leases	  	9
	 Section 5.11.
	  	Licenses, Permits, Etc.	  	9
	 Section 5.12.
	  	Compliance with ERISA	  	9
	 Section 5.13.
	  	Private Offering by the Company	  	10
	 Section 5.14.
	  	Use of Proceeds; Margin Regulations	  	10

  

 -i- 

 Exhibit 10(z) (continued) 
  

					
	 Section 5.15.
	  	Existing Debt; Future Liens	  	11
	 Section 5.16.
	  	Foreign Assets Control Regulations, Etc.	  	11
	 Section 5.17.
	  	Status under Certain Statutes	  	12
	 Section 5.18.
	  	Environmental Matters	  	12
	 Section 5.19.
	  	Notes Rank Pari Passu	  	13
			
	 SECTION 6.
	  	REPRESENTATIONS OF THE PURCHASER	  	13
			
	 Section 6.1.
	  	Purchase for Investment	  	13
	 Section 6.2.
	  	Accredited Investor	  	13
	 Section 6.3.
	  	Source of Funds	  	13
			
	 SECTION 7.
	  	INFORMATION AS TO COMPANY	  	15
			
	 Section 7.1.
	  	Financial and Business Information	  	15
	 Section 7.2.
	  	Officer’s Certificate	  	17
	 Section 7.3.
	  	Visitation	  	18
			
	 SECTION 8.
	  	PAYMENT OF THE NOTES	  	18
			
	 Section 8.1.
	  	Required Prepayments	  	18
	 Section 8.2.
	  	Optional Prepayments with Make-Whole Amount	  	18
	 Section 8.3.
	  	Allocation of Partial Prepayments	  	19
	 Section 8.4.
	  	Maturity; Surrender, Etc.	  	19
	 Section 8.5.
	  	Purchase of Notes	  	19
	 Section 8.6.
	  	Make-Whole Amount for the Series A Notes	  	19
	 Section 8.7.
	  	Change in Control	  	21
			
	 SECTION 9.
	  	AFFIRMATIVE COVENANTS	  	22
			
	 Section 9.1.
	  	Compliance with Law	  	22
	 Section 9.2.
	  	Insurance	  	22
	 Section 9.3.
	  	Maintenance of Properties	  	23
	 Section 9.4.
	  	Payment of Taxes and Claims	  	23
	 Section 9.5.
	  	Corporate Existence, Etc.	  	23
	 Section 9.6.
	  	Designation of Subsidiaries	  	23
	 Section 9.7.
	  	Notes to Rank Pari Passu	  	24
	 Section 9.8.
	  	Additional Subsidiary Guarantors	  	24
	 Section 9.9.
	  	Books and Records	  	24
			
	 SECTION 10.
	  	NEGATIVE COVENANTS	  	24
			
	 Section 10.1.
	  	Consolidated Debt to Consolidated Total Capitalization	  	24
	 Section 10.2.
	  	Priority Debt	  	25
	 Section 10.3.
	  	Limitation on Liens	  	25
	 Section 10.4.
	  	Sales of Asset	  	26
	 Section 10.5.
	  	Merger and Consolidation	  	28
	 Section 10.6.
	  	Transactions with Affiliates	  	28
	 Section 10.7.
	  	Terrorism Sanctions Regulations	  	29

  

 -ii- 

 Exhibit 10(z) (continued) 
  

					
	 SECTION 11.
	  	EVENTS OF DEFAULT	  	29
			
	 SECTION 12.
	  	REMEDIES ON DEFAULT, ETC.	  	31
			
	 Section 12.1.
	  	Acceleration	  	31
	 Section 12.2.
	  	Other Remedies	  	32
	 Section 12.3.
	  	Rescission	  	32
	 Section 12.4.
	  	No Waivers or Election of Remedies, Expenses, Etc.	  	32
			
	 SECTION 13.
	  	REGISTRATION; EXCHANGE; SUBSTITUTION OF NOTES	  	33
			
	 Section 13.1.
	  	Registration of Notes	  	33
	 Section 13.2.
	  	Transfer and Exchange of Notes	  	33
	 Section 13.3.
	  	Replacement of Notes	  	34
			
	 SECTION 14.
	  	PAYMENTS ON NOTES	  	34
			
	 Section 14.1.
	  	Place of Payment	  	34
	 Section 14.2.
	  	Home Office Payment	  	34
			
	 SECTION 15.
	  	EXPENSES, ETC.	  	35
			
	 Section 15.1.
	  	Transaction Expenses	  	35
	 Section 15.2.
	  	Survival	  	35
			
	 SECTION 16.
	  	SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE AGREEMENT	  	35
			
	 SECTION 17.
	  	AMENDMENT AND WAIVER	  	36
			
	 Section 17.1.
	  	Requirements	  	36
	 Section 17.2.
	  	Solicitation of Holders of Notes	  	36
	 Section 17.3.
	  	Binding Effect, Etc.	  	37
	 Section 17.4.
	  	Notes Held by Company, Etc.	  	37
			
	 SECTION 18.
	  	NOTICES	  	37
			
	 SECTION 19.
	  	REPRODUCTION OF DOCUMENTS	  	38
			
	 SECTION 20.
	  	CONFIDENTIAL INFORMATION	  	38
			
	 SECTION 21.
	  	SUBSTITUTION OF PURCHASER	  	40
			
	 SECTION 22.
	  	MISCELLANEOUS	  	40
			
	 Section 22.1.
	  	Successors and Assigns	  	40
	 Section 22.2.
	  	Payments Due on Non-Business Days	  	40

  

 -iii- 

 Exhibit 10(z) (continued) 
  

					
	 Section 22.3.
	  	Accounting Terms	  	40
	 Section 22.4.
	  	Severability	  	41
	 Section 22.5.
	  	Construction	  	41
	 Section 22.6.
	  	Counterparts	  	41
	 Section 22.7.
	  	Governing Law	  	41
	 Section 22.8.
	  	Jurisdiction and Process; Waiver of Jury Trial	  	41

  

 -iv- 

 Exhibit 10(z) (continued) 
  

					
	 SCHEDULE A
	  	—	  	INFORMATION RELATING TO PURCHASERS
			
	 SCHEDULE B
	  	—	  	DEFINED TERMS
			
	 SCHEDULE 4.9
	  	—	  	Changes in Corporate Structure
			
	 SCHEDULE 5.4
	  	—	  	Subsidiaries of the Company, Ownership of Subsidiary Stock, Affiliates
			
	 SCHEDULE 5.5
	  	—	  	Financial Statements
			
	 SCHEDULE 5.11
	  	—	  	Licenses, Permits, Etc.
			
	 SCHEDULE 5.15
	  	—	  	Existing Debt
			
	 SCHEDULE 10.3
	  	—	  	Existing Liens
			
	 EXHIBIT 1
	  	—	  	Form of 5.11% Series 2006-A Senior Notes due December 5, 2011
			
	 EXHIBIT 4.4(a)
	  	—	  	Form of Opinion of Special Counsel to the Company
			
	 EXHIBIT 4.4(b)
	  	—	  	Form of Opinion of Special Counsel to the Purchasers
			
	 EXHIBIT S
	  	—	  	Form of Supplement to Note Purchase Agreement

  

 -v- 

 Exhibit 10(z) (continued) 
 SIGMA-ALDRICH CORPORATION 
 3050 SPRUCE
STREET 
 ST. LOUIS, MISSOURI 63103 
 $100,000,000 5.11% SERIES 2006-A SENIOR NOTES 
 DUE DECEMBER 5, 2011 
 Dated as of 
 December 5, 2006 
 TO THE
PURCHASERS LISTED IN 
 THE ATTACHED SCHEDULE A:

 Ladies and Gentlemen: 
 SIGMA-ALDRICH CORPORATION, a Delaware corporation (the “Company”), agrees with the Purchasers listed in the attached Schedule A (the “Purchasers”) to this Note
Purchase Agreement (this “Agreement”) as follows: 
 SECTION 1. AUTHORIZATION OF
NOTES. 
 Section 1.1. Description of Notes. The Company will authorize the issue and sale of the following Senior
Notes: 
  

											
	 Issue
	  	Series and/or
Tranche	  	Aggregate
Principal
Amount	  	Interest Rate	 	 	Maturity Date
	 Senior Notes
	  	Series 2006-A	  	$	100,000,000	  	5.11	%	 	December 5, 2011

 The Senior Notes described above (the “Series A Notes”) together with each Series
of Additional Notes that may from time to time be issued pursuant to the provisions of Section 2.2 are collectively referred to as the “Notes” (such term shall also include any such notes issued in substitution therefor
pursuant to Section 13 of this Agreement). The Series A Notes shall be substantially in the form set out in Exhibit 1, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized terms used in
this Agreement are defined in Schedule B; references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. 
 Section 1.2. Interest Rate. (a) The Series A Notes shall bear interest (computed on the basis of a 360-day year of twelve 30-day months)
on the unpaid principal thereof from the date 

 Exhibit 10(z) (continued) 
  
 
of issuance at their respective stated rate of interest payable semi-annually in arrears on the 5th day of June and December in each year and at maturity,
commencing on June 5, 2007, until such principal sum shall have become due and payable (whether at maturity, upon notice of prepayment or otherwise) and interest (so computed) on any overdue principal, interest or Make-Whole Amount from the due
date thereof (whether by acceleration or otherwise) at the applicable Default Rate until paid. 
 SECTION 2. SALE
AND PURCHASE OF NOTES. 
 Section 2.1. Series A Notes. Subject to the
terms and conditions of this Agreement, the Company will issue and sell to each Purchaser and each Purchaser will purchase from the Company, at the Closing provided for in Section 3, the Series A Notes in the principal amount specified opposite
such Purchaser’s name in Schedule A at the purchase price of 100% of the principal amount thereof. The obligations of each Purchaser hereunder are several and not joint obligations and each Purchaser shall have no obligation and no liability to
any Person for the performance or nonperformance by any other Purchaser hereunder. 
 Section 2.2. Additional Series of Notes.
The Company may, from time to time, in its sole discretion but subject to the terms hereof, issue and sell one or more additional Series of its unsecured promissory notes under the provisions of this Agreement pursuant to a supplement (a
“Supplement”) substantially in the form of Exhibit S, provided that the aggregate principal amount of Notes of all Series issued pursuant to all Supplements in accordance with the terms of this Section 2.2 shall not
exceed $500,000,000. Each additional Series of Notes (the “Additional Notes”) issued pursuant to a Supplement shall be subject to the following terms and conditions: 
 (i) each Series of Additional Notes, when so issued, shall be differentiated from all previous Series by sequential alphabetical
designation inscribed thereon; 
 (ii) Additional Notes of the same Series may consist of more than one different and separate
tranches and may differ with respect to outstanding principal amounts, maturity dates, interest rates and premiums, if any, and price and terms of redemption or payment prior to maturity, but all such different and separate tranches of the same
Series shall vote as a single class and constitute one Series; 
 (iii) each Series of Additional Notes shall be dated the
date of issue, bear interest at such rate or rates, mature on such date or dates, be subject to such mandatory and optional prepayment on the dates and at the premiums, if any, have such additional or different conditions precedent to closing, such
representations and warranties and such additional covenants as shall be specified in the Supplement under which such Additional Notes are issued and upon execution of any such Supplement, this Agreement shall be amended (a) to reflect such
additional covenants without further action on the part of the holders of the Notes outstanding under this Agreement, provided, that any such additional covenants shall inure to the benefit of all holders of Notes so long as any Additional
Notes issued pursuant to such Supplement remain outstanding, and (b) to reflect such representations and warranties as are contained in such Supplement for the 

  

 -2- 

 Exhibit 10(z) (continued) 
  
 
benefit of the holders of such Additional Notes in accordance with the provisions of Section 16; 
 (iv) each Series of Additional Notes issued under this Agreement shall be in substantially the form of Exhibit 1 to Exhibit S hereto with
such variations, omissions and insertions as are necessary or permitted hereunder; 
 (v) the minimum principal amount of any
Note issued under a Supplement shall be $100,000, except as may be necessary to evidence the outstanding amount of any Note originally issued in a denomination of $100,000 or more; 
 (vi) all Additional Notes shall constitute Senior Debt of the Company and shall rank pari passu with all other outstanding Notes;
and 
 (vii) no Additional Notes shall be issued hereunder if at the time of issuance thereof and after giving effect to the
application of the proceeds thereof, any Default or Event of Default shall have occurred and be continuing. 
 The obligations of the
Additional Purchasers to purchase any Additional Notes shall be subject to the following conditions precedent, in addition to the conditions specified in the Supplement pursuant to which such Additional Notes may be issued: 
 (a) Compliance Certificate. A duly authorized Senior Financial Officer shall execute and deliver to each Additional Purchaser and
each holder of Notes an Officer’s Certificate dated the date of issue of such Series of Additional Notes stating that such officer has reviewed the provisions of this Agreement (including any Supplements hereto) and setting forth the
information and computations (in sufficient detail) required in order to establish whether after giving effect to the issuance of the Additional Notes and after giving effect to the application of the proceeds thereof, the Company is in compliance
with the requirements of Section 10.1 on such date (based upon the financial statements for the most recent fiscal quarter ended prior to the date of such certificate). 
 (b) Execution and Delivery of Supplement. The Company and each such Additional Purchaser shall execute and deliver a Supplement
substantially in the form of Exhibit S hereto. 
 (c) Representations of Additional Purchasers. Each Additional
Purchaser shall have confirmed in the Supplement that the representations set forth in Section 6 are true with respect to such Additional Purchaser on and as of the date of issue of the Additional Notes. 
 (d) Execution and Delivery of Guaranty Ratification. Following the execution and delivery of a Subsidiary Guaranty pursuant to
Section 9.8 hereof, each Subsidiary Guarantor shall execute and deliver a Guaranty Ratification in the form attached to the Subsidiary Guaranty. 
  

 -3- 

 Exhibit 10(z) (continued) 
  
 SECTION 3. CLOSING. 
 The sale and purchase of the Series A Notes to be purchased by each Purchaser shall occur at the offices of Chapman and Cutler LLP, 111 West Monroe Street, Chicago, IL 60603 at 10:00 a.m. Central time, at a closing
(the “Closing”) on December 5, 2006 or on such other Business Day thereafter on or prior to December 31, 2006 as may be agreed upon by the Company and the Purchasers. On the Closing Date, the Company will deliver to each
Purchaser the Series A Notes to be purchased by such Purchaser in the form of a single Series A Note (or such greater number of Series A Notes in denominations of at least $100,000 as such Purchaser may request) dated the date of the Closing Date
and registered in such Purchaser’s name (or in the name of such Purchaser’s nominee), against delivery by such Purchaser to the Company or its order of immediately available funds in the amount of the purchase price therefor by wire
transfer of immediately available funds for the account of the Company to Account Number 1005017999, at U.S. Bank National Association, St. Louis, Missouri, ABA Number 081 000 210, in the Account Name of “Sigma-Aldrich Corporation” If, on
the Closing Date, the Company shall fail to tender such Series A Notes to any Purchaser as provided above in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to any Purchaser’s
satisfaction, such Purchaser shall, at such Purchaser’s election, be relieved of all further obligations under this Agreement, without thereby waiving any rights such Purchaser may have by reason of such failure or such nonfulfillment.

 SECTION 4. CONDITIONS TO CLOSING. 
 Each Purchaser’s obligation to purchase and pay for the Series A Notes to be sold to such Purchaser at the Closing is subject to the fulfillment to
such Purchaser’s satisfaction, prior to or at the Closing, of the following conditions applicable to the Closing Date: 
 Section 4.1. Representations and Warranties of the Company. The representations and warranties of the Company in this Agreement shall be correct when made and at the time of the Closing. 
 Section 4.2. Performance; No Default. The Company shall have performed and complied with all agreements and conditions contained in this
Agreement required to be performed or complied with by the Company prior to or at the Closing, and after giving effect to the issue and sale of the Series A Notes (and the application of the proceeds thereof as contemplated by Section 5.14), no
Default or Event of Default shall have occurred and be continuing. Neither the Company nor any Subsidiary shall have entered into any transaction since the date of the most recent financial statements referred to in Schedule 5.5 hereto that would
have been prohibited by Section 10 hereof had such Sections applied since such date. 
 Section 4.3. Compliance
Certificates. 
 (a) Officer’s Certificate of the Company. The Company shall have delivered to such Purchaser an
Officer’s Certificate, dated the Closing Date, certifying that the conditions specified in Sections 4.1, 4.2 and 4.9 have been fulfilled. 
  

 -4- 

 Exhibit 10(z) (continued) 
  
 (b) Secretary’s Certificate of the Company. The Company shall have delivered to such Purchaser a certificate,
dated the Closing Date, certifying as to the resolutions attached thereto and other corporate proceedings relating to the authorization, execution and delivery of the Series A Notes and this Agreement. 
 Section 4.4. Opinions of Counsel. Such Purchaser shall have received opinions in form and substance satisfactory to such Purchaser, dated the
Closing Date (a) from Bryan Cave LLP, special counsel for the Company, covering the matters set forth in Exhibit 4.4(a) and covering such other matters incident to the transactions contemplated hereby as such Purchaser or its counsel may
reasonably request (and the Company hereby instructs its counsel to deliver such opinion to the Purchasers), and (b) from Chapman and Cutler LLP, the Purchasers’ special counsel in connection with such transactions, substantially in the
form set forth in Exhibit 4.4(b) and covering such other matters incident to such transactions as such Purchaser may reasonably request. 
 Section 4.5. Purchase Permitted By Applicable Law, Etc. On the date of the Closing such Purchaser’s purchase of Series A Notes shall (a) be permitted by the laws and regulations of each jurisdiction to which
such Purchaser is subject, without recourse to provisions (such as section 1405(a)(8) of the New York Insurance Law) permitting limited investments by insurance companies without restriction as to the character of the particular investment,
(b) not violate any applicable law or regulation (including, without limitation, Regulation T, U or X of the Board of Governors of the Federal Reserve System) and (c) not subject such Purchaser to any tax, penalty or liability under or
pursuant to any applicable law or regulation, which law or regulation was not in effect on the date hereof. If requested by such Purchaser, such Purchaser shall have received an Officer’s Certificate certifying as to such matters of fact as
such Purchaser may reasonably specify to enable such Purchaser to determine whether such purchase is so permitted. 
 Section 4.6.
Sale of Other Notes. Contemporaneously with the Closing the Company shall sell to each other Purchaser and each other Purchaser shall purchase the Series A Notes to be purchased by it at the Closing as specified in Schedule A. 
 Section 4.7. Payment of Special Counsel Fees. Without limiting the provisions of Section 15.1, the Company shall have paid on or before
the Closing Date, the reasonable fees, reasonable charges and reasonable disbursements of the Purchasers’ special counsel referred to in Section 4.4 to the extent reflected in a statement of such counsel rendered to the Company at least
one Business Day prior to the Closing Date. 
 Section 4.8. Private Placement Number. A Private Placement Number issued by
Standard & Poor’s CUSIP Service Bureau (in cooperation with the Securities Valuation Office of the National Association of Insurance Commissioners) shall have been obtained for the Series A Notes by special Counsel for the Purchasers.

 Section 4.9. Changes in Corporate Structure. Neither the Company nor any Subsidiary Guarantor shall have changed its
jurisdiction of organization or, except as reflected in Schedule 4.9, been a party to any merger or consolidation, or shall have succeeded to all or any substantial 

  

 -5- 

 Exhibit 10(z) (continued) 
  
 
part of the liabilities of any other entity, at any time following the date of the most recent financial statements referred to in Schedule 5.5. 

Section 4.10. Funding Instructions. At least three Business Days prior to the date of the Closing, each Purchaser shall have received
written instructions signed by a Responsible Officer on letterhead of the Company confirming the information specified in Section 3 including (i) the name and address of the transferee bank, (ii) such transferee bank’s ABA number
and (iii) the account name and number into which the purchase price for the Series A Notes is to be deposited. 
 Section 4.11.
Proceedings and Documents. All corporate and other organizational proceedings in connection with the transactions contemplated by this Agreement and all documents and instruments incident to such transactions shall be satisfactory to such
Purchaser and its special counsel, and such Purchaser and its special counsel shall have received all such counterpart originals or certified or other copies of such documents as such Purchaser or such special counsel may reasonably request.

 SECTION 5. REPRESENTATIONS AND WARRANTIES OF THE
COMPANY. 
 The Company represents and warrants to each Purchaser that, as of the date of this Agreement and as of the Closing
Date: 
 Section 5.1. Organization; Power and Authority. The Company is a corporation duly organized, validly existing and in
good standing under the laws of its jurisdiction of incorporation, and is duly qualified as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which
the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has the corporate power and authority to own or hold under lease the properties it
purports to own or hold under lease, to transact the business it transacts and proposes to transact, to execute and deliver this Agreement and the Series A Notes and to perform the provisions hereof and thereof. 
 Section 5.2. Authorization, Etc. This Agreement and the Notes to be issued on the Closing Date have been duly authorized by all
necessary corporate action on the part of the Company, and this Agreement constitutes, and upon execution and delivery thereof each such Note will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except as such enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and
(ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 Section 5.3. Disclosure. The Company, through its agent, Banc of America Securities LLC, has delivered to you and each Other Purchaser copies of certain information that has been publicly filed with the Securities and
Exchange Commission (such information, together with all other information relating to the Company and its Subsidiaries that has been filed with the Securities Exchange Commission, including without limitation each Form 10-K, Form 10-Q, 

  

 -6- 

 Exhibit 10(z) (continued) 
  
 
Form 8-K being collectively referred to as “Public Filings”), relating to the transactions contemplated hereby. The Public Filings fairly
describes, in all material respects, the general nature of the business and principal properties of the Company and its Restricted Subsidiaries. This Agreement, the Public Filings, the documents, certificates or other writings delivered to the
Purchasers by or on behalf of the Company in connection with the transactions contemplated hereby and the financial statements listed in Schedule 5.5, in each case, delivered to the Purchasers prior to December 1, 2006 (this Agreement, the
Public Filings and such documents, certificates or other writings and such financial statements being referred to, collectively, as the “Disclosure Documents”), taken as a whole, do not contain any untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein not misleading in light of the circumstances under which they were made. Except as disclosed in the Disclosure Documents, since December 31, 2005, there has been
no change in the financial condition, operations, business or properties of the Company or any of its Restricted Subsidiaries except changes that individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect.
There is no fact known to the Company that would reasonably be expected to have a Material Adverse Effect that has not been set forth herein or in the Disclosure Documents. 
 Section 5.4. Organization and Ownership of Shares of Subsidiaries; Affiliates. (a) Schedule 5.4 contains (except as noted therein)
complete and correct lists (i) of the Company’s Restricted and Unrestricted Subsidiaries, showing, as to each Subsidiary, the correct name thereof, the jurisdiction of its organization, and the percentage of shares of each class of its
capital stock or similar equity interests outstanding owned by the Company and each other Subsidiary. The Company’s Public Filings correctly describes the Company’s Affiliates, other than its Subsidiaries, and Company’s directors and
senior officers. 
 (b) All of the outstanding shares of capital stock or similar equity interests of each Subsidiary shown in Schedule 5.4
as being owned by the Company and its Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Company or another Subsidiary free and clear of any Lien (except as otherwise disclosed in Schedule 5.4). 

(c) Each Subsidiary identified in Schedule 5.4 is a corporation or other legal entity duly organized, validly existing and in good standing under the
laws of its jurisdiction of organization, and is duly qualified as a foreign corporation or other legal entity and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which
the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each such Subsidiary has the corporate or other power and authority to own or hold under lease
the properties it purports to own or hold under lease and to transact the business it transacts and proposes to transact. 
 (d) No
Subsidiary is a party to, or otherwise subject to, any legal restriction or any agreement (other than this Agreement, the agreements listed on Schedule 5.4 and customary limitations imposed by corporate law statutes) restricting the ability of such
Subsidiary to pay dividends out of profits or make any other similar distributions of profits to the Company or any 

  

 -7- 

 Exhibit 10(z) (continued) 
  
 
of its Subsidiaries that owns outstanding shares of capital stock or similar equity interests of such Subsidiary. 
 Section 5.5. Financial Statements; Material Liabilities. The Company has delivered to each Purchaser copies of the financial statements of
the Company and its Subsidiaries listed on Schedule 5.5. All of said financial statements (including in each case the related schedules and notes) fairly present in all material respects the consolidated financial position of the Company and its
Subsidiaries as of the respective dates specified in such Schedule and the consolidated results of their operations and cash flows for the respective periods so specified and have been prepared in accordance with GAAP consistently applied throughout
the periods involved except as set forth in the notes thereto (subject, in the case of any interim financial statements, to normal year-end adjustments). The Company and its Subsidiaries do not have any Material liabilities that are not disclosed on
such financial statements or otherwise disclosed in the Disclosure Documents. 
 Section 5.6. Compliance with Laws, Other
Instruments, Etc. The execution, delivery and performance by the Company of this Agreement and the Series A Notes will not (a) contravene, result in any breach of, or constitute a default under, or result in the creation of any Lien
in respect of any property of the Company or any Subsidiary under, any (i) corporate charter or by-laws, (ii) material indenture, mortgage, deed of trust, loan, purchase or credit agreement or lease, or (iii) other material agreement
or instrument to which the Company or any Subsidiary is bound or by which the Company or any Subsidiary or any of their respective properties may be bound or affected, (b) conflict with or result in a breach of any of the terms, conditions or
provisions of any order, judgment, decree, or ruling of any court, arbitrator or Governmental Authority applicable to the Company or any Subsidiary, or (c) violate any provision of any statute or other rule or regulation of any Governmental
Authority applicable to the Company or any Subsidiary. 
 Section 5.7. Governmental Authorizations, Etc. No consent,
approval or authorization of, or registration, filing or declaration with, any Governmental Authority is required in connection with the execution, delivery or performance by the Company of this Agreement or the Series A Notes. 
 Section 5.8. Litigation; Observance of Agreements, Statutes and Orders. (a) There are no actions, suits, investigations or proceedings
pending or, to the knowledge of the Company, threatened against or affecting the Company or any Subsidiary or any property of the Company or any Subsidiary in any court or before any arbitrator of any kind or before or by any Governmental Authority
that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. 
 (b) Neither the Company nor any
Subsidiary is in default under any term of any agreement or instrument to which it is a party or by which it is bound, or any order, judgment, decree or ruling of any court, arbitrator or Governmental Authority or is in violation of any applicable
law, ordinance, rule or regulation (including without limitation Environmental Laws or the USA Patriot Act) of any Governmental Authority, which default or violation, individually or in the aggregate, would reasonably be expected to have a Material
Adverse Effect. 
  

 -8- 

 Exhibit 10(z) (continued) 
  
 Section 5.9. Taxes. The Company and its Subsidiaries have filed all income tax returns that are required to have
been filed in any jurisdiction, and have paid all taxes shown to be due and payable on such returns and all other taxes and assessments payable by them, to the extent such taxes and assessments have become due and payable and before they have become
delinquent, except for any taxes and assessments (a) the amount of which is not individually or in the aggregate Material or (b) the amount, applicability or validity of which is currently being contested in good faith by appropriate
proceedings and with respect to which the Company or a Subsidiary, as the case may be, has established adequate reserves in accordance with GAAP. The Company knows of no basis for any other tax or assessment that would reasonably be expected to have
a Material Adverse Effect. The charges, accruals and reserves on the books of the Company and its Subsidiaries in respect of federal, state or other taxes for all fiscal periods are adequate. The federal income tax liabilities of the Company and its
Subsidiaries have been finally determined (whether by reason of completed audits or the statute of limitations having run) for all fiscal years up to and including the fiscal year ended December 31, 2001. 
 Section 5.10. Title to Property; Leases. The Company and its Restricted Subsidiaries have good and sufficient title to their
respective properties which the Company and its Restricted Subsidiaries own or purport to own that individually or in the aggregate are Material, including all such properties reflected in the most recent audited balance sheet referred to in
Section 5.5 or purported to have been acquired by the Company or any Restricted Subsidiary after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this
Agreement. All leases that individually or in the aggregate are Material are valid and subsisting and are in full force and effect in all material respects. 
 Section 5.11. Licenses, Permits, Etc. Except as disclosed in Schedule 5.11, 
 (a)
the Company and its Restricted Subsidiaries own or possess all licenses, permits, franchises, authorizations, patents, copyrights, proprietary software, service marks, trademarks and trade names, or rights thereto, that individually or in the
aggregate are Material, without known conflict with the rights of others; 
 (b) to the best knowledge of the Company, no
product of the Company or any of its Restricted Subsidiaries infringes in any Material respect any license, permit, franchise, authorization, patent, copyright, proprietary software, service mark, trademark, trade name or other right owned by any
other Person; and 
 (c) to the best knowledge of the Company, there is no Material violation by any Person of any right of
the Company or any of its Restricted Subsidiaries with respect to any patent, copyright, proprietary software, service mark, trademark, trade name or other right owned or used by the Company or any of its Restricted Subsidiaries. 
 Section 5.12. Compliance with ERISA. (a) The Company and each ERISA Affiliate have operated and administered each Plan in compliance
with all applicable laws except for such instances of noncompliance as have not resulted in and would not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any ERISA Affiliate has incurred any liability pursuant
to Title I or IV of ERISA or the penalty or excise tax provisions of the 

  

 -9- 

 Exhibit 10(z) (continued) 
  
 
Code relating to employee benefit plans (as defined in section 3 of ERISA), and no event, transaction or condition has occurred or exists that would
reasonably be expected to result in the incurrence of any such liability by the Company or any ERISA Affiliate, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate, in either case
pursuant to Title I or IV of ERISA or to such penalty or excise tax provisions or to section 401(a)(29) or 412 of the Code or section 4068 of ERISA, other than such liabilities or Liens as would not be individually or in the aggregate Material.

 (b) The present value of the aggregate benefit liabilities under each of the Plans (other than Multiemployer Plans), determined as of the
end of such Plan’s most recently ended plan year on the basis of the actuarial assumptions specified for funding purposes in such Plan’s most recent actuarial valuation report, did not exceed the aggregate current value of the assets of
such Plan allocable to such benefit liabilities by more than $40,000,000 in the aggregate for all Plans. The term “benefit liabilities” has the meaning specified in section 4001 of ERISA and the terms “current
value” and “present value” have the meaning specified in section 3 of ERISA. 
 (c) The Company and its ERISA
Affiliates have not incurred any withdrawal liabilities (and are not subject to contingent withdrawal liabilities) under section 4201 or 4204 of ERISA in respect of Multiemployer Plans that individually or in the aggregate are Material. 

(d) The expected post-retirement benefit obligation (determined as of the last day of the Company’s most recently ended fiscal year in accordance
with Financial Accounting Standards Board Statement No. 106, without regard to liabilities attributable to continuation coverage mandated by section 4980B of the Code) of the Company and its Subsidiaries is an amount approximately equal to
$60,000,000. 
 (e) The execution and delivery of this Agreement and the issuance and sale of the Series A Notes hereunder will not involve
any transaction that is subject to the prohibitions of Section 406 of ERISA or in connection with which a tax would be imposed pursuant to Section 4975(c)(1)(A)-(D) of the Code. The representation by the Company in the first sentence
of this Section 5.12(e) is made in reliance upon and subject to the accuracy of each Purchaser’s representation in Section 6.3 as to the sources of the funds to be used to pay the purchase price of the Series A Notes to be purchased
by such Purchaser. 
 Section 5.13. Private Offering by the Company. Neither the Company nor anyone acting on the Company’s
behalf has offered the Series A Notes or any similar securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any Person other than the Purchasers and not more than 3
other Institutional Investors, each of which has been offered the Series A Notes in connection with a private sale for investment. Neither the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the
issuance or sale of the Series A Notes to the registration requirements of Section 5 of the Securities Act or to the registration requirements of any securities or blue sky laws of any applicable jurisdiction. 
 Section 5.14. Use of Proceeds; Margin Regulations. The Company will apply the proceeds of the sale of the Series A Notes to refinance
existing indebtedness, to purchase shares 

  

 -10- 

 Exhibit 10(z) (continued) 
  
 
of the capital stock of the Company which will be immediately retired and for general corporate purposes of the Company. No part of the proceeds from the
sale of the Series A Notes hereunder will be used, directly or indirectly, for the purpose of buying or carrying any margin stock within the meaning of Regulation U of the Board of Governors of the Federal Reserve System (12 CFR 221), other than a
portion of the proceeds that may be used to purchase the capital stock of the Company which will be immediately retired, or for the purpose of buying or carrying or trading in any securities under such circumstances as to involve the Company in a
violation of Regulation X of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12 CFR 220). Margin stock does not constitute more than 5% of the value of the consolidated assets of the Company
and its Subsidiaries and the Company does not have any present intention that margin stock will constitute more than 5% of the value of such assets (it being understood that for the purposes of making such representation, the Company has assumed
that the value of any treasury stock held by the Company is $0). As used in this Section, the terms “margin stock” and “purpose of buying or carrying” shall have the meanings assigned to them in said Regulation U.

 Section 5.15. Existing Debt; Future Liens. (a) Except as described therein, Schedule 5.15 sets forth a complete and
correct list of all outstanding Debt of the Company and its Restricted Subsidiaries as of September 30, 2006, since which date there has been no Material change in the amounts, interest rates, sinking funds, installment payments or maturities
of the Debt of the Company or its Restricted Subsidiaries. Neither the Company nor any Restricted Subsidiary is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Debt of the Company or
such Restricted Subsidiary, and no event or condition exists with respect to any Debt of the Company or any Restricted Subsidiary, that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such
Debt to become due and payable before its stated maturity or before its regularly scheduled dates of payment. 
 (b) Except as disclosed in
Schedule 5.15, neither the Company nor any Restricted Subsidiary has agreed or consented to cause or permit in the future (upon the happening of a contingency or otherwise) any of its property, whether now owned or hereafter acquired, to be subject
to a Lien not permitted by Section 10.3. 
 (c) Neither the Company nor any Subsidiary is a party to, or otherwise subject to any
provision contained in, any instrument evidencing Debt of the Company or such Subsidiary, any agreement relating thereto or any other agreement (including, but not limited to, its charter or other organizational document) which limits the amount of,
or otherwise imposes restrictions on the incurring of, Debt of the Company, except as specifically indicated in Schedule 5.15. 
 Section 5.16. Foreign Assets Control Regulations, Etc. (a) Neither the sale of the Series A Notes by the Company hereunder nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or any
of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto. 
  

 -11- 

 Exhibit 10(z) (continued) 
  
 (b) Neither the Company nor any Subsidiary is a Person described or designated in the Specially Designated Nationals and
Blocked Persons List of the Office of Foreign Assets Control or in Section 1 of the Anti-Terrorism Order or, to the knowledge of the Company, engages in any dealings or transactions with any such Person. The Company and its Subsidiaries are in
compliance, in all material respects, with the USA Patriot Act. 
 (c) No part of the proceeds from the sale of the Series A Notes hereunder
will be used, directly or indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain,
retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended, assuming in all cases that such Act applies to the Company. 
 Section 5.17. Status under Certain Statutes. Neither the Company nor any Restricted Subsidiary is an “investment company”
registered or required to be registered under the Investment Company Act of 1940, as amended, or is subject to regulation under the Public Utility Holding Company Act of 1935, as amended, the ICC Termination Act of 1995, as amended, or the Federal
Power Act, as amended. 
 Section 5.18. Environmental Matters. (a) Neither the Company nor any Restricted Subsidiary has
knowledge of any claim or has received any notice of any claim, and no proceeding has been instituted raising any claim against the Company or any of its Restricted Subsidiaries or any of their respective real properties now or formerly owned,
leased or operated by any of them, or other assets, alleging any damage to the environment or violation of any Environmental Laws, except, in each case, such as would not reasonably be expected to result in a Material Adverse Effect. 
 (b) Neither the Company nor any Restricted Subsidiary has knowledge of any facts which would give rise to any claim, public or private, of violation of
Environmental Laws or damage to the environment emanating from, occurring on or in any way related to real properties now or formerly owned, leased or operated by any of them or to other assets or their use, except, in each case, such as would not
reasonably be expected to result in a Material Adverse Effect. 
 (c) Neither the Company nor any of its Restricted Subsidiaries has stored
any Hazardous Materials on real properties now or formerly owned, leased or operated by any of them or has disposed of any Hazardous Materials in each case in a manner contrary to any Environmental Laws in each case in any manner that could
reasonably be expected to result in a Material Adverse Effect. 
 (d) All buildings on all real properties now owned, leased or operated by
the Company or any of its Restricted Subsidiaries are in compliance with applicable Environmental Laws, except where failure to comply could not reasonably be expected to result in a Material Adverse Effect. 
  

 -12- 

 Exhibit 10(z) (continued) 
  
 Section 5.19. Notes Rank Pari Passu. The obligations of the Company under this Agreement and the Notes rank
pari passu in right of payment with all other senior unsecured Debt (actual or contingent) of the Company, including, without limitation, all senior unsecured Debt of the Company described in Schedule 5.15 hereto. 
 SECTION 6. REPRESENTATIONS OF THE PURCHASER. 
 Section 6.1. Purchase for Investment. Each Purchaser severally represents that it is purchasing the Series A Notes for its own account
or for one or more separate accounts maintained by it or for the account of one or more pension or trust funds and not with a view to the distribution thereof (other than any Notes purchased by Banc of America Securities LLC on the Closing Date
which are intended to be resold to a “qualified institutional buyer” pursuant to Rule 144A of the Securities Act), provided that the disposition of such Purchaser’s or such pension or trust funds’ property shall at all
times be within such Purchaser’s or such pension or trust funds’ control. Each Purchaser understands that the Series A Notes have not been registered under the Securities Act and may be resold only if registered pursuant to the provisions
of the Securities Act or if an exemption from registration is available, except under circumstances where neither such registration nor such an exemption is required by law, and that the Company is not required to register the Series A Notes.

 Section 6.2. Accredited Investor. Each Purchaser represents that it is an “accredited investor” (as defined in Rule
501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act acting for its own account (and not for the account of others) or as a fiduciary or agent for others (which others are also “accredited investors”). Each
Purchaser further represents that such Purchaser has had the opportunity to ask questions of the Company and received answers concerning the terms and conditions of the sale of the Series A Notes. 
 Section 6.3. Source of Funds. Each Purchaser severally represents that at least one of the following statements is an accurate representation
as to each source of funds (a “Source”) to be used by such Purchaser to pay the purchase price of the Series A Notes to be purchased by such Purchaser hereunder: 
 (a) the Source is an “insurance company general account” (as the term is defined in the United States Department of Labor’s
Prohibited Transaction Exemption (“PTE”) 95-60) in respect of which the reserves and liabilities (as defined by the annual statement for life insurance companies approved by the National Association of Insurance Commissioners (the
“NAIC Annual Statement”)) for the general account contract(s) held by or on behalf of any employee benefit plan together with the amount of the reserves and liabilities for the general account contract(s) held by or on behalf of any
other employee benefit plans maintained by the same employer (or affiliate thereof as defined in PTE 95-60) or by the same employee organization in the general account do not exceed 10% of the total reserves and liabilities of the general account
(exclusive of separate account liabilities) plus surplus as set forth in the NAIC Annual Statement filed with such Purchaser’s state of domicile; or 
  

 -13- 

 Exhibit 10(z) (continued) 
  
 (b) the Source is a separate account that is maintained solely in connection with such Purchaser’s
fixed contractual obligations under which the amounts payable, or credited, to any employee benefit plan (or its related trust) that has any interest in such separate account (or to any participant or beneficiary of such plan (including any
annuitant)) are not affected in any manner by the investment performance of the separate account; or 
 (c) the Source is
either (i) an insurance company pooled separate account, within the meaning of PTE 90-1 or (ii) a bank collective investment fund, within the meaning of the PTE 91-38 and, except as disclosed by such Purchaser to the Company in writing
pursuant to this clause (c), no employee benefit plan or group of plans maintained by the same employer or employee organization beneficially owns more than 10% of all assets allocated to such pooled separate account or collective investment fund;
or 
 (d) the Source constitutes assets of an “investment fund” (within the meaning of Part V of PTE 84-14 (the
“QPAM Exemption”)) managed by a “qualified professional asset manager” or “QPAM” (within the meaning of Part V of the QPAM Exemption), no employee benefit plan’s assets that are included in such investment fund,
when combined with the assets of all other employee benefit plans established or maintained by the same employer or by an affiliate (within the meaning of Section V(c)(1) of the QPAM Exemption) of such employer or by the same employee organization
and managed by such QPAM, exceed 20% of the total client assets managed by such QPAM, the conditions of Part I(c) and (g) of the QPAM Exemption are satisfied, as of the last day of its most recent calendar quarter, the QPAM does not own a 10%
or more interest in the Company and no person controlling or controlled by the QPAM (applying the definition of “control” in Section V(e) of the QPAM Exemption) owns a 20% or more interest in the Company (or less than 20% but greater than
10%, if such person exercises control over the management or policies of the Company by reason of its ownership interest) and (i) the identity of such QPAM and (ii) the names of all employee benefit plans whose assets are included in such
investment fund have been disclosed to the Company in writing pursuant to this clause (d); or 
 (e) the Source constitutes
assets of a “plan(s)” (within the meaning of Section IV of PTE 96-23 (the “INHAM Exemption”)) managed by an “in-house asset manager” or “INHAM” (within the meaning of Part IV of the INHAM exemption),
the conditions of Part I(a), (g) and (h) of the INHAM Exemption are satisfied, neither the INHAM nor a person controlling or controlled by the INHAM (applying the definition of “control” in Section IV(d) of the INHAM Exemption)
owns a 5% or more interest in the Company and (i) the identity of such INHAM and (ii) the name(s) of the employee benefit plan(s) whose assets constitute the Source have been disclosed to the Company in writing pursuant to this clause (e);
or 
 (f) the Source is a governmental plan; or 
  

 -14- 

 Exhibit 10(z) (continued) 
  
 (g) the Source is one or more employee benefit plans, or a separate account or trust fund comprised of one
or more employee benefit plans, each of which has been identified to the Company in writing pursuant to this clause (g); or 
 (h) the Source does not include assets of any employee benefit plan, other than a plan exempt from the coverage of ERISA. 
 As used in this
Section 6.3, the terms “employee benefit plan,” “governmental plan,” and “separate account” shall have the respective meanings assigned to such terms in section 3 of ERISA. 
 SECTION 7. INFORMATION AS TO COMPANY. 
 Section 7.1. Financial and Business Information. The Company shall deliver to each holder of Notes that is an Institutional Investor:

 (a) Quarterly Statements — within 60 days after the end of each quarterly fiscal period in each fiscal year of
the Company (other than the last quarterly fiscal period of each such fiscal year), 
 (i) a consolidated balance sheet of the
Company and its Subsidiaries as at the end of such quarter, and 
 (ii) consolidated statements of income, changes in
shareholders’ equity and cash flows of the Company and its Subsidiaries, for such quarter and (in the case of the second and third quarters) for the portion of the fiscal year ending with such quarter, 
 setting forth in each case in comparative form the figures for the corresponding periods in the previous fiscal year, all in reasonable detail, prepared
in accordance with GAAP applicable to quarterly financial statements generally, and certified by a Senior Financial Officer as fairly presenting, in all material respects, the financial position of the companies being reported on and their results
of operations and cash flows, subject to changes resulting from year-end adjustments, provided that the Company shall be permitted to provide such deliveries electronically; 
 (b) Annual Statements — within 105 days after the end of each fiscal year of the Company, 
 (i) a consolidated balance sheet of the Company and its Subsidiaries, as at the end of such year, and 
 (ii) consolidated statements of income, changes in shareholders’ equity and cash flows of the Company and its Subsidiaries, for such
year, 

  

 -15- 

 Exhibit 10(z) (continued) 
  
 
setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and
accompanied by an opinion thereon of independent certified public accountants of recognized national standing, which opinion shall state that such financial statements present fairly, in all material respects, the financial position of the companies
being reported upon and their results of operations and cash flows and have been prepared in conformity with GAAP, and that the examination of such accountants in connection with such financial statements has been made in accordance with generally
accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the circumstances, provided that the Company shall be permitted to provide such deliveries electronically; 
 (c) Unrestricted Subsidiaries — In the event that one or more Unrestricted Subsidiaries shall either (i) own more than
10% of the total consolidated assets of the Company and its Subsidiaries, or (ii) account for more than 10% of the consolidated gross revenues of the Company and its Subsidiaries, determined in each case in accordance with GAAP, then, within
the respective periods provided in Section 7.1(a) and (b) above, the Company shall deliver to each holder of Notes that is an Institutional Investor, unaudited financial statements of the character and for the dates and periods as in said
Sections 7.1(a) and (b) covering such group of Unrestricted Subsidiaries (on a consolidated basis), together with a consolidating statement reflecting eliminations or adjustments required to reconcile the financial statements of such group of
Unrestricted Subsidiaries to the financial statements delivered pursuant to Sections 7.1(a) and (b); 
 (d) SEC and Other
Reports — except for filings referred to in Section 7.1(a) and (b) above, promptly upon their becoming available one copy of (i) each financial statement, report, notice or proxy statement sent by the Company or any
Subsidiary to public securities holders generally, and (ii) each regular or periodic report, each registration statement (without exhibits except as expressly requested by such holder), and each prospectus and all amendments thereto filed by
the Company or any Subsidiary with the Securities and Exchange Commission and of all press releases and other statements made available generally by the Company or any Subsidiary to the public concerning developments that are Material; 

(e) Notice of Default or Event of Default — promptly, and in any event within five Business Days after a Responsible
Officer becomes aware of the existence of any Default or Event of Default or that any Person has given any notice or taken any action with respect to a claimed default hereunder or that any Person has given any notice or taken any action with
respect to a claimed default of the type referred to in Section 11(g), a written notice specifying the nature and period of existence thereof and what action the Company is taking or proposes to take with respect thereto; 
 (f) ERISA Matters — promptly, and in any event within five Business Days after a Responsible Officer becomes aware of any of
the following, a written notice setting forth the nature thereof and the action, if any, that the Company or an ERISA Affiliate proposes to take with respect thereto: 
  

 -16- 

 Exhibit 10(z) (continued) 
  
 (i) with respect to any Plan, any reportable event, as defined in Section 4043(c) of ERISA and the
regulations thereunder, for which notice thereof has not been waived pursuant to such regulations as in effect on the date thereof; or 
 (ii) the taking by the PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Plan, or the receipt by the Company or any ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan; or 
 (iii) any event, transaction or condition that would result in the incurrence of any liability by the Company or any ERISA Affiliate
pursuant to Title I or IV of ERISA or the imposition of a penalty or excise tax under the provisions of the Code relating to employee benefit plans, or the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA
Affiliate pursuant to Title I or IV of ERISA or such penalty or excise tax provisions, if such liability or Lien, taken together with any other such liabilities or Liens then existing, would reasonably be expected to have a Material Adverse Effect;

 (g) Notices from Governmental Authority — promptly, and in any event within 30 days of receipt thereof, copies
of any notice to the Company or any Subsidiary from any federal or state Governmental Authority relating to any order, ruling, statute or other law or regulation that would reasonably be expected to have a Material Adverse Effect; 
 (h) Supplements — promptly and in any event within 10 Business Days after the execution and delivery of any Supplement, a copy
thereof; and 
 (i) Requested Information — with reasonable promptness, such other data and information relating
to the business, operations, affairs, financial condition, assets or properties of the Company or any of its Subsidiaries or relating to the ability of the Company to perform its obligations hereunder and under the Notes as from time to time may be
reasonably requested by any such holder of Notes or such information regarding the Company required to satisfy the requirements of 17 C.F.R. §230.144A, as amended from time to time, in connection with any contemplated transfer of the Notes.

 Section 7.2. Officer’s Certificate. Each set of financial statements delivered to a holder of Notes pursuant to
Section 7.1(a) or Section 7.1(b) hereof shall be accompanied by a certificate of a Senior Financial Officer setting forth: 
 (a) Covenant Compliance — the information required in order to establish whether the Company was in compliance with the requirements of Section 10.1 through Section 10.5 hereof, inclusive, during the quarterly or
annual period covered by the 

  

 -17- 

 Exhibit 10(z) (continued) 
  
 
statements then being furnished (including with respect to each such Section, where applicable, the calculations of the maximum or minimum amount, ratio or
percentage, as the case may be, permissible under the terms of such Sections, and the calculation of the amount, ratio or percentage then in existence); and 
 (b) Event of Default — a statement that such officer has reviewed the relevant terms hereof and such review shall not have
disclosed the existence during the quarterly or annual period covered by the statements then being furnished of any condition or event that constitutes a Default or an Event of Default or, if any such condition or event existed or exists, specifying
the nature and period of existence thereof and what action the Company shall have taken or proposes to take with respect thereto. 
 Section 7.3. Visitation. The Company shall permit the representatives of each holder of Notes that is an Institutional Investor: 
 (a) No Default — if no Default or Event of Default then exists, at the expense of such holder and upon reasonable prior notice to the Company, to visit the principal executive office of the Company, to
discuss the affairs, finances and accounts of the Company and its Subsidiaries with the Company’s officers, and (with the consent of the Company, which consent will not be unreasonably withheld) its independent public accountants, and (with the
consent of the Company, which consent will not be unreasonably withheld) to visit the other offices and properties of the Company and each Restricted Subsidiary, all at reasonable times but in no event more often than two times in any consecutive
twelve month period; and 
 (b) Default — if a Default or Event of Default then exists, at the expense of the
Company, to visit and inspect any of the offices or properties of the Company or any Restricted Subsidiary, to examine all their respective books of account, records, reports and other papers, to make copies and extracts therefrom, and to discuss
their respective affairs, finances and accounts with their respective officers and independent public accountants (and by this provision the Company authorizes said accountants to discuss the affairs, finances and accounts of the Company and its
Subsidiaries), all at such times and as often as may be requested. 
 SECTION 8. PAYMENT OF THE
NOTES. 
 Section 8.1. Required Prepayments. There are no required prepayments on the Series A Notes. The entire
unpaid principal amount of the Series A Notes shall become due and payable on December 5, 2011. 
 Section 8.2. Optional
Prepayments with Make-Whole Amount. The Company may, at its option, upon notice as provided below, prepay at any time all, or from time to time any part of, the Notes, in an amount not less than 10% of the original aggregate principal amount of
the Notes to be prepaid in the case of a partial prepayment (or such lesser amount as shall be required to effect a partial prepayment resulting from an offer of prepayment pursuant to Section 10.4), at 100% of the principal amount so prepaid,
together with interest accrued thereon 

  

 -18- 

 Exhibit 10(z) (continued) 
  
 
to the date of such prepayment, plus the Make-Whole Amount determined for the prepayment date with respect to such principal amount of each Note then
outstanding. The Company will give each holder of Notes written notice of each optional prepayment under this Section 8.2 not less than 30 days and not more than 60 days prior to the date fixed for such prepayment. Each such notice shall
specify such date, the aggregate principal amount of the Notes of the applicable Series to be prepaid on such date, the principal amount of each Note held by such holder to be prepaid (determined in accordance with Section 8.3), and the
interest to be paid on the prepayment date with respect to such principal amount being prepaid, and shall be accompanied by a certificate of a Senior Financial Officer as to the estimated applicable Make-Whole Amount due in connection with such
prepayment (calculated as if the date of such notice were the date of the prepayment), setting forth the details of such computation. Two Business Days prior to such prepayment, the Company shall deliver to each holder of Notes of the Series to be
prepaid a certificate of a Senior Financial Officer specifying the calculation of each such Make-Whole Amount as of the specified prepayment date. 
 Section 8.3. Allocation of Partial Prepayments. In the case of each partial prepayment of the Notes pursuant to the provisions of Section 8.2, the principal amount of the Notes to be prepaid shall be allocated among all of
the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid principal amounts thereof. All regularly scheduled partial prepayments made with respect to any Series of Additional Notes pursuant to any Supplement
shall be allocated as provided therein. 
 Section 8.4. Maturity; Surrender, Etc. In the case of each prepayment of Notes
pursuant to this Section 8, the principal amount of each Note to be prepaid shall mature and become due and payable on the date fixed for such prepayment (which shall be a Business Day), together with interest on such principal amount accrued
to such date and the applicable Make-Whole Amount. From and after such date, unless the Company shall fail to pay such principal amount when so due and payable, together with the interest and Make-Whole Amount as aforesaid, interest on such
principal amount shall cease to accrue. Any Note paid or prepaid in full shall be surrendered to the Company and cancelled and shall not be reissued, and no Note shall be issued in lieu of any prepaid principal amount of any Note. 
 Section 8.5. Purchase of Notes. The Company will not and will not permit any Affiliate to purchase, redeem, prepay or otherwise acquire,
directly or indirectly, any of the outstanding Notes except (a) upon the payment or prepayment of the Notes in accordance with the terms of this Agreement (including any Supplement hereto) and the Notes or (b) pursuant to a written offer
to purchase any outstanding Notes made by the Company or an Affiliate pro rata to the holders of the Notes upon the same terms and conditions. The Company will promptly cancel all Notes acquired by it or any Affiliate pursuant to any payment,
prepayment or purchase of Notes pursuant to any provision of this Agreement and no Notes may be issued in substitution or exchange for any such Notes. 
 Section 8.6. Make-Whole Amount for the Series A Notes. The term “Make-Whole Amount” means with respect to any Series A Note an amount equal to the excess, if any, of the Discounted Value
of the Remaining Scheduled Payments with respect to the Called Principal of such Series A Note, over the amount of such Called Principal, provided that the Make-Whole 

  

 -19- 

 Exhibit 10(z) (continued) 
  
 
Amount may in no event be less than zero. For the purposes of determining the Make-Whole Amount, the following terms have the following meanings with respect
to the Called Principal of such Series A Note: 
 “Called Principal” means, the principal of any Series A
Note that is to be prepaid pursuant to Section 8.2 or has become or is declared to be immediately due and payable pursuant to Section 12.1, as the context requires. 
 “Discounted Value” means, the amount obtained by discounting all Remaining Scheduled Payments from their respective
scheduled due dates to the Settlement Date with respect to such Called Principal, in accordance with accepted financial practice and at a discount factor (applied on the same periodic basis as that on which interest on such Note is payable) equal to
the Reinvestment Yield. 
 “Reinvestment Yield” means, 0.50% plus the yield to maturity calculated by using
(i) the yields reported, as of 10:00 A.M. (New York City time) on the second Business Day preceding the Settlement Date on screen “PX-1” on the Bloomberg Financial Market Service (or such other information service as may replace
Bloomberg) for actively traded U.S. Treasury securities having a maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date, or (ii) if such yields are not reported as of such time or the yields reported as
of such time are not ascertainable, the Treasury Constant Maturity Series Yields reported, for the latest day for which such yields have been so reported as of the second Business Day preceding the Settlement Date, in Federal Reserve Statistical
Release H.15 (519) (or any comparable successor publication) for actively traded U.S. Treasury securities having a constant maturity equal to the Remaining Average Life of such Called Principal as of such Settlement Date. In either case, the
yield will be determined, if necessary, by (a) converting U.S. Treasury bill quotations to bond-equivalent yields in accordance with accepted financial practice and (b) interpolating linearly on a straight line basis between (1) the
actively traded U.S. Treasury security with the maturity closest to and greater than the Remaining Average Life and (2) the actively traded U.S. Treasury security with the maturity closest to and less than the Remaining Average Life.

 “Remaining Average Life” means, the number of years (calculated to the nearest one-twelfth year) obtained
by dividing (i) such Called Principal into (ii) the sum of the products obtained by multiplying (a) the principal component of each Remaining Scheduled Payment by (b) the number of years (calculated to the nearest one-twelfth
year) that will elapse between the Settlement Date and the scheduled due date of such Remaining Scheduled Payment. 
 “Remaining Scheduled Payments” means, all payments of such Called Principal and interest thereon that would be due after the Settlement Date if no payment of such Called Principal were made prior to its scheduled due date,
provided that if such Settlement Date is not a date on which interest payments are due to be made under the terms of such Note, then the amount of the next succeeding scheduled interest payment 

  

 -20- 

 Exhibit 10(z) (continued) 
  
 
will be reduced by the amount of interest accrued to such Settlement Date and required to be paid on such Settlement Date pursuant to Section 8.2 or
12.1. 
 “Settlement Date” means, the date on which such Called Principal is to be prepaid pursuant to
Section 8.2 or has become or is declared to be immediately due and payable pursuant to Section 12.1, as the context requires. 
 Section 8.7. Change in Control. (a) Notice of Change in Control or Control Event. The Company will, within 15 Business Days after any Responsible Officer has knowledge of the occurrence of any Change in Control or
Control Event, give written notice of such Change in Control or Control Event to each holder of Notes unless notice in respect of such Change in Control (or the Change in Control contemplated by such Control Event) shall have been given
pursuant to subparagraph (b) of this Section 8.7. If a Change in Control has occurred, such notice shall contain and constitute an offer to prepay Notes of each Series as described in Section 8.7(c) and shall be accompanied by the
certificate described in Section 8.7(g). 
 (b) Condition to Company Action. The Company will not take any action that
consummates or finalizes a Change in Control unless (i) at least 15 Business Days prior to such action it shall have given to each holder of Notes written notice containing and constituting an offer to prepay Notes as described in
Section 8.7(c), accompanied by the certificate described in Section 8.7(g), and (ii) contemporaneously with such action, it prepays all Notes required to be prepaid in accordance with this Section 8.7. 
 (c) Offer to Prepay Notes. The offer to prepay Notes contemplated by Section 8.7(a) and (b) shall be an offer to prepay, in accordance
with and subject to this Section 8.7, all, but not less than all, the Notes held by each holder (in this case only, “holder” in respect of any Note registered in the name of a nominee for a disclosed beneficial owner shall mean
such beneficial owner) on a date specified in such offer (the “Proposed Prepayment Date”). If such Proposed Prepayment Date is in connection with an offer contemplated by Section 8.7(a), such date shall be not less than 45 days
and not more than 60 days after the date of such offer (if the Proposed Prepayment Date shall not be specified in such offer, the Proposed Prepayment Date shall be the 60th day after the date of such offer). 
 (d) Acceptance and Rejection. A holder of Notes may accept or reject the offer to prepay made pursuant to this Section 8.7 by causing a
notice of such acceptance or rejection to be delivered to the Company at least 15 days prior to the Proposed Prepayment Date. A failure by a holder of Notes to respond to an offer to prepay made pursuant to this Section 8.7 shall be deemed to
constitute a rejection of such offer by such holder. 
 (e) Prepayment. Prepayment of the Notes to be prepaid pursuant to this
Section 8.7 shall be at 100% of the principal amount of such Notes, together with interest on such Notes accrued to the date of prepayment. The prepayment shall be made on the Proposed Prepayment Date except as provided in Section 8.7(f).

  

 -21- 

 Exhibit 10(z) (continued) 
  
 (f) Deferral Pending Change in Control. The obligation of the Company to prepay Notes pursuant to the offers required
by subparagraph (a) or (b) and accepted in accordance with subparagraph (d) of this Section 8.7 is subject to the occurrence of the Change in Control in respect of which such offers and acceptances shall have been made. In the
event that such Change in Control does not occur on the Proposed Prepayment Date in respect thereof, the prepayment shall be deferred until and shall be made on the date on which such Change in Control occurs. The Company shall keep each holder of
Notes reasonably and timely informed of (i) any such deferral of the date of prepayment, (ii) the date on which such Change in Control and the prepayment are expected to occur, and (iii) any determination by the Company that efforts
to effect such Change in Control have ceased or been abandoned (in which case the offers and acceptances made pursuant to this Section 8.7 in respect of such Change in Control shall be deemed rescinded). 
 (g) Officer’s Certificate. Each offer to prepay the Notes pursuant to this Section 8.7 shall be accompanied by a certificate, executed
by a Senior Financial Officer of the Company and dated the date of such offer, specifying: (i) the Proposed Prepayment Date; (ii) that such offer is made pursuant to this Section 8.7; (iii) the principal amount of each Note
offered to be prepaid; (iv) the interest that would be due on each Note offered to be prepaid, accrued to the Proposed Prepayment Date; (v) that the conditions of this Section 8.7 have been fulfilled; and (vi) in reasonable
detail, the nature and date or proposed date of the Change in Control. 
 SECTION 9. AFFIRMATIVE COVENANTS.

 The Company covenants that so long as any of the Notes are outstanding: 
 Section 9.1. Compliance with Law. Without limiting Section 10.7, the Company will, and will cause each of its Subsidiaries to, comply
with all laws, ordinances or governmental rules or regulations to which each of them is subject, including, without limitation, ERISA, the USA Patriot Act and Environmental Laws, and will obtain and maintain in effect all licenses, certificates,
permits, franchises and other governmental authorizations necessary to the ownership of their respective properties or to the conduct of their respective businesses, in each case to the extent necessary to ensure that non-compliance with such laws,
ordinances or governmental rules or regulations or failures to obtain or maintain in effect such licenses, certificates, permits, franchises and other governmental authorizations would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. 
 Section 9.2. Insurance. The Company will, and will cause each of its Restricted Subsidiaries
to, maintain, with financially sound and reputable insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms and in such amounts (including deductibles,
co-insurance and self-insurance, if adequate reserves are maintained with respect thereto) as is customary in the case of entities of established reputations engaged in the same or a similar business and similarly situated except for any
non-maintenance that would not reasonably be expected to have a Material Adverse Effect. 
  

 -22- 

 Exhibit 10(z) (continued) 
  
 Section 9.3. Maintenance of Properties. The Company will, and will cause each of its Restricted Subsidiaries to,
maintain and keep, or cause to be maintained and kept, their respective properties in good repair, working order and condition (other than ordinary wear and tear), so that the business carried on in connection therewith may be properly conducted at
all times, provided that this Section shall not prevent the Company or any Restricted Subsidiary from discontinuing the operation and the maintenance of any of its properties if such discontinuance is desirable in the conduct of its business
and the Company has concluded that such discontinuance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 9.4. Payment of Taxes and Claims. The Company will, and will cause each of its Subsidiaries to, file all income or similar tax returns required to be filed in any jurisdiction and to pay and
discharge all taxes shown to be due and payable on such returns and all other taxes, assessments, governmental charges, or levies payable by any of them, to the extent such taxes and assessments have become due and payable and before they have
become delinquent, and all claims for which sums have become due and payable that have or might become a Lien on properties or assets of the Company or any Subsidiary not permitted by Section 10.3, provided that neither the Company nor
any Subsidiary need pay any such tax or assessment or claim if (i) the amount, applicability or validity thereof is contested by the Company or such Subsidiary on a timely basis in good faith and in appropriate proceedings, and the Company or a
Subsidiary has established adequate reserves therefor in accordance with GAAP on the books of the Company or such Subsidiary or (ii) the non-filing or nonpayment, as the case may be, of all such taxes and assessments and claims in the aggregate
would not reasonably be expected to have a Material Adverse Effect. 
 Section 9.5. Corporate Existence, Etc. Subject to Sections
10.4 and 10.5, the Company will at all times preserve and keep in full force and effect its corporate existence, and will at all times preserve and keep in full force and effect the corporate existence of each of its Restricted Subsidiaries (unless
merged into the Company or a Restricted Subsidiary) and all rights and franchises of the Company and its Restricted Subsidiaries unless, in the good faith judgment of the Company, the termination of or failure to preserve and keep in full force and
effect such corporate existence, right or franchise would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 9.6. Designation of Subsidiaries. The Company may from time to time cause any Subsidiary (other than a Subsidiary Guarantor) to be designated as an Unrestricted Subsidiary or any Unrestricted
Subsidiary to be designated a Restricted Subsidiary; provided, however, that at the time of such designation and immediately after giving effect thereto, (a) no Default or Event of Default would exist under the terms of this Agreement,
and (b) the Company and its Restricted Subsidiaries would be in compliance with all of the covenants set forth in this Section 9 and Section 10 if tested on the date of such action and provided, further, that once a Subsidiary
has been designated an Unrestricted Subsidiary, it shall not thereafter be redesignated as a Restricted Subsidiary on more than one occasion and once a Subsidiary has been designated a Restricted Subsidiary, it shall not thereafter be redesignated
as an Unrestricted Subsidiary on more than one occasion. Within ten (10) days following any designation described above, the Company will deliver to you a notice of such designation accompanied by a certificate signed by 

  

 -23- 

 Exhibit 10(z) (continued) 
  
 
a Senior Financial Officer of the Company certifying compliance with all requirements of this Section 9.6 and setting forth all information required in
order to establish such compliance. 
 Section 9.7. Notes to Rank Pari Passu. The Notes and all other obligations under this
Agreement of the Company are and at all times shall remain direct and unsecured obligations of the Company ranking pari passu as against the assets of the Company with all other Notes from time to time issued and outstanding hereunder without
any preference among themselves and pari passu with all outstanding Debt of the Company in an original principal amount in excess of $10,000,000 which is not expressed to be subordinate or junior in rank to any other unsecured Debt of the
Company. 
 Section 9.8. Subsidiary Guarantors. The Company will cause any Subsidiary which is required by the terms of any Debt
of the Company in an original principal amount in excess of $10,000,000 to become a party to, or otherwise guarantee, such Debt to deliver to each of the holders of the Notes (concurrently with the incurrence of any such obligation) the following
items: 
 (a) a duly executed Subsidiary Guaranty in scope, form and substance satisfactory to the Required Holders;

 (b) a certificate signed by an authorized Responsible Officer of the Company making representations and warranties to the
effect of those contained in Sections 5.4, 5.6 and 5.7, with respect to such Subsidiary and the Subsidiary Guaranty, as applicable; and 
 (c) an opinion of counsel (who may be in-house counsel for the Company) addressed to each of the holders of the Notes satisfactory to the Required Holders, to the effect that the Subsidiary Guaranty by such Person has
been duly authorized, executed and delivered and that the Subsidiary Guaranty constitutes the legal, valid and binding contract and agreement of such Person enforceable in accordance with its terms, except as an enforcement of such terms may be
limited by bankruptcy, insolvency, fraudulent conveyance and similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles. 
 Section 9.9. Books and Records. The Company will, and will cause each of its Restricted Subsidiaries to, maintain proper books of record and
account in conformity with GAAP and all applicable requirements of any Governmental Authority having legal or regulatory jurisdiction over the Company or such Restricted Subsidiary, as the case may be. 
 SECTION 10. NEGATIVE COVENANTS. 
 The Company covenants that so long as any of the Notes are outstanding: 
 Section 10.1. Consolidated
Debt to Consolidated Total Capitalization. The Company will not at any time permit the ratio of Consolidated Debt to Consolidated Total Capitalization to exceed 60%. 
  

 -24- 

 Exhibit 10(z) (continued) 
  
 Section 10.2. Priority Debt. The Company will not at any time permit the aggregate amount of all Priority Debt
to exceed 30% of Consolidated Net Worth, (Consolidated Net Worth to be determined as of the end of the then most recently ended fiscal quarter of the Company). 
 Section 10.3. Limitation on Liens. The Company will not, and will not permit any of its Restricted Subsidiaries to, directly or indirectly create, incur, assume or permit to exist (upon the happening of a
contingency or otherwise) any Lien on or with respect to any property or asset (including, without limitation, any document or instrument in respect of goods or accounts receivable) of the Company or any such Restricted Subsidiary, whether now owned
or held or hereafter acquired, or any income or profits therefrom, or assign or otherwise convey any right to receive income or profits (unless it makes, or causes to be made, effective provision whereby the Notes will be equally and ratably secured
with any and all other obligations thereby secured, such security to be pursuant to an agreement reasonably satisfactory to the Required Holders and, in any such case, the Notes shall have the benefit, to the fullest extent that, and with such
priority as, the holders of the Notes may be entitled under applicable law, of an equitable Lien on such property), except: 
 (a) Liens for taxes, assessments or other governmental charges that are not yet due and payable or the payment of which is not at the time required by Section 9.4; 
 (b) any attachment or judgment Lien, unless the judgment it secures shall not, within 60 days after the entry thereof, have been
discharged or execution thereof stayed pending appeal, or shall not have been discharged within 60 days after the expiration of any such stay; 
 (c) Liens incidental to the conduct of business or the ownership of properties and assets (including landlords’, carriers’, warehousemen’s, mechanics’, materialmen’s and other similar Liens
for sums not yet due and payable) and Liens to secure the performance of bids, tenders, leases, or trade contracts, or to secure statutory obligations (including obligations under workers compensation, unemployment insurance and other social
security legislation), surety or appeal bonds or other Liens incurred in the ordinary course of business and not in connection with the borrowing of money; 
 (d) leases or subleases granted to others, easements, rights-of-way, restrictions and other similar charges or encumbrances, in each case incidental to the ownership of property or assets or the ordinary conduct of
the business of the Company or any of its Restricted Subsidiaries, or Liens incidental to minor survey exceptions and the like, provided that such Liens do not, in the aggregate, materially detract from the value of such property; 

(e) Liens securing Debt of a Restricted Subsidiary to the Company or to a Restricted Subsidiary; 
 (f) Liens existing as of the Closing Date and reflected in Schedule 10.3; 
  

 -25- 

 Exhibit 10(z) (continued) 
  
 (g) Liens incurred after the Closing Date given to secure the payment of the purchase price incurred in
connection with the acquisition, construction or improvement of property (other than accounts receivable or inventory) useful and intended to be used in carrying on the business of the Company or a Restricted Subsidiary, including Liens existing on
such property at the time of acquisition or construction thereof or Liens incurred within 365 days of such acquisition or completion of such construction or improvement, provided that (i) the Lien shall attach solely to the property
acquired, purchased, constructed or improved; (ii) at the time of acquisition, construction or improvement of such property (or, in the case of any Lien incurred within three hundred sixty-five (365) days of such acquisition or completion
of such construction or improvement, at the time of the incurrence of the Debt secured by such Lien), the aggregate amount remaining unpaid on all Debt secured by Liens on such property, whether or not assumed by the Company or a Restricted
Subsidiary, shall not exceed the lesser of (y) the cost of such acquisition, construction or improvement or (z) the Fair Market Value of such property (as determined in good faith by one or more officers of the Company to whom authority to
enter into the transaction has been delegated by the board of directors of the Company); and (iii) at the time of such incurrence and after giving effect thereto, no Default or Event of Default would exist; 
 (h) any Lien existing on property of a Person immediately prior to its being consolidated with or merged into the Company or a Restricted
Subsidiary or its becoming a Restricted Subsidiary (other than pursuant to Section 9.6), or any Lien existing on any property acquired by the Company or any Restricted Subsidiary at the time such property is so acquired (whether or not the Debt
secured thereby shall have been assumed), provided that (i) no such Lien shall have been created or assumed in contemplation of such consolidation or merger or such Person’s becoming a Restricted Subsidiary or such acquisition of
property, (ii) each such Lien shall extend solely to the item or items of property so acquired and, if required by the terms of the instrument originally creating such Lien, other property which is an improvement to or is acquired for specific
use in connection with such acquired property, and (iii) at the time of such incurrence and after giving effect thereto, no Default or Event of Default would exist; 
 (i) any extensions, renewals or replacements of any Lien permitted by the preceding subparagraphs (f), (g) and (h) of this
Section 10.3, provided that (i) no additional property shall be encumbered by such Liens, (ii) the unpaid principal amount of the Debt or other obligations secured thereby shall not be increased on or after the date of any
extension, renewal or replacement, and (iii) at such time and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing; 
 (j) Liens securing Priority Debt of the Company or any Restricted Subsidiary, provided that the aggregate principal amount of any
such Priority Debt shall be permitted by Section 10.2. 
 Section 10.4. Sales of Assets. The Company will not, and will not
permit any Restricted Subsidiary to, sell, lease or otherwise dispose of any substantial part (as defined below) of the 

  

 -26- 

 Exhibit 10(z) (continued) 
  
 
assets of the Company and its Restricted Subsidiaries; provided, however, that the Company or any Restricted Subsidiary may sell, lease or otherwise
dispose of assets constituting a substantial part of the assets of the Company and its Restricted Subsidiaries if such assets are sold in an arms length transaction and, at such time and after giving effect thereto, no Default or Event of Default
shall have occurred and be continuing and an amount equal to the net proceeds received from such sale, lease or other disposition (but only with respect to that portion of such assets that exceeds the definition of “substantial part” set
forth below) shall be used within 365 days of such sale, lease or disposition, in any combination: 
 (1) to acquire
productive assets used or useful in carrying on the business of the Company and its Restricted Subsidiaries and having a value at least equal to the value of such assets sold, leased or otherwise disposed of; and/or 
 (2) to prepay or retire Senior Debt of the Company and/or its Restricted Subsidiaries, provided that (i) the Company shall
offer to prepay each outstanding Note in a principal amount which equals the Ratable Portion for such Note, and (ii) any such prepayment of the Notes shall be made at par, together with accrued interest thereon to the date of such prepayment,
but without the payment of the Make-Whole Amount. Any offer of prepayment of the Notes pursuant to this Section 10.4 shall be given to each holder of the Notes by written notice that shall be delivered not less than fifteen (15) days and
not more than sixty (60) days prior to the proposed prepayment date. Each such notice shall state that it is given pursuant to this Section and that the offer set forth in such notice must be accepted by such holder in writing and shall also
set forth (i) the prepayment date, (ii) a description of the circumstances which give rise to the proposed prepayment and (iii) a calculation of the Ratable Portion for such holder’s Notes. Each holder of the Notes which desires
to have its Notes prepaid shall notify the Company in writing delivered not less than five (5) Business Days prior to the proposed prepayment date of its acceptance of such offer of prepayment. Prepayment of Notes pursuant to this
Section 10.4 shall be made in accordance with Section 8.2 (but without payment of the Make-Whole Amount). 
 As used in this
Section 10.4, a sale, lease or other disposition of assets shall be deemed to be a “substantial part” of the assets of the Company and its Restricted Subsidiaries if the book value of such assets, when added to the book value of all
other assets sold, leased or otherwise disposed of by the Company and its Restricted Subsidiaries during the period of 12 consecutive months ending on the date of such sale, lease or other disposition, exceeds 10% of the book value of Consolidated
Total Assets, determined as of the end of the fiscal quarter immediately preceding such sale, lease or other disposition; provided that there shall be excluded from any determination of a “substantial part” any (i) sale or
disposition of assets in the ordinary course of business of the Company and its Restricted Subsidiaries, (ii) any transfer of assets from the Company to any Restricted Subsidiary or from any Restricted Subsidiary to the Company or a Restricted
Subsidiary and (iii) any sale or transfer of property acquired by the Company or any Restricted Subsidiary after the date of this Agreement to any Person within 365 days following the acquisition or construction of such property by the Company
or any Restricted Subsidiary if the Company or a Restricted Subsidiary shall concurrently with such sale or transfer, lease such property, as lessee. 
  

 -27- 

 Exhibit 10(z) (continued) 
  
 Section 10.5. Merger and Consolidation. The Company will not, and will not permit any of its Restricted
Subsidiaries to, consolidate with or merge with any other Person or convey, transfer or lease substantially all of its assets in a single transaction or series of transactions to any Person; provided that: 
 (1) any Restricted Subsidiary of the Company may (x) consolidate with or merge with, or convey, transfer or lease substantially all
of its assets in a single transaction or series of transactions to, (i) the Company or a Restricted Subsidiary so long as in any merger or consolidation involving the Company, the Company shall be the surviving or continuing corporation or
(ii) any other Person so long as the survivor is the Restricted Subsidiary, or (y) convey, transfer or lease all of its assets in compliance with the provisions of Section 10.4; and 
 (2) the foregoing restriction does not apply to the consolidation or merger of the Company with, or the conveyance, transfer or lease of
substantially all of the assets of the Company in a single transaction or series of transactions to, any Person so long as: 
 (a) the successor formed by such consolidation or the survivor of such merger or the Person that acquires by conveyance, transfer or lease substantially all of the assets of the Company as an entirety, as the case may be (the
“Successor Corporation”), shall be a solvent entity organized and existing under the laws of the United States of America, any State thereof or the District of Columbia; 
 (b) if the Company is not the Successor Corporation, such Successor Corporation shall have executed and delivered to each holder of Notes
its assumption of the due and punctual performance and observance of each covenant and condition of this Agreement (and each Supplement thereto) and the Notes (pursuant to such agreements and instruments as shall be reasonably satisfactory to the
Required Holders), and the Successor Corporation shall have caused to be delivered to each holder of Notes (A) an opinion of nationally recognized independent counsel, to the effect that all agreements or instruments effecting such assumption
are enforceable in accordance with their terms and (B) if applicable, an acknowledgment from each Subsidiary Guarantor that the Subsidiary Guaranty continues in full force and effect; and 
 (c) immediately after giving effect to such transaction no Default or Event of Default would exist. 
 Section 10.6. Transactions with Affiliates. The Company will not and will not permit any Restricted Subsidiary to enter into directly or
indirectly any Material transaction or Material group of related transactions (including without limitation the purchase, lease, sale or exchange of properties of any kind or the rendering of any service) with any Affiliate (other than the Company
or another Restricted Subsidiary), except pursuant to the reasonable requirements of the Company’s or such Restricted Subsidiary’s business and upon fair and reasonable terms that are not less favorable to the Company or such Restricted
Subsidiary than would be obtainable in a comparable arm’s-length transaction with a Person not an Affiliate. 
  

 -28- 

 Exhibit 10(z) (continued) 
  
 Section 10.7. Terrorism Sanctions Regulations. The Company will not and will not permit any Subsidiary to
(a) become a Person described or designated in the Specially Designated Nationals and Blocked Persons List of the Office of Foreign Assets Control or in Section 1 of the Anti-Terrorism Order or (b) engage in any dealings or
transactions with any such Person. 
 SECTION 11. EVENTS OF DEFAULT. 
 An “Event of Default” shall exist if any of the following conditions or events shall occur and be continuing: 
 (a) the Company defaults in the payment of any principal or Make-Whole Amount, if any, on any Note when the same becomes due and payable,
whether at maturity or at a date fixed for prepayment or by declaration or otherwise; or 
 (b) the Company defaults in the
payment of any interest on any Note for more than five Business Days after the same becomes due and payable; or 
 (c) the
Company defaults in the performance of or compliance with any term contained in Section 10 or any covenant in a Supplement which specifically provides that it shall have the benefit of this paragraph (c) or any Subsidiary Guarantor
defaults in the performance of or compliance with any term of the Subsidiary Guaranty beyond any period of grace or cure period provided with respect thereto; or 
 (d) the Company defaults in the performance of or compliance with any term contained in Sections 10.3, 10.5 and 10.6 and such default is
not remedied with five (5) days after the earlier of (i) a Responsible Officer obtaining actual knowledge of such default and (ii) the Company receiving written notice of such default from any holder of a Note (any such written notice
to be identified as a “notice of default” and to refer specifically to this paragraph (d) of Section 11); or 
 (e) the Company defaults in the performance of or compliance with any term contained herein or in any Supplement (other than those referred to in paragraphs (a), (b), (c) and (d) of this Section 11) and such default is not
remedied within 30 days after the earlier of (i) a Responsible Officer obtaining actual knowledge of such default or (ii) the Company receiving written notice of such default from any holder of a Note (any such written notice to be
identified as a “notice of default” and to refer specifically to this paragraph (d) of Section 11); or 
 (f) following the execution and delivery of any Subsidiary Guaranty pursuant to Section 9.8 hereof, if any Subsidiary Guaranty ceases to be a legally valid, binding and enforceable obligation or contract of a Subsidiary Guarantor, or
any Subsidiary Guarantor or any party by, through or on account of any such Person, challenges the validity, binding nature or enforceability of any such Subsidiary Guaranty; or 
  

 -29- 

 Exhibit 10(z) (continued) 
  
 (g) any representation or warranty made in writing by or on behalf of the Company or Subsidiary Guarantor in
this Agreement or any Subsidiary Guaranty or by any officer of the Company or any Subsidiary Guarantor in any writing furnished in connection with the transactions contemplated hereby or by any Subsidiary Guaranty proves to have been false or
incorrect in any material respect on the date as of which made; or 
 (h) (i) the Company or any Restricted Subsidiary is
in default (as principal or as guarantor or other surety) in the payment of any principal of or premium or make-whole amount or interest (in the payment amount of at least $100,000) on any Debt other than the Notes that is outstanding in an
aggregate principal amount of at least $10,000,000 beyond any period of grace provided with respect thereto, or (ii) the Company or any Restricted Subsidiary is in default in the performance of or compliance with any term of any instrument,
mortgage, indenture or other agreement relating to any Debt other than the Notes in an aggregate principal amount of at least $10,000,000 or any other condition exists, and as a consequence of such default or condition such Debt has become, or has
been declared, due and payable, or (iii) as a consequence of the occurrence or continuation of any event or condition (other than the passage of time or the right of the holder of Debt to convert such Debt into equity interests), the Company or
any Restricted Subsidiary has become obligated to purchase or repay Debt other than the Notes before its regular maturity or before its regularly scheduled dates of payment in an aggregate outstanding principal amount of at least $10,000,000; or

 (i) the Company, any Material Subsidiary or any Subsidiary Guarantor (i) is generally not paying, or admits in writing
its inability to pay, its debts as they become due, (ii) files, or consents by answer or otherwise to the filing against it of, a petition for relief or reorganization or arrangement or any other petition in bankruptcy, for liquidation or to
take advantage of any bankruptcy, insolvency, reorganization, moratorium or other similar law of any jurisdiction, (iii) makes an assignment for the benefit of its creditors, (iv) consents to the appointment of a custodian, receiver,
trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, (v) is adjudicated as insolvent or to be liquidated, or (vi) takes corporate action for the purpose of any of the
foregoing; or 
 (j) a court or governmental authority of competent jurisdiction enters an order appointing, without consent
by the Company, any of its Material Subsidiaries or any Subsidiary Guarantor, a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, or constituting an order
for relief or approving a petition for relief or reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or
liquidation of the Company, any of its Material Subsidiaries or any Subsidiary Guarantor, or any such petition shall be filed against the Company, any of its Material Subsidiaries or any Subsidiary Guarantor and such petition shall not be dismissed
within 60 days; or 
  

 -30- 

 Exhibit 10(z) (continued) 
  
 (k) a final judgment or judgments at any one time outstanding for the payment of money aggregating in excess
of $10,000,000 (other than any judgment in which a third party insurance provider has agreed in writing that it shall pay the full amount of such judgment) are rendered against one or more of the Company, its Restricted Subsidiaries or any
Subsidiary Guarantor and which judgments are not, within 60 days after entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within 60 days after the expiration of such stay; or 
 (l) if (i) any Plan shall fail to satisfy the minimum funding standards of ERISA or the Code for any plan year or part thereof or a
waiver of such standards or extension of any amortization period is sought or granted under Section 412 of the Code, (ii) a notice of intent to terminate any Plan shall have been or is reasonably expected to be filed with the PBGC or the
PBGC shall have instituted proceedings under Section 4042 of ERISA to terminate or appoint a trustee to administer any Plan or the PBGC shall have notified the Company or any ERISA Affiliate that a Plan may become a subject of any such
proceedings, (iii) the aggregate “amount of unfunded benefit liabilities” (within the meaning of Section 4001(a)(18) of ERISA) under all Plans, determined in accordance with Title IV of ERISA, shall exceed $10,000,000,
(iv) the Company or any ERISA Affiliate shall have incurred or is reasonably expected to incur any liability pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, (v) the
Company or any ERISA Affiliate withdraws from any Multiemployer Plan, or (vi) the Company or any Subsidiary establishes or amends any employee welfare benefit plan that provides post-employment welfare benefits in a manner that could increase
the liability of the Company or any Subsidiary thereunder; and any such event or events described in clauses (i) through (vi) above, either individually or together with any other such event or events, could reasonably be expected to have
a Material Adverse Effect. 
 As used in Section 11(l), the terms “employee benefit plan” and “employee welfare benefit
plan” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 SECTION 12. REMEDIES
ON DEFAULT, ETC. 
 Section 12.1. Acceleration. (a) If an Event of Default with
respect to the Company described in paragraph (i) or (j) of Section 11 (other than an Event of Default described in clause (i) of paragraph (i) or described in clause (vi) of paragraph (i) by virtue of the fact
that such clause encompasses clause (i) of paragraph (i)) has occurred, all the Notes of every Series then outstanding shall automatically become immediately due and payable. 
 (b) If any other Event of Default has occurred and is continuing, any holder or holders of more than 50% in aggregate principal amount of the Notes at
the time outstanding may at any time at its or their option, by notice or notices to the Company, declare all the Notes then outstanding to be immediately due and payable. 
 (c) If any Event of Default described in paragraph (a) or (b) of Section 11 has occurred and is continuing with respect to any Notes, any
holder or holders of Notes at the time 

  

 -31- 

 Exhibit 10(z) (continued) 
  
 
outstanding affected by such Event of Default may at any time, at its or their option, by notice or notices to the Company, declare all the Notes held by
such holder or holders to be immediately due and payable. 
 Upon any Note’s becoming due and payable under this Section 12.1,
whether automatically or by declaration, such Note will forthwith mature and the entire unpaid principal amount of such Note, plus (i) all accrued and unpaid interest thereon (including, but not limited to, interest accrued thereon at the
Default Rate) and (ii) the Make-Whole Amount determined in respect of such principal amount (to the full extent permitted by applicable law), shall all be immediately due and payable, in each and every case without presentment, demand, protest
or further notice, all of which are hereby waived. The Company acknowledges, and the parties hereto agree, that each holder of a Note has the right to maintain its investment in the Notes free from repayment by the Company (except as herein
specifically provided for) and that the provision for payment of a Make-Whole Amount by the Company in the event that the Notes are prepaid or are accelerated as a result of an Event of Default, is intended to provide compensation for the
deprivation of such right under such circumstances. 
 Section 12.2. Other Remedies. If any Default or Event of Default has
occurred and is continuing, and irrespective of whether any Notes have become or have been declared immediately due and payable under Section 12.1, the holder of any Note at the time outstanding may proceed to protect and enforce the rights of
such holder by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein or in any Note, or for an injunction against a violation of any of the terms hereof or thereof,
or in aid of the exercise of any power granted hereby or thereby or by law or otherwise. 
 Section 12.3. Rescission. At any time
after the Notes have been declared due and payable pursuant to clause (b), (c) or (d) of Section 12.1, the holders of not less than 51% in aggregate principal amount of the Notes then outstanding, by written notice to the Company, may
rescind and annul any such declaration and its consequences if (a) the Company has paid all overdue interest on the Notes, all principal of and Make-Whole Amount on any Notes that are due and payable and are unpaid other than by reason of such
declaration, and all interest on such overdue principal and Make-Whole Amount and (to the extent permitted by applicable law) any overdue interest in respect of the Notes, at the Default Rate, (b) neither the Company nor any other Person shall
have paid any amounts which have become due solely by reason of such declaration, (c) all Events of Default and Defaults, other than non-payment of amounts that have become due solely by reason of such declaration, have been cured or have been
waived pursuant to Section 17, and (d) no judgment or decree has been entered for the payment of any monies due pursuant hereto or to any Notes. No rescission and annulment under this Section 12.3 will extend to or affect any
subsequent Event of Default or Default or impair any right consequent thereon. 
 Section 12.4. No Waivers or Election of Remedies,
Expenses, Etc. No course of dealing and no delay on the part of any holder of any Note in exercising any right, power or remedy shall operate as a waiver thereof or otherwise prejudice such holder’s rights, powers or remedies. No right,
power or remedy conferred by this Agreement or by any Note upon any holder thereof shall be exclusive of any other right, power or remedy referred to herein or therein or now or 

  

 -32- 

 Exhibit 10(z) (continued) 
  
 
hereafter available at law, in equity, by statute or otherwise. Without limiting the obligations of the Company under Section 15, the Company will pay
to the holder of each Note on demand such further amount as shall be sufficient to cover all costs and expenses of such holder incurred in any enforcement or collection under this Section 12, including, without limitation, reasonable
attorneys’ fees, expenses and disbursements. 
 SECTION 13. REGISTRATION; EXCHANGE;
SUBSTITUTION OF NOTES. 
 Section 13.1. Registration of Notes. The Company shall keep
at its principal executive office a register for the registration and registration of transfers of Notes. The name and address of each holder of one or more Notes, each transfer thereof and the name and address of each transferee of one or more
Notes shall be registered in such register. Prior to due presentment for registration of transfer, the Person in whose name any Note shall be registered shall be deemed and treated as the owner and holder thereof for all purposes hereof, and the
Company shall not be affected by any notice or knowledge to the contrary. The Company shall give to any holder of a Note that is an Institutional Investor promptly upon request therefor, a complete and correct copy of the names and addresses of all
registered holders of Notes. 
 Section 13.2. Transfer and Exchange of Notes. Upon surrender of any Note to the Company at the
address and to the attention of the designated officer (all as specified in Section 18(iv)), for registration of transfer or exchange (and in the case of a surrender for registration of transfer accompanied by a written instrument of transfer
duly executed by the registered holder of such Note or such holder’s attorney duly authorized in writing and accompanied by the relevant name, address and other information for notices of each transferee of such Note or part thereof), within
ten Business Days thereafter, the Company shall execute and deliver, at the Company’s expense (except as provided below), one or more new Notes (as requested by the holder thereof) of the same Series (and of the same tranche if such Series has
separate tranches) in exchange therefor, in an aggregate principal amount equal to the unpaid principal amount of the surrendered Note. Each such new Note shall be payable to such Person as such holder may request and shall be substantially in the
form of the Note of such Series originally issued hereunder or pursuant to any Supplement. Each such new Note shall be dated and bear interest from the date to which interest shall have been paid on the surrendered Note or dated the date of the
surrendered Note if no interest shall have been paid thereon. The Company may require payment of a sum sufficient to cover any stamp tax or governmental charge imposed in respect of any such transfer of Notes. Notes shall not be transferred in
denominations of less than $100,000, provided that if necessary to enable the registration of transfer by a holder of its entire holding of Notes, one Note may be in a denomination of less than $100,000. Any transferee, by its acceptance of a
Note registered in its name (or the name of its nominee), shall be deemed to have made the representation set forth in Section 6.3, provided, that in lieu thereof such holder may (in reliance upon information provided by the Company,
which shall not be unreasonably withheld) make a representation to the effect that the purchase by any holder of any Note will not constitute a non-exempt prohibited transaction under section 406(a) of ERISA. 
 The Notes have not been registered under the Securities Act or under the securities laws of any state and may not be transferred or resold unless
registered under the Securities Act and 

  

 -33- 

 Exhibit 10(z) (continued) 
  
 
all applicable state securities laws or unless an exemption from the requirement for such registration is available. 
 Section 13.3. Replacement of Notes. Upon receipt by the Company at the address and to the attention of the designated officer (all as
specified in Section 18(iv)) of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note (which evidence shall be, in the case of an Institutional Investor, notice from such
Institutional Investor of such ownership and such loss, theft, destruction or mutilation), and 
 (a) in the case of loss,
theft or destruction, of indemnity reasonably satisfactory to it (provided that if the holder of such Note is, or is a nominee for, an original Purchaser or another holder of a Note with a minimum net worth of at least $50,000,000 or a
Qualified Institutional Buyer, such Person’s own unsecured agreement of indemnity shall be deemed to be satisfactory), or 
 (b) in the case of mutilation, upon surrender and cancellation thereof, 
 the Company at its own expense shall execute and deliver not more than
five Business Days following satisfaction of such conditions, in lieu thereof, a new Note of the same Series (and of the same tranche if such Series has separate tranches), dated and bearing interest from the date to which interest shall have been
paid on such lost, stolen, destroyed or mutilated Note or dated the date of such lost, stolen, destroyed or mutilated Note if no interest shall have been paid thereon. 
 SECTION 14. PAYMENTS ON NOTES. 
 Section 14.1. Place of Payment. Subject to Section 14.2, payments of principal, Make-Whole Amount and interest becoming due and payable on the Notes shall be made in New York, New York at the principal office of Banc of
America Securities LLC in such jurisdiction. The Company may at any time, by notice to each holder of a Note, change the place of payment of the Notes so long as such place of payment shall be either the principal office of the Company in such
jurisdiction or the principal office of a bank or trust company in such jurisdiction. 
 Section 14.2. Home Office Payment. So
long as any Purchaser or Additional Purchaser or such Purchaser’s nominee or such Additional Purchaser’s nominee shall be the holder of any Note, and notwithstanding anything contained in Section 14.1 or in such Note to the contrary,
the Company will pay all sums becoming due on such Note for principal, Make-Whole Amount and interest by the method and at the address specified for such purpose for such Purchaser on Schedule A hereto or, in the case of any Additional Purchaser,
Schedule A attached to any Supplement pursuant to which such Additional Purchaser is a party, or by such other method or at such other address as such Purchaser or Additional Purchaser shall have from time to time specified to the Company in writing
for such purpose, without the presentation or surrender of such Note or the making of any notation thereon, except that upon written request of the Company made concurrently with or reasonably promptly after payment or prepayment in full of any
Note, such Purchaser or Additional Purchaser shall surrender such Note for cancellation, reasonably promptly after any such request, to the Company at its principal executive office or at 

  

 -34- 

 Exhibit 10(z) (continued) 
  
 
the place of payment most recently designated by the Company pursuant to Section 14.1. Prior to any sale or other disposition of any Note held by any
Purchaser or Additional Purchaser or such Person’s nominee, such Person will, at its election, either endorse thereon the amount of principal paid thereon and the last date to which interest has been paid thereon or surrender such Note to the
Company in exchange for a new Note or Notes pursuant to Section 13.2. The Company will afford the benefits of this Section 14.2 to any Institutional Investor that is the direct or indirect transferee of any Note. 
 SECTION 15. EXPENSES, ETC. 
 Section 15.1. Transaction Expenses. Whether or not the transactions contemplated hereby are consummated, the Company will pay all costs and expenses (including reasonable attorneys’ fees of a special
counsel for the Purchasers or any Additional Purchasers and, if reasonably required by the Required Holders, local or other counsel) incurred by each Purchaser and each Additional Purchaser and each other holder of a Note in connection with such
transactions and in connection with any amendments, waivers or consents under or in respect of this Agreement (including any Supplement) or the Notes (whether or not such amendment, waiver or consent becomes effective), including, without
limitation: (a) the costs and expenses incurred in enforcing or defending (or determining whether or how to enforce or defend) any rights under this Agreement (including any Supplement) or the Notes or in responding to any subpoena or other
legal process or informal investigative demand issued in connection with this Agreement (including any Supplement) or the Notes, or by reason of being a holder of any Note, and (b) the costs and expenses, including financial advisors’
fees, incurred in connection with the insolvency or bankruptcy of the Company or any Subsidiary or in connection with any work-out or restructuring of the transactions contemplated hereby and by the Notes. The Company will pay, and will save each
Purchaser, each Additional Purchaser and each other holder of a Note harmless from, all claims in respect of any fees, costs or expenses if any, of brokers and finders (other than those, if any, retained by a Purchaser or other holder in connection
with its purchase of the Notes). 
 Section 15.2. Survival. The obligations of the Company under this Section 15 will
survive the payment or transfer of any Note, the enforcement, amendment or waiver of any provision of this Agreement, any Supplement or the Notes, and the termination of this Agreement or any Supplement. 
 SECTION 16. SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE
AGREEMENT. 
 All representations and warranties contained herein or in any Supplement shall survive the execution and delivery
of this Agreement, such Supplement and the Notes, the purchase or transfer by any Purchaser or any Additional Purchaser of any such Note or portion thereof or interest therein and the payment of any Note and may be relied upon by any subsequent
holder of any such Note, regardless of any investigation made at any time by or on behalf of any Purchaser or any Additional Purchaser or any other holder of any such Note. All statements contained in any certificate or other instrument delivered by
or on behalf of the Company pursuant to this Agreement or any Supplement shall be deemed representations and warranties of the Company under this Agreement; provided, that the representations and warranties contained in any 

  

 -35- 

 Exhibit 10(z) (continued) 
  
 
Supplement shall only be made for the benefit of the Additional Purchasers which are party to such Supplement and the holders of the Notes issued pursuant to
such Supplement, including subsequent holders of any Note issued pursuant to such Supplement, and shall not require the consent of the holders of existing Notes. Subject to the preceding sentence, this Agreement (including every Supplement) and the
Notes embody the entire agreement and understanding between the Purchasers and the Additional Purchasers and the Company and supersede all prior agreements and understandings relating to the subject matter hereof. 
 SECTION 17. AMENDMENT AND WAIVER. 
 Section 17.1. Requirements. (a) This Agreement (including any Supplement) and the Notes may be amended, and the observance of any term
hereof or of the Notes may be waived (either retroactively or prospectively), with (and only with) the written consent of the Company and the Required Holders, except that (i) no amendment or waiver of any of the provisions of Section 1,
2, 3, 4, 5, 6 or 21 hereof or the corresponding provision of any Supplement, or any defined term (as it is used in any such Section or such corresponding provision of any Supplement), will be effective as to any holder of Notes unless consented to
by such holder of Notes in writing, and (ii) no such amendment or waiver may, without the written consent of all of the holders of Notes at the time outstanding affected thereby, (A) subject to the provisions of Section 12 relating to
acceleration or rescission, change the amount or time of any prepayment or payment of principal of, or reduce the rate or change the time of payment or method of computation of interest (if such change results in a decrease in the interest rate) or
of the Make-Whole Amount on, the Notes, (B) change the percentage of the principal amount of the Notes the holders of which are required to consent to any such amendment or waiver, or (C) amend any of Sections 8, 11(a), 11(b), 12, 17 or
20. 
 (b) Supplements. Notwithstanding anything to the contrary contained herein, the Company may enter into any Supplement providing
for the issuance of one or more Series of Additional Notes consistent with Sections 2.2 hereof without obtaining the consent of any holder of any other Series of Notes. 
 Section 17.2. Solicitation of Holders of Notes. 
 (a) Solicitation. The Company will
provide each holder of the Notes (irrespective of the amount of Notes then owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered decision
with respect to any proposed amendment, waiver or consent in respect of any of the provisions hereof, any Supplement or of the Notes. The Company will deliver executed or true and correct copies of each amendment, waiver or consent effected pursuant
to the provisions of this Section 17 to each holder of outstanding Notes promptly following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes. 
 (b) Payment. The Company will not directly or indirectly pay or cause to be paid any remuneration, whether by way of supplemental or additional
interest, fee or otherwise, or grant any security or provide other credit support, to any holder of Notes as consideration for or as an inducement to the entering into by any holder of Notes of any waiver or amendment of any of 

  

 -36- 

 Exhibit 10(z) (continued) 
  
 
the terms and provisions hereof or any Supplement unless such remuneration is concurrently paid, or security is concurrently granted or other credit support
is concurrently provided, on the same terms, ratably to each holder of Notes then outstanding even if such holder did not consent to such waiver or amendment. 
 (c) Consent in Contemplation of Transfer. Any consent made pursuant to this Section 17 by a holder of Notes that has transferred or has agreed to transfer its Notes to the Company, any Subsidiary or any
Affiliate of the Company and has provided or has agreed to provide such written consent as a condition to such transfer shall be void and of no force or effect except solely as to such holder, and any amendments effected or waivers granted or to be
effected or granted that would not have been or would not be so effected or granted but for such consent (and the consents of all other holders of Notes that were acquired under the same or similar conditions) shall be void and of no force or effect
except solely as to such holder. 
 Section 17.3. Binding Effect, Etc. Any amendment or waiver consented to as provided in this
Section 17 applies equally to all holders of Notes and is binding upon them and upon each future holder of any Note and upon the Company without regard to whether such Note has been marked to indicate such amendment or waiver. No such amendment
or waiver will extend to or affect any obligation, covenant, agreement, Default or Event of Default not expressly amended or waived or impair any right consequent thereon. No course of dealing between the Company and the holder of any Note nor any
delay in exercising any rights hereunder or under any Note shall operate as a waiver of any rights of any holder of such Note. As used herein, the term “this Agreement” and references thereto shall mean this Agreement as it may from time
to time be amended or supplemented. 
 Section 17.4. Notes Held by Company, Etc. Solely for the purpose of determining whether
the holders of the requisite percentage of the aggregate principal amount of Notes then outstanding approved or consented to any amendment, waiver or consent to be given under this Agreement or the Notes, or have directed the taking of any action
provided herein or in the Notes to be taken upon the direction of the holders of a specified percentage of the aggregate principal amount of Notes then outstanding, Notes directly or indirectly owned by the Company or any of its Affiliates shall be
deemed not to be outstanding. 
 SECTION 18. NOTICES. 
 All notices and communications provided for hereunder shall be in writing and sent (a) by telecopy if the sender on the same day sends a confirming
copy of such notice by a recognized overnight delivery service (charges prepaid), or (b) by a recognized overnight delivery service (with charges prepaid). Any such notice must be sent: 
 (i) if to a Purchaser or such Purchaser’s nominee, to such Purchaser or such Purchaser’s nominee at the address specified for
such communications in Schedule A to this Agreement, or at such other address as such Purchaser or such Purchaser’s nominee shall have specified to the Company in writing pursuant to this Section 18; 
  

 -37- 

 Exhibit 10(z) (continued) 
  
 (ii) if to an Additional Purchaser or such Additional Purchaser’s nominee, to such Additional Purchaser
or such Additional Purchaser’s nominee at the address specified for such communications in Schedule A to any Supplement, or at such other address as such Additional Purchaser or such Additional Purchaser’s nominee shall have specified to
the Company in writing, 
 (iii) if to any other holder of any Note, to such holder at such address as such other holder shall
have specified to the Company in writing pursuant to this Section 18, or 
 (iv) if to the Company, to the Company at its
address set forth at the beginning hereof to the attention of Chief Financial Officer, with a copy to the General Counsel, or at such other address as the Company shall have specified to the holder of each Note in writing. 
 Notices under this Section 18 will be deemed given only when actually received. 
 SECTION 19. REPRODUCTION OF DOCUMENTS. 
 This
Agreement and all documents relating thereto, including, without limitation, (a) consents, waivers and modifications that may hereafter be executed, (b) documents received by any Purchaser at the Closing or by any Additional Purchaser
(except the Notes themselves), and (c) financial statements, certificates and other information previously or hereafter furnished to any Purchaser or any Additional Purchaser, may be reproduced by such Purchaser or such Additional Purchaser by
any photographic, photostatic, electronic, digital, or other similar process and such Purchaser or such Additional Purchaser may destroy any original document so reproduced. The Company agrees and stipulates that, to the extent permitted by
applicable law, any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether or not such reproduction was made by such Purchaser or
such Additional Purchaser in the regular course of business) and any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence. This Section 19 shall not prohibit the Company or any other
holder of Notes from contesting any such reproduction to the same extent that it could contest the original, or from introducing evidence to demonstrate the inaccuracy of any such reproduction. 
 SECTION 20. CONFIDENTIAL INFORMATION. 
 For the purposes of this Section 20, “Confidential Information” means information delivered to any Purchaser or any Additional Purchaser by or on behalf of the Company or any Subsidiary in
connection with the transactions contemplated by or otherwise pursuant to this Agreement that is proprietary in nature and that was clearly marked or labeled or otherwise adequately identified when received by such Purchaser as being confidential
information of the Company or such Subsidiary, provided that such term does not include information that (a) was publicly known or otherwise known to such Purchaser or such Additional Purchaser prior to the time of such disclosure,
(b) subsequently becomes publicly known through no act or omission by 

  

 -38- 

 Exhibit 10(z) (continued) 
  
 
such Purchaser or such Additional Purchaser or any Person acting on such Purchaser’s or such Additional Purchaser’s behalf, (c) otherwise
becomes known to such Purchaser or such Additional Purchaser other than through disclosure by the Company or any Subsidiary or (d) constitutes financial statements delivered to such Purchaser or such Additional Purchaser under Section 7.1
that are otherwise publicly available. Each Purchaser and each Additional Purchaser will maintain the confidentiality of such Confidential Information in accordance with procedures adopted by such Purchaser or such Additional Purchaser in good faith
to protect confidential information of third parties delivered to such Purchaser or such Additional Purchaser, provided that such Purchaser or such Additional Purchaser may deliver or disclose Confidential Information to (i) such
Purchaser’s or such Additional Purchaser’s directors, trustees, officers, employees, agents, attorneys and affiliates (to the extent such disclosure reasonably relates to the administration of the investment represented by such
Purchaser’s or such Additional Purchaser’s Notes), (ii) such Purchaser’s or such Additional Purchaser’s financial advisors and other professional advisors who agree to hold confidential the Confidential Information
substantially in accordance with the terms of this Section 20, (iii) any other holder of any Note, (iv) any Institutional Investor to which such Purchaser or such Additional Purchaser sells or offers to sell such Note or any part
thereof or any participation therein (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 20), (v) any Person from which such Purchaser or such Additional
Purchaser offers to purchase any security of the Company (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 20), (vi) any federal or state regulatory
authority having jurisdiction over such Purchaser or such Additional Purchaser, (vii) the National Association of Insurance Commissioners or any similar organization, or any nationally recognized rating agency that requires access to
information about such Purchaser’s or such Additional Purchaser’s investment portfolio, or (viii) any other Person to which such delivery or disclosure may be necessary or appropriate (w) to effect compliance with any law, rule,
regulation or order applicable to such Purchaser or such Additional Purchaser, (x) in response to any subpoena or other legal process, (y) in connection with any litigation to which such Purchaser or such Additional Purchaser is a party or
(z) if an Event of Default has occurred and is continuing, to the extent such Purchaser or such Additional Purchaser may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection
of the rights and remedies under such Purchaser’s or such Additional Purchaser’s Notes, any Subsidiary Guaranty and this Agreement. Following a specific written request from the Company, you agree to cooperate with the Company or any
Subsidiary to the extent the Company or such Subsidiary seeks to object to, or file pleadings or motions with respect to (all objections, pleadings and the like to be at the sole expense of the Company, including reimbursement to each holder of the
Notes by the Company for any out of pocket costs, fees and/or expenses that such holder may incur as a result of such cooperation), any disclosure pursuant to clause (vii) (except in the case of the National Association of Insurance
Commissioners) or pursuant to clause (viii) (except in the case of the matters addressed in subclause (y) or (z) thereof); provided that you shall under no circumstances be required to cooperate to the extent that you shall
determine (in your sole discretion) that such cooperation would be prohibited by any law or other legal or regulatory requirement applicable to you. Each holder of a Note, by its acceptance of a Note, will be deemed to have agreed to be bound by and
to be entitled to the benefits of this Section 20 as though it were a party to this Agreement. On reasonable request by the Company in connection 

  

 -39- 

 Exhibit 10(z) (continued) 
  
 
with the delivery to any holder of a Note of information required to be delivered to such holder under this Agreement or requested by such holder (other than
a holder that is a party to this Agreement or its nominee), such holder will enter into an agreement with the Company embodying the provisions of this Section 20. 
 SECTION 21. SUBSTITUTION OF PURCHASER. 
 Each
Purchaser and each Additional Purchaser shall have the right to substitute any one of its Affiliates as the purchaser of the Notes that it has agreed to purchase hereunder, by written notice to the Company, which notice shall be signed by both such
Purchaser or such Additional Purchaser and such Affiliate, shall contain such Affiliate’s agreement to be bound by this Agreement and shall contain a confirmation by such Affiliate of the accuracy with respect to it of the representations set
forth in Section 6. Upon receipt of such notice, any reference to such Purchaser or such Additional Purchaser in this Agreement (other than in this Section 21), shall be deemed to refer to such Affiliate in lieu of such original Purchaser
or such original Additional Purchaser. In the event that such Affiliate is so substituted as a Purchaser or an Additional Purchaser hereunder and such Affiliate thereafter transfers to such original Purchaser or such original Additional Purchaser
all of the Notes then held by such Affiliate, upon receipt by the Company of notice of such transfer, any reference to such Affiliate as a “Purchaser” or an “Additional Purchaser” in this Agreement (other than in this
Section 21), shall no longer be deemed to refer to such Affiliate, but shall refer to such original Purchaser or such original Additional Purchaser, and such original Purchaser or such original Additional Purchaser shall again have all the
rights of an original holder of the Notes under this Agreement. 
 SECTION 22. MISCELLANEOUS. 
 Section 22.1. Successors and Assigns. All covenants and other agreements contained in this Agreement (including all covenants and other
agreements contained in any Supplement) by or on behalf of any of the parties hereto bind and inure to the benefit of their respective successors and assigns (including, without limitation, any subsequent holder of a Note) whether so expressed or
not. 
 Section 22.2. Payments Due on Non-Business Days. Anything in this Agreement or the Notes to the contrary notwithstanding
(but without limiting the requirement in Section 8.4 that the notice of any optional prepayment specify a Business Day as the date fixed for such prepayment), any payment of principal of or Make-Whole Amount or interest on any Note that is due
on a date other than a Business Day shall be made on the next succeeding Business Day without including the additional days elapsed in the computation of the interest payable on such next succeeding Business Day; provided that if the maturity date
of any Note is a date other than a Business Day, the payment otherwise due on such maturity date shall be made on the next succeeding Business Day and shall include the additional days elapsed in the computation of interest payable on such next
succeeding Business Day. 
 Section 22.3. Accounting Terms. All accounting terms used herein which are not expressly defined in
this Agreement have the meanings respectively given to them in accordance with GAAP. Except as otherwise specifically provided herein, (i) all computations made 

  

 -40- 

 Exhibit 10(z) (continued) 
  
 
pursuant to this Agreement shall be made in accordance with GAAP, and (ii) all financial statements shall be prepared in accordance with GAAP.

 Section 22.4. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as
to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by
law) not invalidate or render unenforceable such provision in any other jurisdiction. 
 Section 22.5. Construction. Each
covenant contained herein shall be construed (absent express provision to the contrary) as being independent of each other covenant contained herein, so that compliance with any one covenant shall not (absent such an express contrary provision) be
deemed to excuse compliance with any other covenant. Where any provision herein refers to action to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or
indirectly by such Person. 
 For the avoidance of doubt, all Schedules and Exhibits attached to this Agreement shall be deemed to be a part
hereof. 
 Section 22.6. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an
original but all of which together shall constitute one instrument. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto. 
 Section 22.7. Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be
governed by, the law of the State of New York excluding choice-of-law principles of the law of such State that would permit the application of the laws of a jurisdiction other than such State. 
 Section 22.8. Jurisdiction and Process; Waiver of Jury Trial. (a) The Company irrevocably submits to the non-exclusive jurisdiction of
any New York State or federal court sitting in the Borough of Manhattan, The City of New York, over any suit, action or proceeding arising out of or relating to this Agreement or the Notes. To the fullest extent permitted by applicable law, the
Company irrevocably waives and agrees not to assert, by way of motion, as a defense or otherwise, any claim that it is not subject to the jurisdiction of any such court, any objection that it may now or hereafter have to the laying of the venue of
any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 
 (b) The Company consents to process being served by or on behalf of any holder of Notes in any suit, action or proceeding of the nature referred to in
Section 22.8(a) by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, return receipt requested, to it at its address specified in Section 18 or at such other address of
which such holder shall then have been notified pursuant to said Section. The Company agrees that such service upon receipt (i) shall be deemed in every respect effective service of process upon it in any such suit, action or proceeding and
(ii) shall, to the fullest 

  

 -41- 

 Exhibit 10(z) (continued) 
  
 
extent permitted by applicable law, be taken and held to be valid personal service upon and personal delivery to it. Notices hereunder shall be conclusively
presumed received as evidenced by a delivery receipt furnished by the United States Postal Service or any reputable commercial delivery service. 
 (c) Nothing in this Section 22.8 shall affect the right of any holder of a Note to serve process in any manner permitted by law, or limit any right that the holders of any of the Notes may have to bring proceedings against the Company
in the courts of any appropriate jurisdiction or to enforce in any lawful manner a judgment obtained in one jurisdiction in any other jurisdiction. 
 (d) THE PARTIES HERETO HEREBY WAIVE TRIAL BY JURY IN ANY ACTION
BROUGHT ON OR WITH RESPECT TO THIS AGREEMENT, THE NOTES OR ANY
OTHER DOCUMENT EXECUTED IN CONNECTION HEREWITH OR THEREWITH. 
 *    *    *    *    * 
  

 -42- 

 Exhibit 10(z) (continued) 
  
 The execution hereof by the Purchasers shall constitute a contract among the Company and the Purchasers for the uses and
purposes hereinabove set forth. This Agreement may be executed in any number of counterparts, each executed counterpart constituting an original but all together only one agreement. 
  

					
	Very truly yours,
	
	SIGMA-ALDRICH CORPORATION
		
	By	 	/s/ Kirk A. Richter
		 	Name:	 	Kirk A. Richter
		 	Title:	 	Treasurer
		
	By	 	/s/ Richard A. Keffer
		 	Name:	 	Richard A. Keffer
		 	Title:	 	Vice President, Secretary

 Exhibit 10(z) (continued) 
  

					
	THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY
		
	By	 	/s/ David A. Barras
		 	Name:	 	David A. Barras
		 	Title:	 	Its Authorized Representative

 Note Purchase Agreement 

 Exhibit 10(z) (continued) 
  

			
	 NAME AND ADDRESS OF PURCHASER
	  	 PRINCIPAL AMOUNT OF
 NOTES TO BE PURCHASED

		
	THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY	  	$100,000,000

 720 East Wisconsin Avenue 
 Milwaukee, Wisconsin 53202 
 Attention: Securities Department 
 Fax Number: (414) 665-7124 
 Payments 
 All
payments on or in respect of the Notes to be by bank wire transfer of Federal or other immediately available funds (identifying each payment as “Sigma-Aldrich Corporation, 5.11% Series 2006-A Senior Notes due December 5, 2011; PPN 826552
A# 8, principal, premium or interest”) to: 
 US Bank 
 777 East Wisconsin Avenue 
 Milwaukee, Wisconsin 53202 
 ABA# 075000022 
 For the account of:
Northwestern Mutual Life 
 Account No. ************ 
 Notices 
 All notices and communications to be addressed as first provided above, except notices with respect to payments
and written confirmation of each such payment to be addressed, Attention: Investment Operations, Fax Number: (414) 665-6998. 
 Name of Nominee in which
Notes are to be issued: None 
 Taxpayer I.D. Number: 39-0509570 
  

	***	Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

 SCHEDULE A 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 DEFINED TERMS 
 As used herein, the following terms have the respective meanings set forth below or set forth in the Section hereof following such term: 
 “Additional Notes” is defined in Section 2.2. 
 “Additional Purchasers” means purchasers of Additional Notes. 
 “Affiliate” means, at any time, and with respect to any Person, (a) any other Person that at such time directly or indirectly through one or more intermediaries Controls, or is Controlled by, or is under common Control
with, such first Person, and (b) any Person beneficially owning or holding, directly or indirectly, 10% or more of any class of voting or equity interests of the Company or any Subsidiary or any Person of which the Company and its Subsidiaries
beneficially own or hold, in the aggregate, directly or indirectly, 10% or more of any class of voting or equity interests. As used in this definition, “Control” means the possession, directly or indirectly, of the power to direct
or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Unless the context otherwise clearly requires, any reference to an “Affiliate” is a
reference to an Affiliate of the Company. 
 “Anti-Terrorism Order” means Executive Order No. 13,224 of
September 24, 2001, Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit or Support Terrorism, 66 U.S. Fed. Reg. 49, 079 (2001), as amended. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on which commercial banks in New York, New York are required or
authorized to be closed. 
 “Capital Lease” means, at any time, a lease with respect to which the lessee is required
concurrently to recognize the acquisition of an asset and the incurrence of a liability in accordance with GAAP. 
 “Capital Lease
Obligation” means, with respect to any Person and a Capital Lease, the amount of the obligation of such Person as the lessee under such Capital Lease which would, in accordance with GAAP, appear as a liability on a balance sheet of such
Person. 
 “Change in Control” means any of the following events or circumstances: (a) if any Person or Persons acting
in concert together with Affiliates thereof, shall in the aggregate, directly or indirectly, control or own (beneficially or otherwise) more than 50% (by number of shares) of the issued and outstanding stock of the Company; or (b) if any person
(as such term is used in section 13(d) and section 14(d)(2) of the Exchange Act as in effect on the date of the Closing) or related persons constituting a group (as such term is used in Rule 13d-5 under the Exchange Act) become the “beneficial
owners” (as such term is used in Rule 13d-3 under the Exchange Act as in effect on the date of the Closing), directly or indirectly, of more than 50% of the total voting power of all classes then outstanding of the Company’s voting stock.

 SCHEDULE B 
 (to
Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 “Closing” is defined in Section 3. 
 “Closing Date” means the date of the Closing. 
 “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to time. 
 “Company” means Sigma-Aldrich Corporation, a Delaware corporation. 
 “Confidential Information” is defined in Section 20. 
 “Consolidated Debt” means as of any date of determination the total amount of all Debt of the Company and its Restricted Subsidiaries determined on a consolidated basis in accordance with GAAP.

 “Consolidated Net Worth” shall mean the consolidated stockholder’s equity of the Company and its Restricted
Subsidiaries, as defined according to GAAP. 
 “Consolidated Total Assets” means, as of any date of determination, the total
amount of all assets of the Company and its Restricted Subsidiaries, determined on a consolidated basis in accordance with GAAP. 
 “Consolidated Total Capitalization” means, at any time, the sum of (i) Consolidated Net Worth and (ii) Consolidated Debt. 
 “Control Event” means: (a) the execution by the Company or any of its Subsidiaries or Affiliates of any agreement or letter of intent with respect to any proposed transaction or event or series
of transactions or events which, individually or in the aggregate, may reasonably be expected to result in a Change in Control; or (b) the execution of any written agreement which, when fully performed by the parties thereto, would result in a
Change in Control; or (c) the making of any written offer by any person (as such term is used in section 13(d) and section 14(d)(2) of the Exchange Act as in effect on the date of the Closing) or related persons constituting a group (as such
term is used in Rule 13d-5 under the Exchange Act as in effect on the date of the Closing) to the holders of the common stock of the Company, which offer, if accepted by the requisite number of holders, would result in a Change in Control.

 “Debt” means, with respect to any Person means, at any time, without duplication, including both short and long term,
obligations, 
 (a) its liabilities for borrowed money and its redemption obligations in respect of mandatorily redeemable
Preferred Stock; 
 (b) its liabilities for the deferred purchase price of property acquired by such Person excluding:
(i) contingent “earn-out” liabilities which are not anticipated (by the Company) to be Material; and (ii) accounts payable arising in the ordinary course of 

  

 B-2 

 Exhibit 10(z) (continued) 
  
 
business but including all liabilities created or arising under any conditional sale or other title retention agreement with respect to any such property;

 (c) all liabilities appearing on its balance sheet in accordance with GAAP in respect of Capital Leases; 
 (d) all liabilities for borrowed money secured by any Lien with respect to any property owned by such Person (whether or not it has
assumed or otherwise become liable for such liabilities); 
 (e) all its liabilities in respect of letters of credit or
instruments serving a similar function issued or accepted for its account by banks and other financial institutions (whether or not representing obligations for borrowed money) excluding letters of credit backing up worker’s compensation
claims, bid bonds and other similar obligations incurred in the Company’s and its Subsidiaries’ ordinary course of business to the extent that the aggregate face amount of such excluded items is not, on an accumulated basis, Material;

 (f) Swaps of such Person, excluding foreign forward currency contracts; and 
 (g) any Guaranty of such Person with respect to liabilities of a type described in any of clauses (a) through (f) hereof.

 Debt of any Person shall include all obligations of such Person of the character described in clauses (a) through (e) to the
extent such Person remains legally liable in respect thereof notwithstanding that any such obligation is deemed to be extinguished under GAAP. 
 “Default” means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of notice or both, become an Event of Default. 
 “Default Rate” means with respect to the Notes of any Series that rate of interest that is 2% per annum above the rate of interest
stated in clause (a) of the first paragraph of the Notes of such Series (and of such tranche if such Series has separate tranches). 
 “Environmental Laws” means any and all federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or
governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including but not limited to those related to hazardous substances or wastes, air emissions and discharges to
waste or public systems. 
 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time,
and the rules and regulations promulgated thereunder from time to time in effect. 
  

 B-3 

 Exhibit 10(z) (continued) 
  
 “ERISA Affiliate” means any trade or business (whether or not incorporated) that is treated as a single
employer together with the Company under section 414 of the Code. 
 “Event of Default” is defined in Section 11.

 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Fair Market Value” means, at any time and with respect to any property, the sale value of such property that would be realized in an
arm’s-length sale at such time between an informed and willing buyer and an informed and willing seller (neither being under a compulsion to buy or sell), as reasonably determined in the good faith opinion of the Company’s board of
directors. 
 “GAAP” means those generally accepted accounting principles as in effect from time to time in the United
States of America. 
 “Governmental Authority” means 
 (a) the government of 
 (i) the United States of America or any state or other political subdivision thereof, or 
 (ii) any jurisdiction in
which the Company or any Restricted Subsidiary conducts all or any part of its business, or which has jurisdiction over any properties of the Company or any Restricted Subsidiary, or 
 (b) any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, any such
government. 
 “Government Obligations” shall mean direct obligations of the United States of America or any agency or
instrumentality of the United States of America, the payment or guarantee of which constitutes a full faith and credit obligation of the United States of America. 
 “Guaranty” means, with respect to any Person, any obligation (except the endorsement in the ordinary course of business of negotiable instruments for deposit or collection) of such Person guaranteeing
or in effect guaranteeing any Debt, dividend or other obligation of any other Person in any manner, whether directly or indirectly, including (without limitation) obligations incurred through an agreement, contingent or otherwise, by such Person:

 (a) to purchase such Debt or obligation or any property constituting security therefor primarily for the purpose of
assuring the owner of such Debt or obligation of the ability of any other Person to make payment of the Debt or obligation; 
 (b) to advance or supply funds (i) for the purchase or payment of such Debt or obligation, or (ii) to maintain any working capital or other balance sheet condition or any 

  

 B-4 

 Exhibit 10(z) (continued) 
  
 
income statement condition of any other Person or otherwise to advance or make available funds for the purchase or payment of such Debt or obligation;

 (c) to lease properties or to purchase properties or services primarily for the purpose of assuring the owner of such Debt
or obligation of the ability of any other Person to make payment of the Debt or obligation; or 
 (d) otherwise to assure the
owner of such Debt or obligation against loss in respect thereof. 
 In any computation of the Debt or other liabilities of the obligor under
any Guaranty, the Debt or other obligations that are the subject of such Guaranty shall be assumed to be direct obligations of such obligor. 
 “Hazardous Material” means any and all pollutants, toxic or hazardous wastes or other substances that might pose a hazard to health and safety, the removal of which may be required or the generation, manufacture, refining,
production, processing, treatment, storage, handling, transportation, transfer, use, disposal, release, discharge, spillage, seepage or filtration of which is or shall be restricted, prohibited or penalized by any applicable law including, but not
limited to, asbestos, urea formaldehyde foam insulation, polychlorinated biphenyls, petroleum, petroleum products, lead based paint, radon gas or similar restricted, prohibited or penalized substances. 
 “holder” means, with respect to any Note, the Person in whose name such Note is registered in the register maintained by the Company
pursuant to Section 13.1. 
 “Institutional Investor” means (a) any original purchaser of a Note, (b) any
holder of more than $2,000,000 of the aggregate principal amount of the Notes then outstanding, and (c) any bank, trust company, savings and loan association or other financial institution, any pension plan, any investment company, any
insurance company, any broker or dealer, or any other similar financial institution or entity, regardless of legal form. 
 “Lease
Rentals” shall mean, for any period, the aggregate amount of fixed rental or operating lease expense payable by the Company and its Restricted Subsidiaries with respect to leases of real and personal property (excluding Capital Lease
Obligations) determined in accordance with GAAP. 
 “Lien” means, with respect to any Person, any mortgage, lien, pledge,
charge, security interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention agreement (other than an operating lease) or
Capital Lease, upon or with respect to any property or asset of such Person (including, in the case of stock, shareholder agreements, voting trust agreements and all similar arrangements). 
  

 B-5 

 Exhibit 10(z) (continued) 
  
 “Make-Whole Amount” shall have the meaning (i) set forth in Section 8.6 with respect to any
Series A Note and (ii) set forth in the applicable Supplement with respect to any other Series of Notes. 
 “Material”
means material in relation to the business, operations, affairs, financial condition, assets or properties of the Company and its Restricted Subsidiaries taken as a whole. 
 “Material Adverse Effect” means a material adverse effect on (a) the business, operations, affairs, financial condition, assets or
properties of the Company and its Restricted Subsidiaries taken as a whole, or (b) the ability of the Company to perform its obligations under this Agreement (including any Supplement) and the Notes, (c) the ability of any Subsidiary
Guarantor to perform its obligations under the Subsidiary Guaranty or (d) the validity or enforceability of this Agreement (including any Supplement), the Notes or the Subsidiary Guaranty. 
 “Material Subsidiary” means, at any time, any Restricted Subsidiary of the Company which, together with all other Restricted
Subsidiaries of such Restricted Subsidiary, accounts for more than (i) 5% of the consolidated assets of the Company and its Restricted Subsidiaries or (ii) 5% of consolidated revenue of the Company and its Restricted Subsidiaries.

 “Moody’s” shall mean Moody Investors Service, Inc. 
 “Multiemployer Plan” means any Plan that is a “multiemployer plan” (as such term is defined in Section 4001(a)(3) of
ERISA). 
 “Notes” is defined in Section 1. 
 “Officer’s Certificate” means a certificate of a Senior Financial Officer or of any other officer of the Company whose
responsibilities extend to the subject matter of such certificate. 
 “PBGC” means the Pension Benefit Guaranty Corporation
referred to and defined in ERISA or any successor thereto. 
 “Person” means an individual, partnership, corporation,
limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof. 
 “Plan” means an “employee benefit plan” (as defined in Section 3(3) of ERISA) that is or, within the preceding five years, has been established or maintained, or to which contributions are or, within the
preceding five years, have been made or required to be made, by the Company or any ERISA Affiliate or with respect to which the Company or any ERISA Affiliate may have any liability. 
 “Preferred Stock” means any class of capital stock of a corporation that is preferred over any other class of capital stock of such
corporation as to the payment of dividends or the payment of any amount upon liquidation or dissolution of such corporation. 
  

 B-6 

 Exhibit 10(z) (continued) 
  
 “Priority Debt” means (without duplication), as of the date of any determination thereof, the sum of
(i) all unsecured Debt of Restricted Subsidiaries (including all Guaranties of Debt of the Company but excluding (x) Debt owing to the Company or any other Restricted Subsidiary, (y) Debt outstanding at the time such Person became a
Restricted Subsidiary (other than an Unrestricted Subsidiary which is designated as a Restricted Subsidiary pursuant to Section 9.6 hereof), provided that such Debt shall have not been incurred in contemplation of such person becoming a
Restricted Subsidiary, and (z) all Guaranties of Debt of the Company by any Restricted Subsidiary which has also guaranteed the Notes and (ii) all Debt of the Company and its Restricted Subsidiaries secured by Liens other than Debt secured
by Liens permitted by subparagraphs (a) through (i), inclusive, of Section 10.3. 
 “property” or
“properties” means, unless otherwise specifically limited, real or personal property of any kind, tangible or intangible, choate or inchoate. 
 “Public Filings” is defined in Section 5.3. 
 “Purchasers” means the
purchasers of the Notes named in Schedule A hereto. 
 “QPAM Exemption” means Prohibited Transaction Class Exemption 84-14
issued by the United States Department of Labor. 
 “Qualified Institutional Buyer” means any Person who is a qualified
institutional buyer within the meaning of such term as set forth in Rule 144(a)(1) under the Securities Act. 
 “Ratable
Portion” means, with respect to any Note, an amount equal to the product of (x) the amount equal to the net proceeds being so applied to the prepayment of Senior Debt in accordance with Section 10.4(2), multiplied by (y) a
fraction the numerator of which is the outstanding principal amount of such Note and the denominator of which is the aggregate principal amount of Senior Debt of the Company and its Restricted Subsidiaries being prepaid pursuant to
Section 10.4(2). 
 “Required Holders” means, at any time, the holders of not less than 51% in principal amount of the
Notes at the time outstanding (exclusive of Notes then owned by the Company or any of its Affiliates and any Notes held by parties who are contractually required to abstain from voting with respect to matters affecting the holders of the Notes).

 “Responsible Officer” means any Senior Financial Officer and any other officer of the Company with responsibility for the
administration of the relevant portion of this Agreement. 
 “Restricted Subsidiary” means any Subsidiary in which:
(i) at least a majority of the voting securities are owned by the Company and/or one or more Restricted Subsidiaries and (ii) the Company has not designated an Unrestricted Subsidiary by notice in writing given to the holders of the Notes.

 “S&P” means Standard & Poor’s Ratings Group, a division of The McGraw-Hill Companies, Inc. 

 

 B-7 

 Exhibit 10(z) (continued) 
  
 “Securities Act” means the Securities Act of 1933, as amended from time to time. 
 “Senior Debt” means, as of the date of any determination thereof, all Consolidated Debt, other than Subordinated Debt. 
 “Senior Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller of the Company.

 “Series” means any series of Notes issued pursuant to this Agreement or any Supplement hereto. 
 “Series A Notes” is defined in Section 1 of this Agreement. 
 “Subordinated Debt” means all unsecured Debt of the Company which shall contain or have applicable thereto subordination provisions
providing for the subordination thereof to other Debt of the Company (including, without limitation, the obligations of the Company under this Agreement, any Supplement or the Notes). 
 “Subsidiary” means, as to any Person, any corporation, association or other business entity in which such Person or one or more of its
Subsidiaries or such Person and one or more of its Subsidiaries owns sufficient equity or voting interests to enable it or them (as a group) ordinarily, in the absence of contingencies, to elect a majority of the directors (or Persons performing
similar functions) of such entity, and any partnership or joint venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries
(unless such partnership can and does ordinarily take major business actions without the prior approval of such Person or one or more of its Subsidiaries). Unless the context otherwise clearly requires, any reference to a “Subsidiary” is a
reference to a Subsidiary of the Company. 
 “Subsidiary Guarantor” means each Subsidiary that is party to the Subsidiary
Guaranty. 
 “Subsidiary Guaranty” means a subsidiary guaranty agreement executed and delivered in connection with
Section 9.8 of this Agreement. 
 “Supplement” is defined in Section 2.2 of this Agreement. 
 “Swaps” means, with respect to any Person, payment obligations with respect to interest rate swaps, currency swaps and similar
obligations obligating such Person to make payments, whether periodically or upon the happening of a contingency. For the purposes of this Agreement, the amount of the obligation under any Swap shall be the amount determined in respect thereof as of
the end of the then most recently ended fiscal quarter of such Person, based on the assumption that such Swap had terminated at the end of such fiscal quarter, and in making such determination, if any agreement relating to such Swap provides for the
netting of amounts payable by and to such Person thereunder or if any such agreement provides for the simultaneous payment of amounts by and to such Person, then in each such case, the amount of such obligation shall be the net amount so determined.

  

 B-8 

 Exhibit 10(z) (continued) 
  
 “tranche” means all Notes of a Series having the same maturity, interest rate and schedule for mandatory
prepayments. 
 “Unrestricted Subsidiary” means any Subsidiary so designated by the Company. 
 “USA Patriot Act” means United States Public Law 107-56, Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism (USA PATRIOT ACT) Act of 2001, as amended from time to time, and the rules and regulations promulgated thereunder from time to time in effect. 
  

 B-9 

 Exhibit 10(z) (continued) 
  
 CHANGES IN CORPORATE STRUCTURE 
 None. 
 SCHEDULE 4.9

 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 SUBSIDIARIES OF THE COMPANY, OWNERSHIP
OF SUBSIDIARY STOCK, AFFILIATES SUBSIDIARIES 
 Each of the subsidiaries
listed below shall be a Restricted Subsidiary unless and until the Company shall elect to designate one more subsidiaries as an Unrestricted Subsidiary pursuant to the provisions of the Note Purchase Agreement. 
  

									
	 	  	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	5, 6	  	Sigma-Aldrich Corporation - St. Louis, MO	  	Research Chemicals	  	Delaware	  	1975
	1.	  	Sigma-Aldrich Co. (Illinois)	  	Research Chemicals	  	Illinois	  	1996
	(A)	  	Sigma Second Street Redevelopment Corporation	  	Real Estate Holding	  	Missouri	  	1983
	(B)	  	Barton/ Second Street Redevelopment Corporation	  	Real Estate Holding	  	Missouri	  	1988
	(C)	  	Barton Real Estate Holdings, Inc.	  	Real Estate Holding	  	Missouri	  	1988
	(D)	  	Sigma Redevelopment Corporation	  	Real Estate Holding	  	Missouri	  	1979
	(E)	  	3506 South Broadway Redevelopment Corp.	  	Real Estate Holding	  	Missouri	  	1995
	(F)	  	Second President Properties Company	  	Research Chemicals	  	Missouri	  	1988
	(G)	  	Olive/Ewing/Laclede Redevelopment Corporation	  	Real Estate Holding	  	Missouri	  	2000
	(H)	  	Midwest Consultants Co. - St. Louis, MO	  	Research Chemicals	  	Missouri	  	1971
	(i)	  	Little Creek Farm, Inc. - Leslie, MO	  	Dormant/Inactive	  	Missouri	  	1980
	(I)	  	Sigma F&D Division, Inc.	  	Dormant/Inactive	  	Missouri	  	1974
	(J)	  	Sigma-Aldrich China, Inc.	  	Research Chemicals	  	Missouri	  	1990
	(K)	  	Pathfinder Laboratories Company	  	Dormant/Inactive	  	Missouri	  	1987
	(L)	  	Planetary Chemical Inc.	  	Dormant/Inactive	  	Missouri	  	1951
	(M)	  	Sigma Pharmaceutical, Inc.	  	Dormant/Inactive	  	Missouri	  	1971
	(N)	  	Sigma-Aldrich B.V. (Netherlands)	  	Research Chemicals	  	Netherlands	  	2000
	(i)	  	Sigma-Aldrich Holding B.V. (Netherlands)	  	Holding Company	  	Netherlands	  	2000
	(ii)	  	Sigma-Aldrich Chemie Holding GmbH (Germany)	  	Research Chemicals	  	Germany	  	1985
	(iii)	  	Sigma-Aldrich Chemie GmbH (Germany)	  	Research Chemicals	  	Germany	  	1974

 SCHEDULE 5.4 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  

										
	 	 	 	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	(iii)	 	 	Sigma-Aldrich Producktions GmbH (Germany)	  	Research Chemicals	  	Germany	  	1998
	(iii)	 	 	Sigma-Ark GmbH (Germany)	  	Research Chemicals	  	Germany	  	1997
	(iii)	 	 	Proligo International GmbH (Germany)	  	Holding Company	  	Germany	  	
	(iv)	 	 	Proligo Biochemie GmbH (Germany)	  	Synthetic Oligo Production	  	Germany	  	
	(v)	 	 	Sigma-Aldrich Laborchemikalien GmbH (Germany)	  	Research Chemicals	  	Germany	  	1997
	(iv)	 	 	Proligo France SAS (France)	  	Synthetic Oligo Production	  	France	  	
	(iv)	 	 	Proligo Singapore Pte., Ltd. (Singapore)	  	Synthetic Oligo Production	  	Singapore	  	1997
	(iv)	 	 	Proligo Japan KK (Japan)	  	Synthetic Oligo Production	  	Japan	  	
	(iv)	 	 	Proligo Australia Pty. Ltd. (Australia)	  	Synthetic Oligo Production	  	Australia	  	1997
	(O)	14	 	Sigma-Aldrich Chemie Verwaltungs GmbH - Munich, Germany	  	Research Chemicals	  	Germany	  	1983
	(P)	14	 	Sigma-Aldrich Grundstucksverwaltung GmbH & Co. K.G. - Munich, Germany	  	Research Chemicals	  	Germany	  	1974
	(Q)	 	 	Sigma-Aldrich Logistik GmbH	  	Research Chemicals	  	Germany	  	2004
	(R)	 	 	Sigma-Aldrich Israel, Ltd. - Rehovot, Israel	  	Research Chemicals	  	Israel	  	1969
	(S)	 	 	Sigma-Aldrich Holding S.a.r.l. (France)	  	Holding Company	  		  	
	(i)	10	 	Aldrich Chemical Foreign Holding LLC - Milwaukee, WI	  	Holding Company	  	Missouri	  	1989
	(ii)	 	 	Sigma-Aldrich Chimie S.N.C. Partnership - Cedex, France	  	Research Chemicals	  	France	  	1989
	(iii)	 	 	Sigma-Aldrich Chimie S.a.r.l. (France) - Cedex, France	  	Research Chemicals	  	France	  	1987
	10(i)	 	 	Sigma Chemical Foreign Holding LLC (Missouri)	  	Holding Company	  	Missouri	  	1989
	(T)	1,2	 	Aldrich Chemical Company, Inc. - Milwaukee, WI	  	Research Chemicals	  	Delaware	  	1996
	(i)	 	 	GLM Holdings, Inc. - Milwaukee, WI	  	Dormant/Inactive	  	Wisconsin	  	1991
	(i)	 	 	Aldrich-Boranes, Inc.	  	Dormant/Inactive	  	Delaware	  	1989
	(U)	 	 	Sigma-Aldrich Business Holdings, Inc.	  	Real Estate Holding	  	Delaware	  	1996

  

 5.4-2 

 Exhibit 10(z) (continued) 
  

										
	 	 	 	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	(i)	 	 	Sigma-Aldrich Research Biochemicals, Inc. - Natick, MA	  	Research Chemicals	  	Delaware	  	1997
	(i)	 	 	Research Biochemicals Limited Partnership	  	Dormant/Inactive	  	Massachusetts	  	1997
	(V)	 	 	Sigma-Aldrich Lancaster, Inc.	  	Research Chemicals	  	Missouri	  	1996
	(i)	 	 	Techcare Systems, Inc. - Redwood, CA	  	Research Chemicals	  	California	  	1984
	(W)	3,4,11	 	Sigma-Genosys of Texas, Inc. - Woodlands, Texas	  	Synthetic Oligo Production	  	Texas	  	1987
	(i)	 	 	Sigma Genosys LP	  	Research Chemicals	  	Texas	  	2001
	11(i)	 	 	Sigma Genosys Holdings, LLC	  	Limited Liability Company	  	Missouri	  	2001
	(X)	 	 	FMI Holdings, Inc. (California)	  	Dormant/Inactive	  	Delaware	  	1998
	(Y)	 	 	Supelco, Inc. - Bellefonte, PA	  	Research Chemicals	  	Delaware	  	1996
	(i)	 	 	Advanced Separation Technologies, Inc.	  	Research Chemicals	  		  	
	(i)	 	 	Advanced Separation Technologies, Ltd. (U.K.)	  	Research Chemicals	  		  	
	(Z)	 	 	James F. Burns Co., Inc.	  	Dormant/Inactive	  	Missouri	  	1972
	(AA)	 	 	KL Acquisition Corp.	  	Dormant/Inactive	  	Missouri	  	1990
	(i)	 	 	Sigma-Aldrich Rus (Russia)	  	Limited Liability Company	  		  	
	(i)	 	 	Chemical Trade, Ltd. (Russia)	  	Research Chemicals	  	Russia	  	1996
	(i)	 	 	MedChem. Ltd. (Russia)	  	Research Chemicals	  	Russia	  	1997
	(ii)	 	 	SAF-Lab (Russia)	  	Research Chemicals	  	Russia	  	1998
	(ii)	 	 	TechMed Biochem, Ltd. (Russia)	  	Dormant/Inactive	  	Russia	  	1994
	(AB)	 	 	Sigma Chemical Corp.	  	Dormant/Inactive	  	Missouri	  	2001
	(AC)	12	 	Sigma-Aldrich Biotechnology Holding Company, Inc.	  	Holding Company	  	Missouri	  	2001
	12(i)	 	 	Sigma-Aldrich Biotechnology LP	  	Research Chemicals	  	Missouri	  	2001
	12(i)	 	 	Sigma-Aldrich Biotechnology Investment LLC	  	Limited Liability Company	  	Missouri	  	2001
	(AD)	 	 	Sigma-Aldrich Manufacturing LLC	  	Limited Liability Company	  	Missouri	  	2004
	2.	9	 	Sigma-Aldrich Inc. - St. Louis, MO	  	Sales & Marketing of Chemical Products	  	Wisconsin	  	1996

  

 5.4-3 

 Exhibit 10(z) (continued) 
  

										
	 	 	 	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	3.	 	 	Sigma- Aldrich Finance Co. - Hamilton, Bermuda	  	Holding Company	  	Missouri	  	1996
	4.	 	 	Sigma-Aldrich & Subs Foreign Sales Corporation – Barbados	  	FSC	  	Barbados	  	1994
	5.	7	 	Sigma-Aldrich Company, Ltd. - Poole, England	  	Research Chemicals	  	United Kingdom	  	1987
	(A)	 	 	Sigma- Aldrich Holding, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1985
	(i)	 	 	Sigma-Genosys Limited (UK)	  	Research Chemicals	  	United Kingdom	  	1997
	(i)	 	 	Sigma Chemical Company, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1963
	(ii)	 	 	Wessex Biochemicals Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1963
	(i)	 	 	Aldrich Chemical Company, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1959
	(ii)	 	 	Webnest, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1973
	(i)	 	 	Bristol Organics Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1970
	(i)	 	 	B-Line Systems Limited (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1990
	(i)	 	 	Ultrafine Ltd.(U.K.)	  	Chemical Mfg.	  	United Kingdom	  	1983
	(B)	 	 	SAFC Biosciences Limited (U.K.)	  	Biopharmaceutical Mfg.	  	United Kingdom	  	1999
	(C)	 	 	Pharmorphix Limited (U.K.)	  	Solid Form Chemistry	  	United Kingdom	  	
	6.	 	 	Sigma-Aldrich (Switzerland) Holding AG – Buchs, Switzerland	  	Holding Company	  	Switzerland	  	1950
	(A)	 	 	Sigma-Aldrich Chemie GmbH (Switzerland)	  	Research Chemicals	  	Switzerland	  	1999
	(B)	 	 	Sigma-Aldrich Production GmbH (Switzerland)	  	Research Chemicals	  	Switzerland	  	1999
	(i)	 	 	Sigma-Aldrich GmbH (Switzerland)	  	Holding Company	  	Switzerland	  	1999
	(C)	 	 	Sigma-Aldrich (Shanghai) Trading Co., Ltd. (China)	  		  		  	
	(D)	 	 	Sigma-Aldrich Denmark A/S – Denmark	  	Research Chemicals	  	Denmark	  	1998
	(E)	 	 	Sigma-Aldrich Finland Oy - Helsinki, Finland	  	Research Chemicals	  	Finland	  	1994
	(F)	 	 	Sigma-Aldrich Norway AS - Oslo, Norway	  	Research Chemicals	  	Norway	  	1996
	(G)	 	 	Sigma-Aldrich Sweden AB - Stockholm, Sweden	  	Research Chemicals	  	Sweden	  	1954

  

 5.4-4 

 Exhibit 10(z) (continued) 
  

										
	 	 	 	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	(H)	 	 	Sigma-Aldrich Italia S.r.l.- Milano, Italy	  	Research Chemicals	  	Italy	  	1987
	(i)	 	 	Sigma-Aldrich S.r.l.- Milano, Italy	  	Research Chemicals	  	Italy	  	2000
	(I)	 	 	Sigma-Aldrich N.V./S.A. - Bornem, Belgium	  	Research Chemicals	  	Belgium	  	1984
	(i)	 	 	Sigma Chemie B.V. (The Netherlands)	  	Research Chemicals	  	Holland	  	1995
	(J)	 	 	Fluka Chemical Corp. (Delaware)	  	Dormant/Inactive	  	Delaware	  	1996
	(K)	 	 	Fluka Chemical Company, Ltd. (U.K.)	  	Dormant/Inactive	  	United Kingdom	  	1967
	7.	 	 	Sigma-Aldrich Foreign Holding Company - St. Louis, Missouri	  	Holding Company	  	Missouri	  	1989
	(A)	 	 	Sigma-Aldrich Handels GmbH - Vienna, Austria	  	Research Chemicals	  	Austria	  	1993
	(B)	 	 	Sigma-Aldrich de Argentina S.A. - Buenos Aires, Argentina	  	Research Chemicals	  	Argentina	  	1997
	(C)	13	 	Sigma-Aldrich Oceania Pty. Limited	  	Holding Company	  	Australia	  	2005
	(D)	8,13	 	Sigma-Aldrich Pty., Limited - N.S.W. 2154, Australia	  	Research Chemicals	  	Australia	  	1991
	(i)	 	 	Sigma-Aldrich Australian General Partnership	  	Holding Company	  	Australia	  	2005
	(ii)	 	 	Sigma-Aldrich New Zealand Co.	  	Research Chemicals	  	New Zealand	  	2005
	(i)	 	 	SAFC Biosciences Pty Ltd.	  	Serum Collection & Processing	  	Australia	  	2002
	(E)	 	 	Sigma-Aldrich Quimica Brasil Ltda. - Sao Paulo, Brazil	  	Research Chemicals	  	Brazil	  	1992
	(F)	 	 	Sigma-Aldrich spol. s.r.o. – Czech Republic	  	Research Chemicals	  	Czech Republic	  	1992
	(G)	 	 	Sigma-Aldrich Canada, Ltd. - Ontario, Canada	  	Research Chemicals	  	Canada	  	1980
	(H)	 	 	Sigma-Aldrich (OM) Ltd. – Athens, Greece	  	Research Chemicals	  	Greece	  	1997
	(I)	 	 	Sigma-Aldrich Kft. - Budapest, Hungary	  	Research Chemicals	  	Hungry	  	1993
	(J)	 	 	Sigma-Aldrich India (Bangalore) Branch	  	Research Chemicals	  	India	  	1992
	(K)	 	 	Sigma-Aldrich Chemicals Pvt Ltd.	  	Research Chemicals	  	India	  	2003
	(L)	 	 	Sigma-Aldrich Financial Services Limited - Dublin, Ireland	  	Holding Company	  	Ireland	  	1998
	(M)	 	 	Sigma-Aldrich Japan K.K. – Tokyo, Japan	  	Research Chemicals	  	Japan	  	1986

  

 5.4-5 

 Exhibit 10(z) (continued) 
  

									
	 	  	 Name of Entity - Principal Place of Business
	  	 Description of Operations
	  	 Jurisdiction of
 Incorporation or
 Organization
	  	Date of
Inc.
	(N)	  	Sigma-Aldrich Holding Ltd. – Seoul, Korea	  	Holding Company	  	Korea	  	
	(i)	  	Sigma-Aldrich Korea, Ltd. – Seoul, Korea	  	Research Chemicals	  	Korea	  	1995
	(O)	  	Sigma-Aldrich Quimica, S.A. de C.V. (Mexico)	  	Research Chemicals	  	Mexico	  	1993
	(P)	  	Sigma-Aldrich Sp. z.o.o - Piznan, Poland	  	Research Chemicals	  	Poland	  	1994
	(Q)	  	Sigma-Aldrich Quimica S.A. - Madrid, Spain	  	Research Chemicals	  	Spain	  	1989
	(i)	  	Sigma-Aldrich Quimica S.A. (Portugal) Branch	  	Research Chemicals	  	Portugal	  	1998
	(R)	  	Sigma-Aldrich Pte, Ltd. (Singapore)	  	Research Chemicals	  	Singapore	  	1994
	(i)	  	Sigma-Aldrich (m) Sdn. Bhd.- Kuala Lumpur, Malaysia	  	Research Chemicals	  	Malaysia	  	1997
	(S)	  	Sigma-Aldrich Pty. Ltd. – Midrand, South Africa	  	Research Chemicals	  	South Africa	  	1995
	(T)	  	Silverberry Limited (Ireland)	  		  	Ireland	  	
	(i)	  	Shrawdine Limited (Ireland)	  		  	Ireland	  	
	(i)	  	Sigma-Aldrich Ireland Ltd. (Ireland)	  	Research Chemicals	  	Ireland	  	1997
	(i)	  	SAFC Arklow Limited (Ireland)	  	Research Chemicals	  	Ireland	  	1982
	8.	  	Sigma-Aldrich Insurance Company Ltd.	  	Insurance Company	  	Bermuda	  	2002
	9.	  	SAFC, Inc. (formerly Tetrionics, Inc.)	  	Pharmacological Compound Manf	  	Wisconsin	  	1990
	10.	  	SAFC-JRH Holding Company, Inc.	  	Holding Company	  	Delaware	  	1998
	(A)	  	SAFC Biosciences Inc.	  	Biopharmaceutical Mfg. & Ser	  	California	  	1979

 Additional Joint Venture and Partnership information. 
  

	1.	Aldrich Chemical Company, Inc. own 60% of AAPL Joint Venture 

  

	2.	Aldrich Chemical Company, Inc. owns 39.11% of CAMAG Chemie-Erzeugnisse and Adsorptionstechnik AG 

  

	3.	Sigma-Genosys of Texas, Inc. and Glen Research Corporation own 50.1% and 49.9% respectively of Genosys Biotin Partners partnership. 

  

	4.	Sigma-Genosys of Texas, Inc. owns 37.5% of Chemicus, Inc. (Chemicus, Inc. is an inactive company as of 12/98) 

  

	5.	Sigma-Aldrich Corporation owns 7% investment of Procognia Limited (in the United Kingdom) 

  

	6.	Sigma-Aldrich Corporation owns 5.5% investment of Rubicon Genomics, Inc. 

  

	7.	Sigma-Aldrich Company Ltd. (UK) purchased equity in Oxford Bio Media, a UK company 

  

 5.4-6 

 Exhibit 10(z) (continued) 
  

	8.	Sigma-Aldrich pty. Ltd. (Australia) purchased equity in Benitec, Ltd., an Australian company 

  

	9.	Sigma-Aldrich, Inc. purchased equity in Cyntellect, Inc. (12.2%)

  

	10.	Ownership interest in Sigma-Aldrich Chimie SNC Partnership (France): Sigma Chemical Foreign Holding Co. 23% and Aldrich Chemical Foreign Holding Co. 77% 

  

	11.	Ownership interest in Sigma-Genosys L.P.Partnership: Sigma-Genosys Holdings, L.L.C. 99% and Sigma-Genosys of Texas, Inc. 1% 

  

	12.	Ownership interest in Sigma-Aldrich Biotechnology L.P. Partnership: Sigma-Aldrich Biotechnology Investment, L.L.C. 99% and Sigma-Aldrich Biotechnology Holding Co., Inc. 1%

  

	13.	Ownership interest in Sigma-Aldrich Australian General Partnership: Sigma-Aldrich Oceania Pty. Limited 99% and Sigma-Aldrich Pty. Limited 1% 

  

	14.	Ownership interest in Sigma-Aldrich Grundstucks-Verwaltung GmbH & Co KG Partnership (Germany): Sigma-Aldrich Co. 95% and Sigma-Aldrich Chemie Verwaltungs GmbH 5%

  

 5.4-7 

 Exhibit 10(z) (continued) 
  
 FINANCIAL STATEMENTS 
 The following Financial Statements are included in and provided with the 2005 Sigma-Aldrich Corporation Annual Report: 
  

	•	 	 Consolidated Statements of Income for the years ended December 31, 2005, 2004 and 2003 

  

	•	 	 Consolidated Balance Sheets as of December 31, 2005 and 2004 

  

	•	 	 Consolidated Statement of Stockholders’ Equity for the years ended December 31, 2005, 2004 and 2003 

  

	•	 	 Consolidated Statements of Cash Flows for the years ended December 31, 2005, 2004 and 2003 

 SCHEDULE 5.5 
 (to Note Purchase
Agreement) 

 Exhibit 10(z) (continued) 
  
 LICENSES, PERMITS, ETC. 
 None. 
 SCHEDULE 5.11

 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 EXISTING DEBT; FUTURE LIENS 
  

	1.	Credit Agreement dated as of December 12, 2001, by and among the Company, the lenders party thereto, and Wells Fargo Bank, National Association, as Administrative Agent, as
amended. 

  

				
	 Lender
	  	Commitment
	 Wells Fargo Bank, National Association
	  	$	25,000,000
	 Wachovia Bank, N.A.
	  	$	22,500,000
	 U.S. Bank N.A.
	  	$	22,500,000
	 ABN AMRO Bank N.V.
	  	$	17,500,000
	 Bank of Tokyo-Mitsubishi, Ltd., Chicago Branch
	  	$	17,500,000
	 BNP Paribas
	  	$	7,500,000
	 Comerica Bank
	  	$	7,500,000
	 Commerce Bank, N.A.
	  	$	7,500,000
	 The Fuji Bank, Limited
	  	$	7,500,000
	 National City Bank of Michigan/Illinois
	  	$	7,500,000
	 The Northern Trust Company
	  	$	7,500,000
	 TOTAL
	  	$	150,000,000

  

	2.	Credit Agreement dated as of February 23, 2005 by and among the Company, the lenders party thereto, and Wells Fargo Bank, National Association, as Administrative Agent.

 REVOLVING COMMITMENTS 
  

				
	 Lender
	  	Commitment
	 Wells Fargo Bank, National Association
	  	$	30,000,000
	 Wachovia Bank, N.A.
	  	$	30,000,000
	 The Bank of Tokyo-Mitsubishi, Ltd., Chicago Branch
	  	$	21,250,000
	 U.S. Bank N.A.
	  	$	17,500,000
	 ABN AMRO Bank N.V.
	  	$	17,500,000
	 Commerce Bank, N.A.
	  	$	8,750,000
	 Comerica Bank
	  	$	6,250,000
	 The Northern Trust Company
	  	$	6,250,000
	 BNP Paribas
	  	$	6,250,000
	 Mizuho Corporate Bank, Ltd.
	  	$	6,250,000
	 TOTAL
	  	$	150,000,000

 SCHEDULE 5.15 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 TERM COMMITMENTS 
  

				
	 Lender
	  	Commitment
	 Wells Fargo Bank, National Association
	  	$	24,000,000
	 Wachovia Bank, N.A.
	  	$	24,000,000
	 The Bank of Tokyo-Mitsubishi, Ltd., Chicago Branch
	  	$	17,000,000
	 U.S. Bank N.A.
	  	$	14,000,000
	 ABN AMRO Bank N.V.
	  	$	14,000,000
	 Commerce Bank, N.A.
	  	$	7,000,000
	 Comerica Bank
	  	$	5,000,000
	 The Northern Trust Company
	  	$	5,000,000
	 BNP Paribas
	  	$	5,000,000
	 Mizuho Corporate Bank, Ltd.
	  	$	5,000,000
	 TOTAL
	  	$	120,000,000

  

	3.	Credit Agreement dated as of December 15, 2005 by and among Sigma-Aldrich (Switzerland) Holding AG, as borrower, the lenders from time to time party thereto, Wells Fargo Bank,
National Association, as Administrative Agent and Lead Arranger. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 Wells Fargo Bank, National Association
	  	CHF 25,999,999
	 BNP Paribas
	  	CHF 17,333,333
	 TOTAL
	  	CHF 43,333,332

  

	4.	Private Placement dated September 12, 2001 by and among the Company, as borrower, the lender thereto, State Farm Life Insurance Company. 

 COMMITMENTS 
  

				
	 Lender
	  	Commitment
	 State Farm Life Insurance Company
	  	$	100,000,000
	 TOTAL
	  	$	100,000,000

  

	5.	Private Placement dated November 20, 2001 by and among the Company, as borrower, the lenders thereto, Prudential Financial and Mass Mutual with November 20, 2006 maturity
date. (Note: this loan was paid off on 11/20/06) 

 COMMITMENTS 
  

				
	 Lender
	  	Commitment
	 Prudential Financial
	  	$	54,000,000
	 Mass Mutual
	  	$	21,000,000
	 TOTAL
	  	$	75,000,000

  

	6.	Commercial Paper Outstanding as of September 30, 2006 

 COMMITMENTS 
  

				
	 Lender
	  	Commitment
	 Various
	  	$	194,800,000
	 TOTAL
	  	$	194,800,000

  

 5.15-2 

 Exhibit 10(z) (continued) 
  

	7.	Revolving Credit Facility by and among Sigma-Aldrich Japan K.K., as borrower, the lender thereto, Bank of Tokyo-Mitsubishi UFJ. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 Bank of Tokyo-Mitsubishi UFJ
	  	YEN 1,200,000,000
	 TOTAL
	  	YEN 1,200,000,000

  

	8.	Revolving Credit Facility by and among Sigma-Aldrich Korea Ltd., as borrower, the lender thereto, Bank of Tokyo-Mitsubishi UFJ. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 Bank of Tokyo-Mitsubishi UFJ
	  	KRW 20,000,000,000
	 TOTAL
	  	KRW 20,000,000,000

  

	9.	Operating Lease by and among Sigma-Aldrich Pte, Ltd.(Singapore), as borrower, the lender thereto, ABN AMRO Bank. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 ABN AMRO Bank
	  	SGD 54,834
	 TOTAL
	  	SGD 54,834

  

	10.	Supply Agreement by and among Proligo International GmbH (Germany), as borrower, the lender thereto, Genset As. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 Genset As
	  	EUR 109,210
	 TOTAL
	  	EUR 109,210

  

	11.	Loan by and among Proligo Biochemie GmbH (Germany), as borrower, the lender thereto, Westdeutsche Kreditbank. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 Westdeutsche Kreditbank
	  	EUR 32,018
	 TOTAL
	  	EUR 32,018

  

 5.15-3 

 Exhibit 10(z) (continued) 
  

	12.	Car Lease by and among Proligo Australia Pty. Ltd. as borrower, the lender thereto, GE Capital Finance. 

 COMMITMENTS 
  

			
	 Lender
	  	Commitment
	 GE Capital Finance
	  	AUD 15,760
	 TOTAL
	  	AUD 15,760

  

 5.15-4 

 Exhibit 10(z) (continued) 
  
 EXISTING LIENS 
 None. 
 SCHEDULE 10.3 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 [FORM OF SERIES A NOTE] 
 SIGMA-ALDRICH CORPORATION 
 5.11% SERIES 2006-A SENIOR NOTE DUE DECEMBER 5, 2011 
  

			
	 No. [            ]
	 	[Date]
	 $[                    ]
	 	PPN 826552 A# 8

 FOR VALUE RECEIVED, the undersigned,
SIGMA-ALDRICH CORPORATION (herein called the “Company”), a corporation organized and existing under the laws of the State of Delaware, hereby promises to pay to
[                    ] or registered assigns, the principal sum of
[                    ] DOLLARS (or so much thereof as shall not have been prepaid) on December 5, 2011 with interest
(computed on the basis of a 360-day year of twelve 30-day months) (a) on the unpaid balance hereof at the rate of 5.11% per annum from the date hereof, payable semi-annually, on the 5th day of June and December in each year and at
maturity, commencing on June 5, 2007, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law, at a rate per annum from time to time equal to 7.11%, on any overdue payment of interest and,
during the continuance of an Event of Default, on the unpaid balance hereof and on any overdue payment of any Make-Whole Amount, payable semiannually as aforesaid (or, at the option of the registered holder hereof, on demand). 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America
at the principal office of Bank of America, N.A. in New York, New York or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreement referred to below. 

This Note is one of a series of Senior Notes (herein called the “Notes”) issued pursuant to the Note Purchase Agreement, dated as of
December 5, 2006 (as from time to time amended, supplemented or modified, the “Note Purchase Agreement”), between the Company and the respective Purchasers named therein and is entitled to the benefits thereof. Each holder of
this Note will be deemed, by its acceptance hereof, to have (i) agreed to the confidentiality provisions set forth in Section 20 of the Note Purchase Agreement and (ii) made the representations set forth in Sections 6.2 and 6.3 of the
Note Purchase Agreement, provided, that in lieu thereof such holder may (in reliance upon information provided by the Company, which shall not be unreasonably withheld) make a representation to the effect that the purchase by any holder of
any Note will not constitute a non-exempt prohibited transaction under section 406(a) of ERISA. Unless otherwise indicated, capitalized terms used in this Note shall have the respective meanings ascribed to such terms in the Note Purchase Agreement.

 This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender of this Note for registration of transfer,
duly endorsed, or accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in
the name of, the transferee. Prior to due presentment for registration of transfer, the 
 EXHIBIT 1 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 Company may treat the person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all
other purposes, and the Company will not be affected by any notice to the contrary. 
 The Company will make required prepayments of
principal on the date and in the amounts specified in the Note Agreement. This Note is subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise.

 Pursuant to the Subsidiary Guaranty Agreement dated as of December 5, 2006 (as amended, restated or otherwise modified from time to
time, the “Subsidiary Guaranty”), certain Subsidiaries of the Company have absolutely and unconditionally guaranteed payment in full of the principal of, Make-Whole Amount, if any, and interest on this Note and the performance by
the Company of its obligations contained in the Note Purchase Agreement all as more fully set forth in said Subsidiary Guaranty. 
 If an
Event of Default, as defined in the Note Purchase Agreement, occurs and is continuing, the principal of this Note may be declared or otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with
the effect provided in the Note Purchase Agreement. 
 This Note shall be construed and enforced in accordance with, and the rights of the
issuer and holder hereof shall be governed by, the law of the State of New York excluding choice-of-law principles of the law of such State that would require the application of the laws of a jurisdiction other than such State. 
  

					
	SIGMA-ALDRICH CORPORATION
		
	By	 	  
		 	Name: 	 	  

					
		 	Title: 	 	  

  

 E-1-2 

 Exhibit 10(z) (continued) 
  
 FORM OF OPINION OF SPECIAL
COUNSEL 
 TO THE COMPANY 
 The closing opinion of Bryan Cave LLP, special counsel to the Company, which is called for by Section 4.4 of the Note Purchase Agreement, shall be
dated the date of Closing and addressed to the Purchasers, shall be satisfactory in scope and form to each Purchaser and shall be to the effect that: 
 1. The Company has the full corporate power and the corporate authority to conduct the activities in which it is now engaged and is duly licensed or qualified and is in good standing as a foreign corporation in each
jurisdiction in which the character of the properties owned or leased by it or the nature of the business transacted by it makes such licensing or qualification necessary except in jurisdictions where the failure to be so qualified or licensed would
not have a material adverse effect on the business of the Company. 
 2. The issuance and sale of the Series A Notes, the execution, delivery
and performance by the Company of the Note Purchase Agreement do not violate any provision of any law or other rule or regulation of any Governmental Authority applicable to the Company or conflict with or result in any breach of any of the
provisions of or constitute a default under or result in the creation or imposition of any Lien upon any property of the Company pursuant to the provisions of the Articles or Certificate of Incorporation or By-laws, or such similar organizational or
governing instrument, as the case may be, of the Company or any agreement or other instrument known to such counsel to which the Company is a party or by which the Company may be bound. 
 3. There are no actions, suits or proceedings pending or, to the knowledge of such counsel after due inquiry, threatened against or affecting the Company
or any Subsidiary in any court or before any governmental authority or arbitration board or tribunal which, if adversely determined, would have a materially adverse effect on the properties, business, profits or condition, (financial or otherwise)
of the Company and its Subsidiaries or the ability of the Company to perform its obligations under the Note Purchase Agreement and the Series A Notes or on the legality, validity or enforceability of the Company’s obligations under the Note
Purchase Agreement and the Series A Notes. To the knowledge of such counsel, neither the Company nor any Subsidiary is in default with respect to any court or governmental authority, or arbitration board or tribunal. 
 4. The Note Purchase Agreement has been duly authorized by all necessary corporate action on the part of the Company, has been duly executed and
delivered by the Company and constitutes the legal, valid and binding contract of the Company enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance and similar laws affecting
creditors’ rights generally, and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law). 
 EXHIBIT 4.4(a) 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 5. The Series A Notes have been duly authorized by all necessary corporate action on the part of the Company, have been duly
executed and delivered by the Company and constitute the legal, valid and binding contract of the Company enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent conveyance and similar laws
affecting creditors’ rights generally, and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law). 
 6. No approval, consent or withholding of objection on the part of, or filing, registration or qualification with, any governmental body, Federal or
state, is necessary in connection with the execution and delivery of the Note Purchase Agreement or the Series A Notes. 
 7. The issuance,
sale and delivery of the Series A Notes under the circumstances contemplated by the Note Purchase Agreement do not, under existing law, require the registration of the Series A Notes under the Securities Act of 1933, as amended, or the qualification
of an indenture under the Trust Indenture Act of 1939, as amended. 
 8. Neither the issuance of the Series A Notes nor the application of
the proceeds of the sale of the Series A Notes will violate or result in a violation of Section 7 of the Securities Exchange Act of 1934, as amended, or any regulation issued pursuant thereto, including, without limitation, Regulation T, U or X
of the Board of Governors of the Federal Reserve System. 
 9. The Company is not an “investment company” or a company
“controlled” by an “investment company,” within the meaning of the Investment Company Act of 1940, as amended. 
 The
opinion of Bryan Cave LLP, shall cover such other matters relating to the sale of the Notes as each Purchaser may reasonably request and successors and assigns of the Purchasers shall be entitled to rely on such opinion. With respect to matters of
fact on which such opinion is based, such counsel shall be entitled to rely on appropriate certificates of public officials and other officers of the Company and its Subsidiaries. 
  

 E-4.4(b)-2 

 Exhibit 10(z) (continued) 
  
 FORM OF OPINION OF SPECIAL
COUNSEL 
 TO THE PURCHASERS 
 The closing opinion of Chapman and Cutler LLP, special counsel to the Purchasers, called for by Section 4.4 of the Note Purchase Agreement, shall be
dated the date of Closing and addressed to each Purchaser, shall be satisfactory in form and substance to each Purchaser and shall be to the effect that: 
 1. The Company is a corporation, validly existing and in good standing under the laws of its jurisdiction of incorporation and has the corporate power and the corporate authority to execute and deliver the Note
Purchase Agreement and to issue the Series A Notes. 
 2. The Note Purchase Agreement has been duly authorized by all necessary corporate
action on the part of the Company, has been duly executed and delivered by the Company and constitutes the legal, valid and binding contract of the Company enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent
conveyance and similar laws affecting creditors’ rights generally, and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law). 
 3. The Series A Notes have been duly authorized by all necessary corporate action on the part of the Company, and the Notes being delivered on the date
hereof have been duly executed and delivered by the Company and constitute the legal, valid and binding obligations of the Company enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent conveyance and similar laws
affecting creditors’ rights generally, and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law). 
 4. The issuance, sale and delivery of the Series A Notes and the execution and delivery of the Subsidiary Guaranty under the circumstances contemplated
by the Note Purchase Agreement and the Subsidiary Guaranty do not, under existing law, require the registration of the Series A Notes or the Subsidiary Guaranty under the Securities Act of 1933, as amended, or the qualification of an indenture under
the Trust Indenture Act of 1939, as amended. 
 EXHIBIT 4.4(b) 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 With respect to matters of fact upon which such opinion is based, Chapman and Cutler LLP may rely on appropriate
certificates of public officials and officers of the Company and upon representations of the Company and the Purchasers delivered in connection with the issuance and sale of the Series A Notes. 
 In rendering the opinion set forth in paragraph 1 above, Chapman and Cutler LLP may rely, as to matters referred to in paragraph 1, solely upon an
examination of the Articles of Incorporation certified by, and a certificate of good standing of the Company from, the Secretary of State of the State of Delaware, the Bylaws of the Company and the general business corporation law of the State of
Delaware. The opinion of Chapman and Cutler LLP is limited to the laws of the State of New York, the general business corporation law of the State of Delaware and the Federal laws of the United States. 
  

 E-4.4(c)-2 

 Exhibit 10(z) (continued) 
  

 SIGMA-ALDRICH CORPORATION

 [NUMBER] SUPPLEMENT TO NOTE PURCHASE AGREEMENT

 Dated as of ______________________ 
 Re:             $                         %
Series              Senior Notes 
 DUE
                         
  

 EXHIBIT S 
 (to Note Purchase Agreement) 

 Exhibit 10(z) (continued) 
  
 SIGMA-ALDRICH CORPORATION 
 3050 SPRUCE STREET 
 ST. LOUIS, MISSOURI 63103 
 Dated as of 
                     ,
20     
 To the Purchaser(s) named in 
 Schedule A hereto 
 Ladies and Gentlemen: 
 This [Number] Supplement to Note Purchase Agreement (the “Supplement”) is between SIGMA-ALDRICH CORPORATION, a Delaware corporation (the “Company”), and the
institutional investors named on Schedule A attached hereto (the “Purchasers”). 
 Reference is hereby made to that certain
Note Purchase Agreement dated as of December 5, 2006 (the “Note Purchase Agreement”) between the Company and the purchasers listed on Schedule A thereto. All capitalized terms not otherwise defined herein shall have the same
meaning as specified in the Note Purchase Agreement. Reference is further made to Section 4.14 of the Note Purchase Agreement which requires that, prior to the delivery of any Additional Notes, the Company and each Additional Purchaser shall
execute and deliver a Supplement. 
 The Company hereby agrees with the Purchaser(s) as follows: 
 1. The Company has authorized the issue and sale of $__________ aggregate principal amount of its _____% Series ______ Senior Notes due _________, ____
(the “Series ______ Notes”). The Series ____ Notes, together with the Series A Notes [and the Series ____ Notes] initially issued pursuant to the Note Purchase Agreement [and the _________ Supplement] and each
series of Additional Notes which may from time to time hereafter be issued pursuant to the provisions of Section 2.2 of the Note Purchase Agreement, are collectively referred to as the “Notes” (such term shall also include any
such notes issued in substitution therefor pursuant to Section 13 of the Note Purchase Agreement). The Series _____ Notes shall be substantially in the form set out in Exhibit 1 hereto with such changes therefrom, if any, as may be approved by
the Purchaser(s) and the Company. 
 2. Subject to the terms and conditions hereof and as set forth in the Note Purchase Agreement and on the
basis of the representations and warranties hereinafter set forth, the Company agrees to issue and sell to each Purchaser, and each Purchaser agrees to purchase from the Company, Series _____ Notes in the principal amount set forth opposite such
Purchaser’s name on Schedule A hereto at a price of 100% of the principal amount thereof on the closing date hereinafter mentioned. 

 Exhibit 10(z) (continued) 
  
 3. The sale and purchase of the Series ______ Notes to be purchased by each Purchaser shall occur at the offices of
[            ] at 10:00 A.M. Chicago time, at a closing (the “Closing”) on ______, ____ or on such other Business Day thereafter on or prior to _______, ____ as may be
agreed upon by the Company and the Purchasers. At the Closing, the Company will deliver to each Purchaser the Series ______ Notes to be purchased by such Purchaser in the form of a single Series ______ Note (or such greater number of Series ______
Notes in denominations of at least $100,000 as such Purchaser may request) dated the date of the Closing and registered in such Purchaser’s name (or in the name of such Purchaser’s nominee), against delivery by such Purchaser to the
Company or its order of immediately available funds in the amount of the purchase price therefor by wire transfer of immediately available funds for the account of the Company to account number
[                    ] at ____________ Bank, [Insert Bank address, ABA number for wire transfers, and any other relevant wire transfer
information]. If, at the Closing, the Company shall fail to tender such Series ______ Notes to any Purchaser as provided above in this Section 3, or any of the conditions specified in Section 4 shall not have been fulfilled to any
Purchaser’s satisfaction, such Purchaser shall, at such Purchaser’s election, be relieved of all further obligations under this Agreement, without thereby waiving any rights such Purchaser may have by reason of such failure or such
nonfulfillment. 
 4. The obligation of each Purchaser to purchase and pay for the Series ______ Notes to be sold to such Purchaser at the
Closing is subject to the fulfillment to such Purchaser’s satisfaction, prior to the Closing, of the conditions set forth in Section 4 of the Note Purchase Agreement with respect to the Series ______ Notes to be purchased at the Closing,
and to the following additional conditions: 
 (a) Except as supplemented, amended or superceded by the representations and
warranties set forth in Exhibit A hereto, each of the representations and warranties of the Company set forth in Section 5 of the Note Purchase Agreement shall be correct as of the date of Closing and the Company shall have delivered to each
Purchaser an Officer’s Certificate, dated the date of the Closing certifying that such condition has been fulfilled. 
 (b) Contemporaneously with the Closing, the Company shall sell to each Purchaser, and each Purchaser shall purchase, the Series ______ Notes to be purchased by such Purchaser at the Closing as specified in Schedule A. 
 5. [Here insert special provisions for Series ______ Notes including prepayment provisions applicable to Series ______ Notes (including Make-Whole
Amount) and closing conditions applicable to Series ______ Notes]. 
 6. Each Purchaser represents and warrants that the representations and
warranties set forth in Section 6 of the Note Purchase Agreement are true and correct on the date hereof with respect to the purchase of the Series ______ Notes by such Purchaser. 
 7. The Company and each Purchaser agree to be bound by and comply with the terms and provisions of the Note Purchase Agreement as fully and completely as
if such Purchaser were an original signatory to the Note Purchase Agreement. 
  

 -2- 

 Exhibit 10(z) (continued) 
  
 The execution hereof shall constitute a contract between the Company and the Purchaser(s) for the uses and purposes
hereinabove set forth, and this agreement may be executed in any number of counterparts, each executed counterpart constituting an original but all together only one agreement. 
  

			
	SIGMA-ALDRICH CORPORATION
		
	By	 	  
		 	Name:
		 	Title:

 Accepted as of __________, _____ 
  

			
	[VARIATION]
		
	By	 	  
		 	Name:
		 	Title:

  

 -3- 

 Exhibit 10(z) (continued) 
  
 INFORMATION RELATING TO PURCHASERS 
  

				
	 NAME AND ADDRESS OF PURCHASER
	  	 PRINCIPAL
 AMOUNT OF
SERIES
 ______ NOTES
TO BE PURCHASED

		
	[NAME OF PURCHASER]	  	$	 
		
	 (1)    All payments by wire transfer of immediately available funds to:
	  		
		
	 with sufficient information to identify the source and application of such funds.
	  		
		
	 (2)    All notices of payments and written confirmations of such wire transfers:
	  		
		
	 (3)    All other communications:
	  		

 SCHEDULE A 
 (to Supplement) 

 Exhibit 10(z) (continued) 
  
 SUPPLEMENTAL REPRESENTATIONS 
 The Company represents and warrants to each Purchaser that except as hereinafter set forth in this Exhibit A, each of the representations and warranties
set forth in Section 5 of the Note Purchase Agreement is true and correct in all material respects as of the date hereof with respect to the Series ______ Notes with the same force and effect as if each reference to “Series A Notes”
set forth therein was modified to refer the “Series ______ Notes” and each reference to “this Agreement” therein was modified to refer to the Note Purchase Agreement as supplemented by the _______ Supplement. The Section
references hereinafter set forth correspond to the similar sections of the Note Purchase Agreement which are supplemented hereby: 
 Section 5.3. Disclosure. The Company, through its agent, Banc of America Securities LLC has delivered to each Purchaser a copy of a Private Placement Memorandum, dated ____________ (the “Memorandum”), relating
to the transactions contemplated by the ______ Supplement. The Memorandum fairly describes, in all material respects, the general nature of the business and principal properties of the Company and its Restricted Subsidiaries. The Note Purchase
Agreement, the Memorandum, the documents, certificates or other writings delivered to each Purchaser by or on behalf of the Company in connection with the transactions contemplated by the Note Purchase Agreement and the _______ Supplement and the
financial statements listed in Schedule 5.5 to the _____ Supplement, taken as a whole, do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein not misleading in light of the
circumstances under which they were made. Since ____________, there has been no change in the financial condition, operations, business, properties or prospects of the Company or any Restricted Subsidiary except changes that individually or in the
aggregate would not reasonably be expected to have a Material Adverse Effect. There is no fact known to the Company that would reasonably be expected to have a Material Adverse Effect that has not been set forth herein or in the Memorandum or in the
other documents, certificates and other writings delivered to each Purchaser by or on behalf of the Company specifically for use in connection with the transactions contemplated hereby. 
 Section 5.4. Organization and Ownership of Shares of Subsidiaries. (a) Schedule 5.4 to the ______ Supplement contains (except as noted
therein) complete and correct lists of (i) the Company’s Restricted and Unrestricted Subsidiaries, and showing, as to each Subsidiary, the correct name thereof, the jurisdiction of its organization, and the percentage of shares of each
class of its capital stock or similar equity interests outstanding owned by the Company and each other Subsidiary, and all other investments of the Company and its Restricted Subsidiaries, (ii) the Company’s Affiliates, other than
Subsidiaries, and (iii) the Company’s directors and senior officers. 
 Section 5.13. Private Offering by the Company.
Neither the Company nor anyone acting on its behalf has offered the Series __ Notes or any similar securities for sale to, or solicited any offer to buy any of the same from, or otherwise approached or negotiated in respect thereof with, any Person
other than the Purchasers and not more than [            ] other Institutional Investors, each of which has been offered the Series ______ Notes at a private sale for investment. Neither
the Company nor anyone acting on its behalf has taken, or will take, any action that would subject the issuance or sale of the Notes to the registration requirements of Section 5 of the Securities Act. 
  

 EXHIBIT A 
 (to Supplement) 

 Exhibit 10(z) (continued) 
  
 Section 5.14. Use of Proceeds; Margin Regulations. The Company will apply the proceeds of the sale of the Series
______ Notes to ______________ and for general corporate purposes. No part of the proceeds from the sale of the Series ______ Notes pursuant to the _____ Supplement will be used, directly or indirectly, for the purpose of buying or carrying any
margin stock within the meaning of Regulation U of the Board of Governors of the Federal Reserve System (12 CFR 221), or for the purpose of buying or carrying or trading in any securities under such circumstances as to involve the Company in a
violation of Regulation X of said Board (12 CFR 224) or to involve any broker or dealer in a violation of Regulation T of said Board (12 CFR 220). Margin stock does not constitute more than 2% of the value of the consolidated assets of the Company
and its Subsidiaries and the Company does not have any present intention that margin stock will constitute more than 2% of the value of such assets. As used in this Section, the terms “margin stock” and “purpose of buying or
carrying” shall have the meanings assigned to them in said Regulation U. 
 Section 5.15. Existing Debt; Future Liens.
(a) Schedule 5.15 to the _________ Supplement sets forth a complete and correct list of all outstanding Debt of the Company and its Restricted Subsidiaries as of _____________, since which date there has been no Material change in the amounts,
interest rates, sinking funds, installment payments or maturities of the Debt of the Company or its Restricted Subsidiaries. Neither the Company nor any Restricted Subsidiary is in default and no waiver of default is currently in effect, in the
payment of any principal or interest on any Debt of the Company or such Subsidiary and no event or condition exists with respect to any Debt of the Company or any Restricted Subsidiary that would permit (or that with notice or the lapse of time, or
both, would permit) one or more Persons to cause such Debt to become due and payable before its stated maturity or before its regularly scheduled dates of payment. 
 [Add any additional Sections as appropriate at the time the Series ______ Notes are issued] 
  

 -2- 

 Exhibit 10(z) (continued) 
  
 [FORM OF SERIES ______ NOTE] 
 SIGMA-ALDRICH CORPORATION 
 ___% SERIES ______ SENIOR NOTE DUE ______________ 
  

			
	 No. [_________]
	  	[Date]
	 $[                    ]
	  	PPN [____________]

 FOR VALUE RECEIVED, the undersigned, Sigma-Aldrich
Corporation, a Delaware corporation (herein called the “Company”), a corporation organized and existing under the laws of the State of ____________, hereby promises to pay to
[                    ], or registered assigns, the principal sum of
[                    ] DOLLARS (or so much thereof as shall not have been prepaid) on _______________, with interest (computed on the basis of
a 360-day year of twelve 30-day months) (a) on the unpaid balance hereof at the rate of ____% per annum from the date hereof, payable semiannually, on the _____ day of ______ and ______ in each year, commencing on the first of such dates after
the date hereof, until the principal hereof shall have become due and payable, and (b) to the extent permitted by law, at a rate per annum from time to time equal to [2% above the stated rate], on any overdue payment of interest and, during the
continuance of an Event of Default, on the unpaid balance hereof and on any overdue payment of any Make-Whole Amount, payable [semiannually] as aforesaid (or, at the option of the registered holder hereof, on demand). 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America
at _____________, in _____________, or at such other place as the Company shall have designated by written notice to the holder of this Note as provided in the Note Purchase Agreement referred to below. 
 This Note is one of a series of Senior Notes (the “Notes”) issued pursuant to a Supplement to the Note Purchase Agreement dated as of
December 5, 2006 (as from time to time amended, supplemented or modified, the “Note Purchase Agreement”), between the Company, the Purchasers named therein and Additional Purchasers of Notes from time to time issued pursuant to
any Supplement to the Note Purchase Agreement. This Note and the holder hereof are entitled equally and ratably with the holders of all other Notes of all series from time to time outstanding under the Note Purchase Agreement to all the benefits
provided for thereby or referred to therein. Each holder of this Note will be deemed, by its acceptance hereof, to have (i) agreed to the confidentiality provisions set forth in Section 20 of the Note Purchase Agreement and (ii) made
the representations set forth in Sections 6.1 and 6.3 of the Note Purchase Agreement, provided that such holder may (in reliance upon information provided by the Company, which shall not be unreasonably withheld) make a representation to the
effect that the purchase by such holder of any Note will not constitute a non-exempt prohibited transaction 

 EXHIBIT 1 
 (to Supplement) 

 Exhibit 10(z) (continued) 
  
 
under Section 406(a) of ERISA. Unless otherwise indicated, capitalized terms used in this Note shall have the respective meanings ascribed to such terms
in the Note Purchase Agreement. 
 This Note is registered with the Company and, as provided in the Note Purchase Agreement, upon surrender
of this Note for registration of transfer, duly endorsed, or accompanied by a written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note of the same series for
a like principal amount will be issued to, and registered in the name of, the transferee. Prior to due presentment for registration of transfer, the Company may treat the person in whose name this Note is registered as the owner hereof for the
purpose of receiving payment and for all other purposes, and the Company will not be affected by any notice to the contrary. 
 [The Company
will make required prepayments of principal on the dates and in the amounts specified in the Note Purchase Agreement.] [This Note is not subject to regularly scheduled prepayments of principal.] This Note is [also] subject to optional prepayment, in
whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise. 
 Pursuant to
the Subsidiary Guaranty Agreement dated as of December 5, 2006 (as amended or modified from time to time, the “Subsidiary Guaranty”), certain Subsidiaries of the Company have absolutely and unconditionally guaranteed payment in
full of the principal of, Make-Whole Amount, if any, and interest on this Note and the performance by the Company of its obligations contained in the Note Purchase Agreement all as more fully set forth in said Subsidiary Guaranty. 
 If an Event of Default, as defined in the Note Purchase Agreement, occurs and is continuing, the principal of this Note may be declared or otherwise
become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement. 
 This Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the law of the [State of New York] excluding choice-of-law principles of the law of such State that
would require the application of the laws of a jurisdiction other than such State. 
  

					
	SIGMA-ALDRICH CORPORATION
		
	By	 	  
		 	Name:	 	  
		 	Title:	 	  

  

 E-1-2 

 Exhibit 10(z) 
  

 EXHIBIT 1 
 (to Supplement)Flexible Deferral Plan

 Exhibit 10(aa) 
 SIGMA-ALDRICH CORPORATION 
 FLEXIBLE DEFERRAL PLAN 
 THIS PLAN, effective as of February 1, 2003 (the “Effective Date”), is established by Sigma-Aldrich Corporation, a Delaware corporation
(hereinafter the “Company”), 3050 Spruce Street, St. Louis, Missouri 63103. 
 RECITALS 
 The Company recognizes the valuable services performed for it by the employees participating in this Plan (herein the “Participants”).

 The Company desires to establish this Plan to permit certain designated employees of the Company and its subsidiaries to defer payment of
a portion of their compensation until the times specified pursuant to this Plan. 
 The Participants participating in this Plan constitute a
select group of management or highly compensated employees. 
 It is the intention of the parties that this arrangement is unfunded for tax
purposes and for purposes of Title I of ERISA. 
 The Company desires to provide the terms and conditions under which such amounts shall be
deferred and paid. 
 AGREEMENTS 
 In consideration of these premises, the Company hereby declares: 
 1. Establishment and Purposes. 
 a. Establishment. Company hereby establishes this Plan as of the Effective Date. 
 b. Name. The Plan shall be known as the “Sigma-Aldrich Corporation Flexible Deferral Plan.” 

 Exhibit 10(aa) (continued) 
  
 c. Purpose. The purpose of this Plan is to allow Participants to defer a portion of their compensation so that such
amounts may be paid to the Participants (or their Beneficiaries) as specified pursuant to this Plan. 
 2. Definitions. 
 Except as otherwise provided herein, the following terms shall have the definitions hereinafter indicated wherever used in this Plan with initial capital
letters: 
 a. Beneficiary: Any person, entity, or any combination thereof, designated by a Participant in a written document in
substantially the form of Section 7 of the Deferral Election Form attached to this Plan as Exhibit 1 and hereby made a part of this Plan (or such other form or by any other means, electronically or otherwise, as the Company may designate from
time to time), to receive benefits under this Plan in the event of the Participant’s death, or in the absence of any such designation, his or her estate. The term “Beneficiary” shall include one or more Beneficiaries, including all
contingent Beneficiaries designated. 
 b. Board of Directors: The Company’s Board of Directors or other governing body at any
time. 
 c. Company: Sigma-Aldrich Corporation, a Delaware corporation, and any corporation or other entity having purchased all or
substantially all of the assets and other property of Sigma-Aldrich Corporation or any successor corporation or other entity resulting from a merger or consolidation with Sigma-Aldrich Corporation. 
 d. Code: The Internal Revenue Code of 1986, as amended. 
 e. Deferral Election Form: A written document under which a Participant elects to defer a portion of his or her compensation in substantially the form of Exhibit 1 attached hereto (or such other form or by any
other means, electronically or otherwise, as the Company may designate from time to time). 
  

 -2- 

 Exhibit 10(aa) (continued) 
  
 f. Deferred Compensation Account: Deferred Compensation Account shall have the meaning set forth in Section 6 of
this Plan. 
 g. Disability or Disabled: A Participant shall be considered “Disabled” or to have a “Disability”
for purposes of this Plan if he or she has a physical or mental condition which, in the judgment of the Committee, totally and permanently prevents the Participant from engaging in any substantial remunerative occupation or employment, not including
any condition resulting from a Participant’s participation in the commission of a felony, or from injury received or disease contracted in the service of the Armed Forces of the United States or of any other country. A determination of
Disability shall be based upon a certification from a physician selected by the Committee, or a determination under the Federal Social Security Act. 
 h. ERISA: The Employee Retirement Income Security Act of 1974, as amended. 
 i. Participant:
An employee of the Company, or a subsidiary of the Company, selected by the Company (or a Committee or other group designated by the Company), in its discretion, to participate in this Plan, provided that all chosen employees shall be members of a
select group of management or highly compensated employees. 
 j. Plan: Plan shall mean this Sigma-Aldrich Corporation Flexible
Deferral Plan. 
 k. Committee: The Committee shall mean and be comprised of the same individuals as may then be serving, at any time
or from time to time, as members of the Pension Plan Committee under the Company’s Sigma-Aldrich Corporation Retirement Security Value Plan, as amended. 
  

 -3- 

 Exhibit 10(aa) (continued) 
  
 1. Trust or Trust Fund: Any trust established to hold amounts set aside by the Company in accordance with Section 6.

 m. Trustee: The institution appointed by the Company and by any additional or successor trustee of the Trust Fund. 
 3. Participation in the Plan. 
 a.
Eligibility. Employees of the Company, or a subsidiary of the Company, selected by the Company (or a Committee or other group designated by the Company), in its discretion, to participate in the Plan, from time to time shall be eligible to
participate in this Plan. Notwithstanding any other provision herein, only individuals who are members of a select group of management or highly compensated employees may participate in this Plan. The Company hereby designates the Committee to
designate, in its discretion, the individuals entitled to participate under this Plan, provided that all individuals participating hereunder must be members of a select group of management or highly compensated employees of the Company, or a
subsidiary of the Company. At any time the Company may designate a different Committee or group to make such designations, or may make such designations itself. 
 b. Deferral Election Form. Participants may elect to commence their participation in this Plan and defer payment of part of their compensation as provided herein by executing a Deferral Election Form in
substantially the form of Exhibit 1 attached hereto (or such other form or by any other means, electronically or otherwise, as the Company may designate from time to time) and delivering said Deferral Election Form to the Company. The current salary
and bonus of a Participant will be thereupon reduced by the amount specified in the Deferral Election Form and said amount credited to the Deferred Compensation Account. 
  

 -4- 

 Exhibit 10(aa) (continued) 
  
 c. Deferral Amounts. Each Deferral Election Form executed under this Plan shall specify the percentage of base salary
and/or bonus which is to be deferred for each year. A Participant can defer a minimum of one percent (1%), but no more than fifty percent (50%), in increments of one percent (1%), of his or her base salary for any year, and a Participant may defer a
minimum of one percent (1%) or up to one hundred percent (100%) of his or her bonus for any year; provided, however, no Participant shall be allowed to defer any part or all of his or her bonus which has been classified by the Company as a
“special bonus”. The amount to be deferred shall be deducted from the compensation otherwise payable to the Participant. A Participant may elect to defer none of his or her base salary and/or none of his or her bonus. For the purposes of
this Plan, base salary means the aggregate compensation paid to a Participant by the Company or by a subsidiary of the Company employing the Participant, including salary, overtime pay, commissions, bonuses (except as specified herein) and all other
items that constitute wages within the meaning of Section 3401(a) of the Code, including the amounts deferred by the Participants under this Plan but does not include any other amounts contributed to, or received under, any other plan of
deferred compensation. Compensation excludes all stock option transactions, expense account reimbursements, automobile allowances and moving expense reimbursements. 
 d. Election Periods. At times designated by the Company, each Participant may execute and
deliver a Deferral Election Form with the Company in the form and manner directed by the Company. A base salary and bonus deferral period ends each December 31st and a new deferral period begins January 1st. The election to defer for each new year must be made by December 15th of the
previous year (except in the case of new employees of the Company, or a subsidiary of the Company, becoming eligible to participate in the Plan, the Deferral Election Form shall be executed and delivered within 45 days following said new
Participant’s employment 
  

 -5- 

 Exhibit 10(aa) (continued) 
  
 commencement date or within such other longer period of time as permitted by the Company from time to time). A Participant who desires to
continue to participate in this Plan shall file a Deferral Election Form each year. Subject to the other provisions of this Plan providing for various specific rights and privileges of Participants to discontinue or otherwise change elections
hereunder on a prospective basis, a Deferral Election Form becomes irrevocable as of the latest date on which it could be made for each year. 
 e. Discontinuance. If a Participant wishes to discontinue deferrals hereunder, he or she may file a Notice of Discontinuance with the Committee at any time, with such discontinuance becoming effective within fifteen days following
the Committee’s receipt of such Notice of Discontinuance or, if additional time is needed by the Committee to administer or otherwise process such discontinuance, then the effective date of such discontinuance shall be as soon as is
administratively convenient to the Committee. A Participant may change his or her salary deferral election but in no event shall any such changes be given effect by the Company or the Committee more than once per calendar quarter. A Notice of
Deferral Election change will be effective within fifteen (15) days following the Committee’s receipt of such Notice of Deferral Election change or, if additional time is needed by the Committee to administer or otherwise process such
change, then the effective date of such change shall be as soon as is administratively convenient to the Committee. Notwithstanding anything in this subparagraph (e) or elsewhere in the Plan to the contrary, under no circumstances shall any
requested discontinuance or other change be effective with respect to any salary or bonus earned by the electing Participant at any times or for any periods prior to the date the Committee receives the Participant’s Notice of Discontinuance or
Notice of Deferral Election change, as the case may be. 
  

 -6- 

 Exhibit 10(aa) (continued) 
  
 f. Recommencement. Participants who had participated in the
Plan and who subsequently discontinue or otherwise terminate their participation may recommence active participation (beginning on January 1st of the next Plan year after 12 consecutive non-deferral months) by filing a new Deferral Election Form as allowed by the Company. 
 g. Effective Elections. All elections provided for in subparagraphs (a) through (f) in this Section shall only be effective if filed
with or delivered to the Company (or its designee under Section 8 hereunder) in the manner requested or directed by the Company. In addition, all elections provided for in subparagraphs (e) and (f) in this Section shall be made
subject to the prior consent and approval of the Company (or its designee under Section 8 hereunder). 
 4. Participant Elective
Deferrals and Designation of Schedule for Payment of Benefits. 
 a. Compensation Deferral. Subject to the limits specified in
Section 3 herein, during each payroll period in which a Participant has elected to defer compensation under a Deferral Election Form, the Company shall defer payment of such part of the Participant’s compensation as is specified in the
Deferral Election Form (herein the “Participant Elective Deferrals”). Such deferred amounts shall be credited to a Participant’s Deferred Compensation Account on a monthly basis (or more frequently in the Company’s discretion).

 b. Deferral Election Form. In addition to designating the amount of his or her compensation that shall be deferred in a Deferral
Election Form, a Participant may also designate when such amounts shall be paid, as provided in Section 7 of this Plan. 
 5.
Earnings Amounts. In addition to the Participant Elective Deferrals which shall be credited to a Participant’s Deferred Compensation Account, the Company shall also credit (or reduce) a Participant’s Deferred Compensation Account by
an amount equal to the amount that would have been earned (or lost) if the amounts deferred under this Plan had been invested in 
  

 -7- 

 Exhibit 10(aa) (continued) 
  
 hypothetical investments designated by the Participant from time to time, based on a list of hypothetical investments specified by the
Company. The choices to be selected by the Participant among the list of available hypothetical investments may be different based on the Participant’s designation of when a deferral shall become payable (for example, the choices of investments
for retirement deferrals may be different from the choices for deferrals to be distributed while the Participant is still in-service). Such hypothetical earnings shall be referred to in this Plan as the “Earnings Amounts.” The Participant
shall designate the investments used to measure the Earnings Amounts from the list specified by the Company, by a written statement (or form or document) in the form of Section 6 of the Deferral Election Form attached hereto, or in such other
form or by any other means, electronically or otherwise, as the Company may designate from time to time. Such designations shall be made in the manner prescribed by the Company (for example, the Company may require that all designations be made in
one percent (1%) increments). The Participant may change such designations on a daily basis as permitted by the Company. Earnings Amounts shall be credited to (or deducted from) the Participant’s Deferred Compensation Account at least
monthly (or more frequently at the discretion of the Company). Earnings shall be credited (or deducted from) a Deferred Compensation Account until all payments with respect to such account have been made under this Plan. The Company shall not be
liable or otherwise responsible for any decrease in a Participant’s Deferred Compensation Account because of the investment performance of the designated assets. To the extent that a Participant or his or her Beneficiary acquires a right to
receive payments from the Company under the provisions hereof, such right shall be no greater than the right of any unsecured general creditor of the Company or any subsidiary of the Company. 
  

 -8- 

 Exhibit 10(aa) (continued) 
  
 6. Deferred Compensation Account. 
 a. Deferred Compensation Account. The Company shall cause to be established for each Participant a bookkeeping account (the “Deferred Compensation Account”) to provide a convenient method of measuring
the Company’s obligation to each Participant under this Plan. The Company shall record in each account the amounts equal to the Participant Elective Deferrals, and the related Earnings Amounts. Deferred Compensation Accounts shall at all times
remain a part of the general assets of the Company and shall remain available for the payment of Company obligations and the obligations of the Company’s subsidiaries. In addition, at its discretion, the Company may also establish additional
bookkeeping accounts for each Participant, including up to four (4) different in-service accounts in addition to a retirement account. 
 b. Unfunded Arrangement. Neither the existence of this Plan nor any Deferred Compensation Account shall be deemed to create a trust. Any trust referred to in this Plan or created by the Company in connection with this Plan, and any
assets held by the trust to assist the Company in meeting its obligations under this Plan, will constitute an unfunded arrangement for tax purposes and for purposes of Title I of ERISA. Neither the existence of this Plan nor any Deferred
Compensation Account shall entitle any Participant, Beneficiary or other person to a claim or lien against the assets of a Deferred Compensation Account or any other assets of the Company. Any Participant and his or her Beneficiary shall have only
the rights of an unsecured general creditor in regard to receiving the benefits payable under this Plan. 
 c. Status of Trust Fund.
The Company is under no obligation to segregate any assets to provide for the Company’s obligations under this Plan. If the Company does elect to segregate assets into a Trust Fund pursuant to subsection (d) of this Section 6, the
Deferred Compensation Accounts may be maintained on the books of the Trust Fund referenced therein. 
  

 -9- 

 Exhibit 10(aa) (continued) 
  
 d. Creation of Trust Fund. The Company may, but is not required to, establish a Trust Fund and make contributions to
it corresponding to any or all of the obligations of the Company to make payments under this Plan. These contributions shall be credited with income, expenses, gains and losses in accordance with the investment experience of the Trust Fund. The
Committee may direct the Trustee to establish investment funds within the Trust Fund. The Committee may alter the available funds or procedures for allocating the Deferred Compensation Accounts among them at any time. All assets of the Trust Funds
shall remain the property of the Company. No Participant shall have any priority claim on the Trust Fund or any security interest or other right in or to them superior to the rights of general creditors of the Company or any subsidiary of the
Company. 
 7. Benefit Payments. 
 a. Payments Based on Designated Schedule(s). In addition to designating the amount to be deferred, on each Deferral Election Form, the Participant may designate (among a list of options provided by the Company) when the benefits
(equal to the Participant’s Deferred Compensation Account balance) will be paid under this Plan. At a minimum, Participants will have the option to have the amounts paid at retirement age (hereby designated as age 55), and/or at up to four
designated times prior to retirement (thus, up to four “in-service” distributions can be specified). A Participant shall be deemed to have retired, solely for the purpose of this Plan, if his or her employment terminates after he or she
has attained age 55, regardless of his or her prior years of service. Subject to other provisions of this Plan providing for mandatory methods of distributions in the event of various circumstances giving rise to the right to receive the Deferred
Compensation Account, to the extent provided in the applicable Deferral Election Form, the Participant Deferred Compensation Account balance may be paid out in a lump sum or over a specified period of years. 
  

 -10- 

 Exhibit 10(aa) (continued) 
  
 In the case of payments to be made upon retirement, the maximum payment period shall be fifteen (15) years. For payments to be made
while the Participant is still employed on a full-time basis by the Company, or a subsidiary of the Company (i.e., in-service distributions), the payments will be made in a lump sum or in installments, with the maximum payment period being five
(5) years. Notwithstanding the foregoing, however, in the case of in-service distributions, the Participant’s Elective Deferrals must be deferred for at least five (5) years from the date the Participant’s Deferred Compensation
Account was first established. The method of distribution (for example, the length of the installment payment period) can be changed by the Participant (in a manner permitted by the Company) at any time more than sixty (60) days before the
original designated distribution date. The method of distribution designated by the Participant will apply if the Participant’s employment with the Company, or a subsidiary of the Company, terminates at anytime after attaining the normal
retirement age or in the case of any in-service distribution designated by the Participant. When applicable, payments shall be made by the Company within sixty (60) days of the designated date. 
 b. Mandatory Lump Sum Payment. Notwithstanding any other designation by a Participant, if the Participant’s employment with the Company
terminates for any reason (including the Participant’s death or Disability) at any time before the Participant has reached the retirement age specified in subparagraph (a) of this Section 7, an amount equal to the balance of the
Participant’s Deferred Compensation Account at the time shall be paid to the Participant in a lump sum, and the Company shall have no further liability hereunder. In the event the Participant dies after such termination, but before receiving
such a lump sum payment, an amount equal to the Participant’s Deferred Compensation Account shall be paid to the Participant’s designated Beneficiary. 
  

 -11- 

 Exhibit 10(aa) (continued) 
  
 c. Payment Upon the Retired Participant’s Death. If a Participant, who has designated in his or her Deferral
Election Form the payment of his or her Deferred Compensation Account over a number of years, dies at any time following the commencement of his or her payments, the payments shall continue to be made over the then balance of the years, as
designated by the Participant, such payments being paid to the Participant’s Beneficiary. 
 d. Withholding. Notwithstanding any
other provision herein, the Company shall be entitled to withhold from any amount payable hereunder any amount required to be withheld for income, employment or other federal, state or local taxes. 
 e. Payment Only from Company Assets. All distributions from the Plan to Participants and Beneficiaries shall be made in cash, unless the Committee
determines that other property should be distributed. Any payment of benefits to a Participant or his or her Beneficiary shall be made from assets which shall continue, for all purposes, to be a part of the general assets of the Company. No person
shall have or acquire any interest in such assets by virtue of the provisions of this Plan. To the extent that a Participant or his or her Beneficiary acquires a right to receive payments from the Company under the provisions hereof, such right
shall be no greater than the right of any unsecured general creditor of the Company. This Plan constitutes a mere promise by the Company to make benefit payments in the future. 
 f. Beneficiaries. A Participant may designate his or her Beneficiary or Beneficiaries to receive the amounts as provided herein after his or her
death by delivering a writing to the Company in substantially the form of Section 7 of the Deferral Election Form attached hereto (or such other form or by other means, electronically or otherwise, as the Company may designate from time to
time), designating a beneficiary or beneficiaries. In the absence of such a designation, the Company shall pay any such amount to the Participant’s estate. 
  

 -12- 

 Exhibit 10(aa) (continued) 
  
 8. Administration of the Plan and Claims Procedure. 
 a. Determinations. The Committee, or such other Committee or individual designated by the Company, shall make all determinations as to rights to
benefits under this Plan. The Committee shall have full power and authority to interpret, construe and administer this Plan. The interpretation and construction of this Plan by the Committee, and any action taken pursuant thereto, shall be binding
and conclusive upon all parties in interest. All expenses of the Plan’s administration shall be paid by the Company. 
 The Committee,
in carrying out its duties with respect to the administration of the Plan, shall have, in addition to any other power conferred by the Plan or by law, the following powers: 
 (i) to determine all questions relating to eligibility to participate in the Plan; 
 (ii) to compute and certify to the Company the amount and kind of distributions payable to the Participants and Beneficiaries; 
 (iii) to maintain records necessary for the administration of the Plan that are not maintained by the Company or the Trustee, if any; 
 (iv) to interpret the Plan provisions and to make and publish such rules with regard to the Plan’s administration not inconsistent with the terms
hereof; 
 (v) to establish and modify the method of accounting for the Plan; 
 (vi) to employ counsel, accountants and other consultants to aid in exercising its powers and carrying out its duties hereunder; and 
  

 -13- 

 Exhibit 10(aa) (continued) 
  
 (vii) to perform any other acts necessary and proper for the Plan’s administration, except those that are performed by
the Trustee, if any, or as otherwise limited by the Company. 
 b. Reports. The Company shall provide each Participant with a
statement reflecting the amount of the Participant’s Deferred Compensation Account on at least a quarterly basis. 
 c. No
Liability. No Committee member, employee, agent, officer, member, manager, volunteer or director of the Company (or its designee) shall, in any event, be liable to any person for any action taken or omitted to be taken in connection with the
interpretation, construction or administration of this Plan, so long as such action or omission to act is made in good faith. 
 d.
Designation of Committee. The Company hereby designates the Committee to administer this Plan. Said Committee shall have all the authority as is granted to the Company under the terms of this Plan for the administration of this Plan in
accordance with its terms and in ruling on such questions arising out of the administration, interpretation and application of the Plan. The Committee may approve or disapprove all Deferral Election Forms and elections in connection herewith, and
make all other determinations hereunder. Members of the Committee may participate in the Plan, but no member of the Committee shall be entitled to make decisions which relate solely to his or her own participation. The Company reserves the right to
designate a different Committee, or an individual, to administer this Plan from time to time, or to make any determinations directly at any time. If no such Committee or individual is designated at any time, such functions, as appropriate, may be
conducted by the Company’s Board of Directors. The Company’s Board of Directors hereby reserves the right to revoke such designation at any time and to make other designations (and to revoke such designations) at any time. 
  

 -14- 

 Exhibit 10(aa) (continued) 
  
 e. Claims Procedure. The following provisions are hereby made a part of this Plan and are intended to meet the
requirements of ERISA: 
 (1) The named fiduciary under this Plan is the Company. 
 (2) This Plan is unfunded. The Participants shall defer certain amounts under this Plan, but all benefits shall be paid from the Company’s general
assets which at all times shall remain subject to the claims of the Company’s general creditors. 
 (3) Direct payment by the Company
is the basis of payment of benefits under this Plan. 
 (4) The following claims procedures shall apply for purposes of this Plan. Any and
all persons presenting claims hereunder (individually or collectively, “Claimant”) must follow these procedures: 
 (A) For claims
procedure purposes, the Committee shall appoint among themselves a chairperson of the Committee (or the chairperson of any other Committee designated by the Company to administer this Plan, or a designated member of the Board of Directors or other
governing body of the Company). 
 (B) A Claimant shall make a claim for benefits hereunder by submitting a written claim to the Company (or
its designee) in the manner set forth herein for providing notice to the Company under this Plan. The Committee shall decide whether the claim shall be allowed, and the following claims procedure shall apply: 
 (i) If for any reason a claim for benefits under this Plan is denied by the Committee in whole or in part, the Committee shall deliver to the Claimant a
written explanation setting forth: the specific reason or reasons for the adverse determination; references to specific Plan provisions on which the determination is based; a description of any additional 
  

 -15- 

 Exhibit 10(aa) (continued) 
  
 material or information necessary for the Claimant to perfect the claim and an explanation of why such material or information is necessary;
and a description of the Plan’s review procedure including a statement of the Claimant’s rights to bring a civil action under Section 502 of ERISA following an adverse determination on review, all written in a manner calculated to be
understood by the Claimant. For this purpose: 
 (a) The Committee’s claim shall be deemed filed when delivered in writing as provided
herein. 
 (b) The Committee’ s explanation shall be in writing delivered to the Claimant within 90 days after receipt of the claim by
the Plan, unless the Committee determines that special circumstances require an extension of time for processing the claim. If such an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant
prior to the termination of the initial 90 day period. In no event shall such extension exceed a period of 90 days from the end of such initial period. The extension notice shall indicate the special circumstances requiring an extension of time and
the date by which the Committee expects to render the benefit determination. If the period of time is extended because the Claimant has failed to provide necessary information to decide the claim, the period for making the benefit determination
shall be tolled from the date on which the notification of the extension is sent to the Claimant, until the date on which the Claimant provides the information. 
 (ii) The Claimant shall have 60 days following his or her receipt of a notice of adverse benefit determination to file with the Committee a written request for review of the denial. Claimant shall have the opportunity
to submit written comments, documents, records, and other information relating to the claim for benefits. Claimant shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other 

 

 -16- 

 Exhibit 10(aa) (continued) 
  
 information relevant to the Claimant’s claim for benefits. The review of the claim shall take into account all comments, documents,
records, and other information submitted by the Claimant relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. 
 (iii) In the case of a request for review of an adverse benefit determination, the Company shall designate an individual or Committee (herein the
“Reviewer”) to review the claim. On review, the Reviewer shall notify the Claimant not later than 60 days after the Company’s receipt of the request for review, unless the Reviewer determines that special circumstances require an
extension of time for processing the claim, in which case a decision shall be rendered as soon as possible, but not later than 120 days after receipt of the request for review. If such an extension of time for review is required because of special
circumstances, written notice of the extension shall be furnished to the Claimant prior to the commencement of the extension. The extension notice shall indicate the special circumstances requiring an extension of time and the date by which the Plan
expects to render the determination on review. If the period of time is extended because the Claimant has failed to provide necessary information to decide the claim, the period for making the benefit determination shall be tolled from the date on
which the notification of the extension is sent to the Claimant, until the date on which the Claimant provides the information. The decision on review shall be in writing and in the case of an adverse benefit determination shall include:
(1) the specific reason or reasons for the decision; (2) references to the specific Plan provisions on which the benefit determination is based; (3) a statement that the Claimant is entitled to receive, upon request and free of
charge, reasonable access to, and copies of, all documents, records and other information relevant to the Claimant’s claim for benefits; and (4) a statement of the Claimant’s right to bring an action under Section 502(a) of
ERISA, all written in a manner calculated to be understood by the Claimant. If the decision on review is not furnished within such time, the claim shall be deemed denied on review. 
  

 -17- 

 Exhibit 10(aa) (continued) 
  
 9. Non-Assignability of Benefits. Neither any Participant nor any Beneficiary under this Plan shall have any power or
right to transfer, assign, anticipate, hypothecate or otherwise encumber any part or all of the amounts payable hereunder. Such amounts shall not be subject to seizure by any creditor of a Participant or any Beneficiary hereunder, by a proceeding at
law or in equity, nor transferable by operation of law in the event of the bankruptcy or insolvency of any Participant or any Beneficiary hereunder. Any such attempted assignment or transfer shall be void and shall terminate the Participant’s
participation in this Plan; the Company shall thereupon have no further liability hereunder with respect to such Participant and his or her Beneficiary. 
 10. Amendment and Termination. This Plan may not be amended, altered or modified, retroactively, except by a written instrument signed by the Company and the impacted Participants or their respective
successors. The Company may amend, alter, modify or terminate this Plan on a prospective basis at any time, provided further that no such modification or termination shall adversely affect a Participant’s entitlement to benefits attributable to
amounts credited to his or her Deferred Compensation Account prior to the modification or termination of this Plan. Without limiting the generality of the foregoing, the Company reserves the right to discontinue this Plan at any time, and/or change
the eligibility of the Participants as well as the percentage or amounts Participants may defer. This Plan document sets forth the terms and provisions of this Plan and any prior written or oral communications regarding the terms of this Plan shall
not alter or modify the terms of this Plan. 
 11. Impact on Other Benefits. Except as otherwise required by the Code or any other
applicable law, this Plan and the benefits provided herein are in addition to all other benefits which 
  

 -18- 

 Exhibit 10(aa) (continued) 
  
 may be provided by the Company to the Participants from time to time, and shall not reduce, replace or otherwise cause any reduction, in any
manner, with regard to any of such other benefits. In no event shall any provision herein be deemed to amend or modify any employment agreement between the Company and any Participant, and no provision herein shall be deemed to entitle any
Participant to continued employment with the Company. 
 12. Notices. Any notice or other communication required or permitted under
this Plan shall be in writing and, if directed to the Company, shall be sent by United States certified mail, return receipt requested, postage prepaid, addressed to: Sigma-Aldrich Corporation, 3050 Spruce Street, St. Louis, Missouri 63103, Attn:
Flexible Deferral Plan Committee, and, if directed to a Participant or to a Beneficiary, may be hand-delivered or mailed to such Participant or Beneficiary at the last known address for such person as it appears in the Company’s records. A
notice or other communication sent by United States certified mail, return receipt requested, postage prepaid, addressed as provided above, shall be deemed to have been given on the next business day after mailing. 
 13. Governing Law. This Plan shall be governed by and construed in accordance with the laws of the State of Missouri without regard to its
conflict of law rules. 
 14. Headings. The headings of the sections of this Plan are for reference only and are not to be utilized in
construing the Plan. 
 15. Gender. All pronouns of whatever gender refer indifferently to persons or objects of any gender.

 16. Singular and Plural. Singular terms refer also the plural number and vice versa. 
  

 -19- 

 Exhibit 10(aa) (continued) 
  
 17. Severability. If any provision of this Plan is held illegal or invalid for any reason, the remaining provisions
are to remain in full force and effect and to be construed and enforced in accordance with the purposes of the Plan as if the illegal or invalid provision did not exist. 
 IN WITNESS WHEREOF, the Company has executed and adopted this Plan as of the Effective Date. 
  

			
	SIGMA-ALDRICH CORPORATION
		
	By:	 	 /s/ Kirk A. Richtir

		 	Print Name: Kirk A. Richtir
		 	Print Title: Treasurer

  

 -20-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]